{
  "questions": [
    {
      "id": "65cfae831930410b13000015",
      "type": "summary",
      "body": "What is the use of P85-Ab?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37646678",
        "http://www.ncbi.nlm.nih.gov/pubmed/12388663",
        "http://www.ncbi.nlm.nih.gov/pubmed/8388374",
        "http://www.ncbi.nlm.nih.gov/pubmed/14504291",
        "http://www.ncbi.nlm.nih.gov/pubmed/1314371",
        "http://www.ncbi.nlm.nih.gov/pubmed/9488453",
        "http://www.ncbi.nlm.nih.gov/pubmed/18991538",
        "http://www.ncbi.nlm.nih.gov/pubmed/27827005",
        "http://www.ncbi.nlm.nih.gov/pubmed/7541019",
        "http://www.ncbi.nlm.nih.gov/pubmed/14620511"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8388374",
          "text": "A synthetic phosphopeptide corresponding to the kinase insert of the human PDGF beta subunit receptor and monoclonal antibodies raised against the two described p85 isoforms, p85 alpha and p85 beta were used to isolate PtdIns 3-kinase from human T lymphocytes. We demonstrate that T cells express both p85 alpha and p85 beta proteins. Both isoforms tightly associate with a p110 protein and with PtdIns 3-kinase activity in T cells.",
          "beginSection": "abstract",
          "offsetInBeginSection": 109,
          "endSection": "abstract",
          "offsetInEndSection": 541
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8388374",
          "text": "A synthetic phosphopeptide corresponding to the kinase insert of the human PDGF beta subunit receptor and monoclonal antibodies raised against the two described p85 isoforms, p85 alpha and p85 beta were used to isolate PtdIns 3-kinase from human T lymphocytes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 109,
          "endSection": "abstract",
          "offsetInEndSection": 369
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8388374",
          "text": "A synthetic phosphopeptide corresponding to the kinase insert of the human PDGF beta subunit receptor and monoclonal antibodies raised against the two described p85 isoforms, p85 alpha and p85 beta were used to isolate PtdIns 3-kinase from human T lymphocytes. We demonstrate that T cells express both p85 alpha and p85 beta proteins.",
          "beginSection": "abstract",
          "offsetInBeginSection": 109,
          "endSection": "abstract",
          "offsetInEndSection": 443
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12388663",
          "text": "P85 was examined in vitro to assess blood-brain barrier uptake in association with P-glycoprotein effect, DPDPE and morphine being P-glycoprotein substrates. P85 coadministration with DPDPE and biphalin showed increased (p < 0.01) analgesia with both 0.01 and 1.0% P85.",
          "beginSection": "abstract",
          "offsetInBeginSection": 661,
          "endSection": "abstract",
          "offsetInEndSection": 930
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12388663",
          "text": "P85 was examined in vitro to assess blood-brain barrier uptake in association with P-glycoprotein effect, DPDPE and morphine being P-glycoprotein substrates. P85 coadministration with DPDPE and biphalin showed increased (p < 0.01) analgesia with both 0.01 and 1.0% P85. Morphine showed increased (p < 0.01) analgesia with 0.01% P85 only.",
          "beginSection": "abstract",
          "offsetInBeginSection": 661,
          "endSection": "abstract",
          "offsetInEndSection": 998
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12388663",
          "text": "P85 was examined in vitro to assess blood-brain barrier uptake in association with P-glycoprotein effect, DPDPE and morphine being P-glycoprotein substrates.",
          "beginSection": "abstract",
          "offsetInBeginSection": 661,
          "endSection": "abstract",
          "offsetInEndSection": 818
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12388663",
          "text": "This investigation assesses Pluronic P85 (P85) and its potential to enhance opioid peptide analgesia. Two opioid peptides, [D-Pen(2),D-Pen(5)]-enkephalin (DPDPE) and biphalin, were examined as to the benefits of P85 coadministration, above (1.0%) and below (0.01%) the critical micelle concentration, with morphine as a nonpeptide control. P85 was examined in vitro to assess blood-brain barrier uptake in association with P-glycoprotein effect, DPDPE and morphine being P-glycoprotein substrates.",
          "beginSection": "abstract",
          "offsetInBeginSection": 321,
          "endSection": "abstract",
          "offsetInEndSection": 818
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14504291",
          "text": "Furthermore, a reduction of p85 beta specifically increases insulin receptor substrate-2 phosphorylation. Thus, p85 alpha and p85 beta modulate PI 3-kinase-dependent signaling by multiple mechanisms and transmit signals independent of PI 3-kinase activation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1541,
          "endSection": "abstract",
          "offsetInEndSection": 1799
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1314371",
          "text": "The human phosphatidylinositol (PI) 3-kinase p85 alpha subunit gene and its homologue p85 beta were assigned to human chromosomes by analysis of their segregation in a panel of somatic cell hybrids using human-specific polymerase chain reaction primers. The p85 alpha locus was only present in hybrids retaining the human chromosome 5q. The presence of the p85 beta locus coincided with the presence of chromosome 19.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 417
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14504291",
          "text": "Thus, p85 alpha and p85 beta modulate PI 3-kinase-dependent signaling by multiple mechanisms and transmit signals independent of PI 3-kinase activation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1647,
          "endSection": "abstract",
          "offsetInEndSection": 1799
        }
      ],
      "ideal_answer": "P85-Ab is a monoclonal antibody used to isolate PtdIns 3-kinase from human T lymphocytes by binding to the p85 alpha and p85 beta isoforms, which are associated with p110 protein and PtdIns 3-kinase activity in T cells.",
      "exact_answer": "n/a"
    },
    {
      "id": "662fc44b187cba990d000015",
      "type": "list",
      "body": "What are the indicated prophylaxis treatments for acute cholinergic syndrome secondary to irinotecan?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25839059",
        "http://www.ncbi.nlm.nih.gov/pubmed/29705823",
        "http://www.ncbi.nlm.nih.gov/pubmed/30244364",
        "http://www.ncbi.nlm.nih.gov/pubmed/34248544",
        "http://www.ncbi.nlm.nih.gov/pubmed/30564875",
        "http://www.ncbi.nlm.nih.gov/pubmed/11956509",
        "http://www.ncbi.nlm.nih.gov/pubmed/14567522",
        "http://www.ncbi.nlm.nih.gov/pubmed/8911750",
        "http://www.ncbi.nlm.nih.gov/pubmed/11156563",
        "http://www.ncbi.nlm.nih.gov/pubmed/30449850"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25839059",
          "text": "CONCLUSIONS\nLack of difference in the incidence of cholinergic syndrome observed in irinotecan-treated patients suggests atropinediphenoxylate and hyoscyamine may both be effective prophylactic options. The findings support the need for a larger, randomized study to assess and compare these agents with other potential premedications such as scopolamine and atropine in prevention of irinotecan-related cholinergic syndrome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1545,
          "endSection": "abstract",
          "offsetInEndSection": 1970
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25839059",
          "text": "BACKGROUND\nCholinergic syndrome is a well established acute adverse reaction associated with irinotecan. Cholinergic side effects can be ameliorated or prevented with anticholinergic agents. To date, no formal studies have compared atropine-diphenoxylate and hyoscyamine as premedications for prophylaxis of the cholinergic syndrome with irinotecan infusion.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 358
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25839059",
          "text": "To date, no formal studies have compared atropine-diphenoxylate and hyoscyamine as premedications for prophylaxis of the cholinergic syndrome with irinotecan infusion.",
          "beginSection": "abstract",
          "offsetInBeginSection": 191,
          "endSection": "abstract",
          "offsetInEndSection": 358
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25839059",
          "text": "Lack of difference in the incidence of cholinergic syndrome observed in irinotecan-treated patients suggests atropinediphenoxylate and hyoscyamine may both be effective prophylactic options.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1548,
          "endSection": "abstract",
          "offsetInEndSection": 1738
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25839059",
          "text": "CONCLUSIONS\nLack of difference in the incidence of cholinergic syndrome observed in irinotecan-treated patients suggests atropinediphenoxylate and hyoscyamine may both be effective prophylactic options.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1545,
          "endSection": "abstract",
          "offsetInEndSection": 1747
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25839059",
          "text": "LIMITATIONS\nThis study was subjected to vulnerabilities to bias and random error because of its observational retrospective design and small number of participants. CONCLUSIONS\nLack of difference in the incidence of cholinergic syndrome observed in irinotecan-treated patients suggests atropinediphenoxylate and hyoscyamine may both be effective prophylactic options.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1378,
          "endSection": "abstract",
          "offsetInEndSection": 1747
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25839059",
          "text": "LIMITATIONS\nThis study was subjected to vulnerabilities to bias and random error because of its observational retrospective design and small number of participants. CONCLUSIONS\nLack of difference in the incidence of cholinergic syndrome observed in irinotecan-treated patients suggests atropinediphenoxylate and hyoscyamine may both be effective prophylactic options. The findings support the need for a larger, randomized study to assess and compare these agents with other potential premedications such as scopolamine and atropine in prevention of irinotecan-related cholinergic syndrome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1378,
          "endSection": "abstract",
          "offsetInEndSection": 1970
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25839059",
          "text": "Cholinergic side effects can be ameliorated or prevented with anticholinergic agents. To date, no formal studies have compared atropine-diphenoxylate and hyoscyamine as premedications for prophylaxis of the cholinergic syndrome with irinotecan infusion.",
          "beginSection": "abstract",
          "offsetInBeginSection": 105,
          "endSection": "abstract",
          "offsetInEndSection": 358
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29705823",
          "text": "Cholinergic syndrome is an acute adverse reaction associated with irinotecan. Development of cholinergic syndrome can be ameliorated or prevented by administering various anticholinergics, including atropine sulfate or scopolamine butylbromide.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 244
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25839059",
          "text": "To date, no formal studies have compared atropine-diphenoxylate and hyoscyamine as premedications for prophylaxis of the cholinergic syndrome with irinotecan infusion. OBJECTIVES\nTo compare the incidence of cholinergic syndrome with irinotecan using atropine-diphenoxylate or hyoscyamine as premedication.",
          "beginSection": "abstract",
          "offsetInBeginSection": 191,
          "endSection": "abstract",
          "offsetInEndSection": 498
        }
      ],
      "ideal_answer": "The indicated prophylaxis treatments for acute cholinergic syndrome secondary to irinotecan are atropine-diphenoxylate and hyoscyamine. A study found no difference in the incidence of cholinergic syndrome between patients treated with either of these agents, suggesting both are effective prophylactic options. However, a larger, randomized study is needed to confirm these findings and compare these agents with other potential premedications such as scopolamine and atropine.",
      "exact_answer": [
        [
          "atropine-diphenoxylate"
        ],
        [
          "hyoscyamine"
        ]
      ]
    },
    {
      "id": "662cf81b187cba990d000001",
      "type": "summary",
      "body": "What is the function of FAM134B (also called JK-1, RETREG1)?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33199694",
        "http://www.ncbi.nlm.nih.gov/pubmed/31930741",
        "http://www.ncbi.nlm.nih.gov/pubmed/36056188",
        "http://www.ncbi.nlm.nih.gov/pubmed/37813237",
        "http://www.ncbi.nlm.nih.gov/pubmed/37728036",
        "http://www.ncbi.nlm.nih.gov/pubmed/24973512",
        "http://www.ncbi.nlm.nih.gov/pubmed/35477002",
        "http://www.ncbi.nlm.nih.gov/pubmed/29226326",
        "http://www.ncbi.nlm.nih.gov/pubmed/31996076",
        "http://www.ncbi.nlm.nih.gov/pubmed/30556279"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33199694",
          "text": "FAM134B (also called JK-1, RETREG1), a member of the family with sequence similarity 134, was originally discovered as an oncogene in esophageal squamous cell carcinoma. However, its most famous function is that of an ER-phagy-regulating receptor. Over the decades, the powerful biological functions of FAM134B were gradually revealed.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 335
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33199694",
          "text": "FAM134B (also called JK-1, RETREG1), a member of the family with sequence similarity 134, was originally discovered as an oncogene in esophageal squamous cell carcinoma. However, its most famous function is that of an ER-phagy-regulating receptor.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 247
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35477002",
          "text": "FAM134B is also known as the reticulophagy regulator 1 (RETREG1) or JK-1. FAM134B consists of two long hydrophobic fragments with a reticulon-homology domain, an N-terminal cytoplasmic domain, and a C-terminal cytoplasmic domain. FAM134B plays an important role in regulating selective ER-phagy, and is related to the occurrence and development of many diseases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 362
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35477002",
          "text": "FAM134B is also known as the reticulophagy regulator 1 (RETREG1) or JK-1.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 73
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33199694",
          "text": "FAM134B (also called JK-1, RETREG1), a member of the family with sequence similarity 134, was originally discovered as an oncogene in esophageal squamous cell carcinoma.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 169
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35477002",
          "text": "FAM134B is also known as the reticulophagy regulator 1 (RETREG1) or JK-1. FAM134B consists of two long hydrophobic fragments with a reticulon-homology domain, an N-terminal cytoplasmic domain, and a C-terminal cytoplasmic domain.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 229
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29226326",
          "text": "FAM134B (family with sequence similarity 134, member B)/RETREG1 and its functional roles are relatively new in human diseases. This review aimed to summarize various functions of FAM134B since our first discovery of the gene in 2001. The protein encoded by FAM134B is a reticulophagy receptor that regulates turnover of the endoplasmic reticulum (ER) by selective phagocytosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 377
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29226326",
          "text": "FAM134B (family with sequence similarity 134, member B)/RETREG1 and its functional roles are relatively new in human diseases. This review aimed to summarize various functions of FAM134B since our first discovery of the gene in 2001.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 233
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29226326",
          "text": "FAM134B (family with sequence similarity 134, member B)/RETREG1 and its functional roles are relatively new in human diseases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 126
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29226326",
          "text": "This review aimed to summarize various functions of FAM134B since our first discovery of the gene in 2001. The protein encoded by FAM134B is a reticulophagy receptor that regulates turnover of the endoplasmic reticulum (ER) by selective phagocytosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 127,
          "endSection": "abstract",
          "offsetInEndSection": 377
        }
      ],
      "ideal_answer": "FAM134B, also known as JK-1 or RETREG1, is a reticulophagy receptor that regulates the turnover of the endoplasmic reticulum (ER) by selective phagocytosis. It consists of two long hydrophobic fragments with a reticulon-homology domain, an N-terminal cytoplasmic domain, and a C-terminal cytoplasmic domain.",
      "exact_answer": "n/a"
    },
    {
      "id": "661688cefdcbea915f000053",
      "type": "list",
      "body": "What cancers are associated with human papilloma virus?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36730877",
        "http://www.ncbi.nlm.nih.gov/pubmed/36691362",
        "http://www.ncbi.nlm.nih.gov/pubmed/36868166",
        "http://www.ncbi.nlm.nih.gov/pubmed/22044803",
        "http://www.ncbi.nlm.nih.gov/pubmed/35681587",
        "http://www.ncbi.nlm.nih.gov/pubmed/24191906",
        "http://www.ncbi.nlm.nih.gov/pubmed/34622962",
        "http://www.ncbi.nlm.nih.gov/pubmed/33777308",
        "http://www.ncbi.nlm.nih.gov/pubmed/20519038",
        "http://www.ncbi.nlm.nih.gov/pubmed/20370947"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33777308",
          "text": "Squamous cell carcinoma and ameloblastic carcinoma were the cancers associated with HPV. HPV was not identified in the HIV positive patients. CONCLUSION\nhigh-risk human papilloma virus genotypes 16, 33, 35 and 52 are associated with oropharyngeal carcinoma in Nigeria but were not found in HIV patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1266,
          "endSection": "abstract",
          "offsetInEndSection": 1571
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34622962",
          "text": "For the past two decades an increasing number of oropharyngeal cancers have been found to be associated with the human papilloma virus (HPV). These tumors are a biologically distinct entity with better prognosis and excellent response to therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 246
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34622962",
          "text": "For the past two decades an increasing number of oropharyngeal cancers have been found to be associated with the human papilloma virus (HPV).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 141
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35681587",
          "text": "The Involvement of Human Papilloma Virus in Gastrointestinal Cancers.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 69
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22044803",
          "text": "Recently, evidence is mounting that infection with human papilloma virus, most commonly human papilloma virus-16 is responsible for a subset of head and neck squamous cell carcinoma especially tumors of tonsillar origin.",
          "beginSection": "abstract",
          "offsetInBeginSection": 189,
          "endSection": "abstract",
          "offsetInEndSection": 409
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22044803",
          "text": "Human papilloma virus: a new risk factor in a subset of head and neck cancers.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 78
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34622962",
          "text": "For the past two decades an increasing number of oropharyngeal cancers have been found to be associated with the human papilloma virus (HPV). These tumors are a biologically distinct entity with better prognosis and excellent response to therapy. Therefore, a separate staging system has been introduced for HPV-related oropharyngeal tumors in the latest edition of the American Joint Committee on Cancer (AJCC eighth Ed).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 422
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35681587",
          "text": "Human Papilloma Virus (HPV) is one of the most common sexually transmitted infections worldwide. HPV infection has a strong relationship with the onset of cervix uteri, vagina, penis, anus, and oropharynx, but also tonsils and tongue cancers. Some epidemiological data indicate that except for gynecologic cancers, HPV infection can be one of the risk factors associated with a greater risk of induction and progression of gastrointestinal cancers.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 448
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22044803",
          "text": "Recently, evidence is mounting that infection with human papilloma virus, most commonly human papilloma virus-16 is responsible for a subset of head and neck squamous cell carcinoma especially tumors of tonsillar origin. The molecular pathway used by human papilloma virus to trigger malignant transformation of tissue is different from that of other well known risk factors, i.e.",
          "beginSection": "abstract",
          "offsetInBeginSection": 189,
          "endSection": "abstract",
          "offsetInEndSection": 569
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35681587",
          "text": "Human Papilloma Virus (HPV) is one of the most common sexually transmitted infections worldwide. HPV infection has a strong relationship with the onset of cervix uteri, vagina, penis, anus, and oropharynx, but also tonsils and tongue cancers.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 242
        }
      ],
      "ideal_answer": "Human papilloma virus (HPV) is associated with oropharyngeal carcinoma, squamous cell carcinoma, cervix uteri, vagina, penis, anus, tonsils and tongue cancers.",
      "exact_answer": [
        [
          "oropharyngeal carcinoma"
        ],
        [
          "squamous cell carcinoma"
        ],
        [
          "cervix uteri"
        ],
        [
          "vagina"
        ],
        [
          "penis"
        ],
        [
          "anus"
        ],
        [
          "tonsils and tongue cancers"
        ]
      ]
    },
    {
      "id": "662fdb1e187cba990d000019",
      "type": "summary",
      "body": "What is the role of the transcription factor activator protein 2 (AP-2) alpha (TFAP2A) in tumor formation and metastasis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37083077",
        "http://www.ncbi.nlm.nih.gov/pubmed/36831334",
        "http://www.ncbi.nlm.nih.gov/pubmed/34210752",
        "http://www.ncbi.nlm.nih.gov/pubmed/37291585",
        "http://www.ncbi.nlm.nih.gov/pubmed/36410635",
        "http://www.ncbi.nlm.nih.gov/pubmed/35117502",
        "http://www.ncbi.nlm.nih.gov/pubmed/8723999",
        "http://www.ncbi.nlm.nih.gov/pubmed/7555706",
        "http://www.ncbi.nlm.nih.gov/pubmed/12586840",
        "http://www.ncbi.nlm.nih.gov/pubmed/12169772"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37083077",
          "text": "Transcription factor AP‑2 alpha (TFAP2A) is a critical cell growth regulator that is overexpressed in various tumor tissues. However, its role in the development of cervical cancer remains unknown. In the present study, public databases were thus explored and a higher expression of TFAP2A was found in cervical cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 319
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37083077",
          "text": "Transcription factor AP‑2 alpha (TFAP2A) is a critical cell growth regulator that is overexpressed in various tumor tissues. However, its role in the development of cervical cancer remains unknown.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 197
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35117502",
          "text": "BACKGROUND\nTranscription factor AP-2 alpha (TFAP2A) has been reported to participate in various tumors. However, the transcriptional levels and prognostic values of TFAP2A remain elusive in lung adenocarcinoma (LUAD). The purpose of the present study was to investigate the impact of the TFAP2A in LUAD.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 303
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35117502",
          "text": "BACKGROUND\nTranscription factor AP-2 alpha (TFAP2A) has been reported to participate in various tumors. However, the transcriptional levels and prognostic values of TFAP2A remain elusive in lung adenocarcinoma (LUAD).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 217
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35117502",
          "text": "BACKGROUND\nTranscription factor AP-2 alpha (TFAP2A) has been reported to participate in various tumors.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 103
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37083077",
          "text": "Transcription factor AP‑2 alpha (TFAP2A) is a critical cell growth regulator that is overexpressed in various tumor tissues.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 124
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8723999",
          "text": "Activator protein-1 (AP-1) is an inducible transcription factor, and is comprised of multiple protein complexes that include the gene products of the fos and jun gene families. Numerous cellular and viral genes contain AP-1 binding sites within their promoters and, accordingly, AP-1 has been shown to play a role in the regulation of both basal and inducible transcription of these genes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 153,
          "endSection": "abstract",
          "offsetInEndSection": 542
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8723999",
          "text": "They may be constitutively expressed or may only be activated during specific situations. Activator protein-1 (AP-1) is an inducible transcription factor, and is comprised of multiple protein complexes that include the gene products of the fos and jun gene families. Numerous cellular and viral genes contain AP-1 binding sites within their promoters and, accordingly, AP-1 has been shown to play a role in the regulation of both basal and inducible transcription of these genes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 63,
          "endSection": "abstract",
          "offsetInEndSection": 542
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8723999",
          "text": "Activator protein-1 (AP-1) is an inducible transcription factor, and is comprised of multiple protein complexes that include the gene products of the fos and jun gene families.",
          "beginSection": "abstract",
          "offsetInBeginSection": 153,
          "endSection": "abstract",
          "offsetInEndSection": 329
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8723999",
          "text": "Activator protein-1 (AP-1) is an inducible transcription factor, and is comprised of multiple protein complexes that include the gene products of the fos and jun gene families. Numerous cellular and viral genes contain AP-1 binding sites within their promoters and, accordingly, AP-1 has been shown to play a role in the regulation of both basal and inducible transcription of these genes. fos-related antigen-2 (fra-2) has been found to have both similar and unique properties to that of other fos gene members in terms of its regulation and expression.",
          "beginSection": "abstract",
          "offsetInBeginSection": 153,
          "endSection": "abstract",
          "offsetInEndSection": 707
        }
      ],
      "ideal_answer": "Transcription factor AP-2 alpha (TFAP2A) is a critical cell growth regulator that is overexpressed in various tumor tissues, including cervical cancer. However, its specific role in tumor formation and metastasis is not well understood and remains an area of ongoing research.",
      "exact_answer": "n/a"
    },
    {
      "id": "66300f53187cba990d00001d",
      "type": "list",
      "body": "Which vaccines are safe to be administered for all pregnancies?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33773923",
        "http://www.ncbi.nlm.nih.gov/pubmed/36300259",
        "http://www.ncbi.nlm.nih.gov/pubmed/20716021",
        "http://www.ncbi.nlm.nih.gov/pubmed/26619353",
        "http://www.ncbi.nlm.nih.gov/pubmed/17881905",
        "http://www.ncbi.nlm.nih.gov/pubmed/32298219",
        "http://www.ncbi.nlm.nih.gov/pubmed/23444602",
        "http://www.ncbi.nlm.nih.gov/pubmed/35938480",
        "http://www.ncbi.nlm.nih.gov/pubmed/7936516",
        "http://www.ncbi.nlm.nih.gov/pubmed/34730836"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20716021",
          "text": "Most of the vaccines are administered intramusculary or subcutaneously.",
          "beginSection": "abstract",
          "offsetInBeginSection": 162,
          "endSection": "abstract",
          "offsetInEndSection": 233
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17881905",
          "text": "Information based on evidence is necessary for correctly planning schedules and for parents who often fear the administration of too many vaccines. We reviewed the available literature to assess the effects on immunogenicity and safety of simultaneous administration of hexavalent and conjugate pneumococcal and meningococcal C vaccines in healthy children.",
          "beginSection": "abstract",
          "offsetInBeginSection": 159,
          "endSection": "abstract",
          "offsetInEndSection": 516
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36300259",
          "text": "EXPERT OPINION\nIn our opinion, head-to-head comparison studies examining the safety and efficacy of intramuscular injected and pulmonary administered liquid mRNA vaccines should be performed first. When pulmonary delivered mRNA vaccines are shown to be effective and safe, inhalable dry powder formulations should be engineered.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1095,
          "endSection": "abstract",
          "offsetInEndSection": 1423
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36300259",
          "text": "EXPERT OPINION\nIn our opinion, head-to-head comparison studies examining the safety and efficacy of intramuscular injected and pulmonary administered liquid mRNA vaccines should be performed first. When pulmonary delivered mRNA vaccines are shown to be effective and safe, inhalable dry powder formulations should be engineered. Finally, the tolerability of patients with respiratory diseases should be considered.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1095,
          "endSection": "abstract",
          "offsetInEndSection": 1509
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17881905",
          "text": "Children who received simultaneous administration of hexavalent vaccines with conjugate pneumococcal vaccines had a 13-17% additional risk of experiencing fever compared with single administration. CONCLUSION\nFew studies deal with coadministration of vaccines. Hexavalent and conjugate pneumococcal or meningococcal vaccines may however be administered simultaneously without noteworthy negative effects on immunogenicity or safety profile.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1551,
          "endSection": "abstract",
          "offsetInEndSection": 1993
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36300259",
          "text": "Are inhaled mRNA vaccines safe and effective? A review of preclinical studies.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 78
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36300259",
          "text": "When pulmonary delivered mRNA vaccines are shown to be effective and safe, inhalable dry powder formulations should be engineered. Finally, the tolerability of patients with respiratory diseases should be considered.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1293,
          "endSection": "abstract",
          "offsetInEndSection": 1509
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36300259",
          "text": "All relevant papers were found using PubMed/MEDLINE database. EXPERT OPINION\nIn our opinion, head-to-head comparison studies examining the safety and efficacy of intramuscular injected and pulmonary administered liquid mRNA vaccines should be performed first. When pulmonary delivered mRNA vaccines are shown to be effective and safe, inhalable dry powder formulations should be engineered.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1031,
          "endSection": "abstract",
          "offsetInEndSection": 1423
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17881905",
          "text": "Hexavalent and conjugate pneumococcal or meningococcal vaccines may however be administered simultaneously without noteworthy negative effects on immunogenicity or safety profile.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1814,
          "endSection": "abstract",
          "offsetInEndSection": 1993
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17881905",
          "text": "Children who received simultaneous administration of hexavalent vaccines with conjugate pneumococcal vaccines had a 13-17% additional risk of experiencing fever compared with single administration.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1551,
          "endSection": "abstract",
          "offsetInEndSection": 1748
        }
      ],
      "ideal_answer": "Hexavalent, pneumococcal, and meningococcal vaccines are safe to be administered for all pregnancies.",
      "exact_answer": [
        [
          "hexavalent"
        ],
        [
          "pneumococcal"
        ],
        [
          "meningococcal"
        ]
      ]
    },
    {
      "id": "65d36e761930410b13000044",
      "type": "factoid",
      "body": "What is the use of lebrikizumab?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36994947",
        "http://www.ncbi.nlm.nih.gov/pubmed/37266844",
        "http://www.ncbi.nlm.nih.gov/pubmed/37401345",
        "http://www.ncbi.nlm.nih.gov/pubmed/36630140",
        "http://www.ncbi.nlm.nih.gov/pubmed/36948491",
        "http://www.ncbi.nlm.nih.gov/pubmed/27554950",
        "http://www.ncbi.nlm.nih.gov/pubmed/23055690",
        "http://www.ncbi.nlm.nih.gov/pubmed/32104006",
        "http://www.ncbi.nlm.nih.gov/pubmed/27161908",
        "http://www.ncbi.nlm.nih.gov/pubmed/21812663"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23055690",
          "text": "Lebrikizumab, a humanized monoclonal antibody that binds to interleukin (IL)-13, is under development for the treatment of poorly controlled asthma.",
          "beginSection": "abstract",
          "offsetInBeginSection": 58,
          "endSection": "abstract",
          "offsetInEndSection": 206
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27554950",
          "text": "Lebrikizumab for the treatment of asthma.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 41
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27554950",
          "text": "AREAS COVERED\nDiscussion of the rationale for the use of lebrikizumab in asthma. Analysis of the related preclinical and clinical data on lebrikizumab in asthma. EXPERT OPINION\nLebrikizumab demonstrated efficacy in an asthma subset characterized by high serum periostin levels and by heavy eosinophilic inflammation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 450,
          "endSection": "abstract",
          "offsetInEndSection": 768
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23055690",
          "text": "Lebrikizumab in the personalized management of asthma.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 54
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27554950",
          "text": "AREAS COVERED\nDiscussion of the rationale for the use of lebrikizumab in asthma.",
          "beginSection": "abstract",
          "offsetInBeginSection": 450,
          "endSection": "abstract",
          "offsetInEndSection": 530
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27554950",
          "text": "In some patients however additional inhibition of the airways inflammation is necessary. Such compounds might be molecules inhibiting specifically certain inflammation pathways and lebrikizumab an anti IL-13 molecule might represent a relevant example as a potential asthma therapy. AREAS COVERED\nDiscussion of the rationale for the use of lebrikizumab in asthma.",
          "beginSection": "abstract",
          "offsetInBeginSection": 165,
          "endSection": "abstract",
          "offsetInEndSection": 530
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27554950",
          "text": "AREAS COVERED\nDiscussion of the rationale for the use of lebrikizumab in asthma. Analysis of the related preclinical and clinical data on lebrikizumab in asthma.",
          "beginSection": "abstract",
          "offsetInBeginSection": 450,
          "endSection": "abstract",
          "offsetInEndSection": 611
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32104006",
          "text": "Herein, we review the recent data on lebrikizumab, an interleukin (IL)-13 inhibitor, and its potential role in the treatment of AD.",
          "beginSection": "abstract",
          "offsetInBeginSection": 454,
          "endSection": "abstract",
          "offsetInEndSection": 585
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23055690",
          "text": "Published data on the efficacy and safety of lebrikizumab in the treatment of asthma are relatively limited.",
          "beginSection": "abstract",
          "offsetInBeginSection": 698,
          "endSection": "abstract",
          "offsetInEndSection": 806
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32104006",
          "text": "RESULTS\nTwo Phase II randomized controlled clinical trials have been conducted to evaluate the use of lebrikizumab in a total of 289 patients with moderate-severe AD and inadequate response to topical corticosteroids. Patients treated with lebrikizumab experienced significantly more improvement in their AD compared to placebo, as measured by Eczema Area and Severity Index (EASI)-50 and EASI-75 scores, pruritus scores, and reduction in body surface area (BSA).",
          "beginSection": "abstract",
          "offsetInBeginSection": 908,
          "endSection": "abstract",
          "offsetInEndSection": 1371
        }
      ],
      "ideal_answer": "",
      "exact_answer": [
        "treatment of poorly controlled asthma"
      ]
    },
    {
      "id": "662fc981187cba990d000018",
      "type": "yesno",
      "body": "Is CT colonography a cost-effective test for colorectal cancer screening?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29485322",
        "http://www.ncbi.nlm.nih.gov/pubmed/16217110",
        "http://www.ncbi.nlm.nih.gov/pubmed/23006522",
        "http://www.ncbi.nlm.nih.gov/pubmed/17156139",
        "http://www.ncbi.nlm.nih.gov/pubmed/20003555",
        "http://www.ncbi.nlm.nih.gov/pubmed/12173353",
        "http://www.ncbi.nlm.nih.gov/pubmed/19332851",
        "http://www.ncbi.nlm.nih.gov/pubmed/26350285",
        "http://www.ncbi.nlm.nih.gov/pubmed/23182509",
        "http://www.ncbi.nlm.nih.gov/pubmed/28681075"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29485322",
          "text": "Conclusion Because of the higher participation rates, CT colonography screening for colorectal cancer is more cost-effective than colonoscopy screening.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1625,
          "endSection": "abstract",
          "offsetInEndSection": 1777
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29485322",
          "text": "Conclusion Because of the higher participation rates, CT colonography screening for colorectal cancer is more cost-effective than colonoscopy screening. The implementation of CT colonography screening requires previous satisfactory resolution to the question as to how best to deal with extracolonic findings.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1625,
          "endSection": "abstract",
          "offsetInEndSection": 1934
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29485322",
          "text": "The findings were robust for most of the sensitivity analyses, except with regard to relative screening costs and subsequent participation. Conclusion Because of the higher participation rates, CT colonography screening for colorectal cancer is more cost-effective than colonoscopy screening. The implementation of CT colonography screening requires previous satisfactory resolution to the question as to how best to deal with extracolonic findings.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1485,
          "endSection": "abstract",
          "offsetInEndSection": 1934
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17156139",
          "text": "CONCLUSIONS\nCT colonography is an effective screening test for colorectal neoplasia. However, it is more expensive and generally less effective than optical colonoscopy. CT colonography can be reasonably cost-effective when the diagnostic accuracy of CT colonography is high, as with primary 3-dimensional technology, and if costs are about 60% of those of optical colonoscopy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1153,
          "endSection": "abstract",
          "offsetInEndSection": 1530
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17156139",
          "text": "BACKGROUND\nWe examined the cost-effectiveness of 2- and 3-dimensional computerized tomography (CT) colonography as a screening test for colorectal neoplasia. METHODS\nWe created a Markov model of the natural history of colorectal cancer. Effectiveness of screening was based upon the diagnostic accuracy of tests in detecting polyps and cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 345
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17156139",
          "text": "BACKGROUND\nWe examined the cost-effectiveness of 2- and 3-dimensional computerized tomography (CT) colonography as a screening test for colorectal neoplasia. METHODS\nWe created a Markov model of the natural history of colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 238
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29485322",
          "text": "Conclusion Because of the higher participation rates, CT colonography screening for colorectal cancer is more cost-effective than colonoscopy screening. The implementation of CT colonography screening requires previous satisfactory resolution to the question as to how best to deal with extracolonic findings. © RSNA, 2018 Online supplemental material is available for this article.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1625,
          "endSection": "abstract",
          "offsetInEndSection": 2007
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29485322",
          "text": "The findings were robust for most of the sensitivity analyses, except with regard to relative screening costs and subsequent participation. Conclusion Because of the higher participation rates, CT colonography screening for colorectal cancer is more cost-effective than colonoscopy screening.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1485,
          "endSection": "abstract",
          "offsetInEndSection": 1777
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17156139",
          "text": "CONCLUSIONS\nCT colonography is an effective screening test for colorectal neoplasia. However, it is more expensive and generally less effective than optical colonoscopy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1153,
          "endSection": "abstract",
          "offsetInEndSection": 1322
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29485322",
          "text": "Because of the higher participation rates, CT colonography screening for colorectal cancer is more cost-effective than colonoscopy screening",
          "beginSection": "abstract",
          "offsetInBeginSection": 1636,
          "endSection": "abstract",
          "offsetInEndSection": 1776
        }
      ],
      "ideal_answer": "Yes, CT colonography is a cost-effective test for colorectal cancer screening due to higher participation rates compared to colonoscopy screening. However, the implementation of CT colonography screening requires previous satisfactory resolution to the question as to how best to deal with extracolonic findings.",
      "exact_answer": "yes"
    },
    {
      "id": "662cf888187cba990d000002",
      "type": "yesno",
      "body": "is Cryoglobulinemic vasculitis (CV), also known as mixed cryoglobulinemic syndrome (MCS), a systemic vasculitis that affects large blood vessels.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37698547",
        "http://www.ncbi.nlm.nih.gov/pubmed/36169798",
        "http://www.ncbi.nlm.nih.gov/pubmed/33292799",
        "http://www.ncbi.nlm.nih.gov/pubmed/16344620",
        "http://www.ncbi.nlm.nih.gov/pubmed/10971876",
        "http://www.ncbi.nlm.nih.gov/pubmed/37476365",
        "http://www.ncbi.nlm.nih.gov/pubmed/29433114",
        "http://www.ncbi.nlm.nih.gov/pubmed/24852904",
        "http://www.ncbi.nlm.nih.gov/pubmed/23271426",
        "http://www.ncbi.nlm.nih.gov/pubmed/27034078"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37698547",
          "text": "INTRODUCTION\nCryoglobulinemic vasculitis (CV), also known as mixed cryoglobulinemic syndrome (MCS), is a systemic vasculitis that affects small blood vessels. It exhibits a wide range of clinical manifestations, making its treatment a continuing challenge for physicians. AREAS COVERED\nWe conducted a comprehensive review to evaluate the current status of diagnosis, management, and treatment of mixed cryoglobulinemia (MC).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 426
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37698547",
          "text": "INTRODUCTION\nCryoglobulinemic vasculitis (CV), also known as mixed cryoglobulinemic syndrome (MCS), is a systemic vasculitis that affects small blood vessels. It exhibits a wide range of clinical manifestations, making its treatment a continuing challenge for physicians.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 271
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37698547",
          "text": ": Cryoglobulinemic vasculitis (CV), also known as mixed cryoglobulinemic syndrome (MCS), is a systemic vasculitis that affects small blood vessels.",
          "beginSection": "abstract",
          "offsetInBeginSection": 12,
          "endSection": "abstract",
          "offsetInEndSection": 159
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37698547",
          "text": "INTRODUCTION\nCryoglobulinemic vasculitis (CV), also known as mixed cryoglobulinemic syndrome (MCS), is a systemic vasculitis that affects small blood vessels.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 158
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37476365",
          "text": "Mixed cryoglobulinemic vasculitis (CV) is occasionally caused by autoimmune diseases including systemic sclerosis. Multiorgan involvement such as skin, kidney, and peripheral nerve involvement is common in mixed CV. However, central nervous system (CNS) involvement is extremely rare.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 284
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37476365",
          "text": "Mixed cryoglobulinemic vasculitis (CV) is occasionally caused by autoimmune diseases including systemic sclerosis. Multiorgan involvement such as skin, kidney, and peripheral nerve involvement is common in mixed CV.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 215
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37476365",
          "text": "Mixed cryoglobulinemic vasculitis (CV) is occasionally caused by autoimmune diseases including systemic sclerosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 114
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37476365",
          "text": "Multiorgan involvement such as skin, kidney, and peripheral nerve involvement is common in mixed CV. However, central nervous system (CNS) involvement is extremely rare. Here, we report a case of overlap syndrome of limited cutaneous systemic sclerosis and mixed cryoglobulinemic vasculitis with CNS involvement.",
          "beginSection": "abstract",
          "offsetInBeginSection": 115,
          "endSection": "abstract",
          "offsetInEndSection": 427
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16344620",
          "text": "PURPOSE OF REVIEW\nCryoglobulinemic vasculitis is an immune-complex-mediated systemic vasculitis involving small-medium-sized vessels. A causative role of hepatitis C virus in over 80% patients has been definitively established, with heterogeneous geographical distribution.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 273
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16344620",
          "text": "PURPOSE OF REVIEW\nCryoglobulinemic vasculitis is an immune-complex-mediated systemic vasculitis involving small-medium-sized vessels. A causative role of hepatitis C virus in over 80% patients has been definitively established, with heterogeneous geographical distribution. This review focuses on recent etiopathogenetic, clinico-diagnostic, and therapeutical studies.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 368
        }
      ],
      "ideal_answer": "No, Cryoglobulinemic vasculitis (CV), also known as mixed cryoglobulinemic syndrome (MCS), is a systemic vasculitis that affects small blood vessels, not large blood vessels.",
      "exact_answer": "no"
    },
    {
      "id": "66155e7dfdcbea915f00004c",
      "type": "list",
      "body": "Consequences for the newborn of infection by Zika virus during pregnancy.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37458166",
        "http://www.ncbi.nlm.nih.gov/pubmed/36867568",
        "http://www.ncbi.nlm.nih.gov/pubmed/37482558",
        "http://www.ncbi.nlm.nih.gov/pubmed/37042942",
        "http://www.ncbi.nlm.nih.gov/pubmed/27079865",
        "http://www.ncbi.nlm.nih.gov/pubmed/28384133",
        "http://www.ncbi.nlm.nih.gov/pubmed/32830420",
        "http://www.ncbi.nlm.nih.gov/pubmed/29523447",
        "http://www.ncbi.nlm.nih.gov/pubmed/28578821",
        "http://www.ncbi.nlm.nih.gov/pubmed/28320497"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32830420",
          "text": "Although postnatal Zika virus infection typically causes mild or no symptoms, effects on infants born to prenatally infected mothers can be severe and include structural birth defects and neurodevelopmental effects. The risk of a structural birth defect among infants born to mothers with confirmed or suspected Zika virus infection during pregnancy has ranged from 5 to 10%. The timing of Zika infection during pregnancy affects risk, with higher risks with the first-trimester infection.",
          "beginSection": "abstract",
          "offsetInBeginSection": 581,
          "endSection": "abstract",
          "offsetInEndSection": 1070
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28578821",
          "text": "Infection by Zika virus during pregnancy can cause developmental damage to the fetus, and the altered immune response during pregnancy could contribute to disease during Zika infection.",
          "beginSection": "abstract",
          "offsetInBeginSection": 188,
          "endSection": "abstract",
          "offsetInEndSection": 373
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27079865",
          "text": "[Zika virus infection during pregnancy].",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 40
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29523447",
          "text": "Adverse outcomes of pregnancy-associated Zika virus infection.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 62
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28578821",
          "text": "Zika Virus: Mechanisms of Infection During Pregnancy.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 53
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32830420",
          "text": "The timing of Zika infection during pregnancy affects risk, with higher risks with the first-trimester infection. Neurodevelopmental effects are seen even in infants who appear normal in the newborn period. Although cases of Zika virus infection have fallen in the Americas, the Zika virus remains an active threat in some regions of the world.",
          "beginSection": "abstract",
          "offsetInBeginSection": 957,
          "endSection": "abstract",
          "offsetInEndSection": 1301
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32830420",
          "text": "The timing of Zika infection during pregnancy affects risk, with higher risks with the first-trimester infection. Neurodevelopmental effects are seen even in infants who appear normal in the newborn period.",
          "beginSection": "abstract",
          "offsetInBeginSection": 957,
          "endSection": "abstract",
          "offsetInEndSection": 1163
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32830420",
          "text": "Although postnatal Zika virus infection typically causes mild or no symptoms, effects on infants born to prenatally infected mothers can be severe and include structural birth defects and neurodevelopmental effects. The risk of a structural birth defect among infants born to mothers with confirmed or suspected Zika virus infection during pregnancy has ranged from 5 to 10%.",
          "beginSection": "abstract",
          "offsetInBeginSection": 581,
          "endSection": "abstract",
          "offsetInEndSection": 956
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28384133",
          "text": "Birth defects potentially associated with Zika virus infection during pregnancy include brain abnormalities and/or microcephaly, eye abnormalities, other consequences of central nervous system dysfunction, and neural tube defects and other early brain malformations.",
          "beginSection": "abstract",
          "offsetInBeginSection": 601,
          "endSection": "abstract",
          "offsetInEndSection": 867
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32830420",
          "text": "The risk of a structural birth defect among infants born to mothers with confirmed or suspected Zika virus infection during pregnancy has ranged from 5 to 10%. The timing of Zika infection during pregnancy affects risk, with higher risks with the first-trimester infection. Neurodevelopmental effects are seen even in infants who appear normal in the newborn period.",
          "beginSection": "abstract",
          "offsetInBeginSection": 797,
          "endSection": "abstract",
          "offsetInEndSection": 1163
        }
      ],
      "ideal_answer": "Infection by Zika virus during pregnancy can cause structural birth defects and neurodevelopmental effects in the newborn. The risk of a structural birth defect among infants born to mothers with confirmed or suspected Zika virus infection during pregnancy has ranged from 5 to 10%. The timing of Zika infection during pregnancy affects risk, with higher risks with the first-trimester infection. Neurodevelopmental effects are seen even in infants who appear normal in the newborn period.",
      "exact_answer": [
        [
          "structural birth defects"
        ],
        [
          "neurodevelopmental effects"
        ],
        [
          "microcephaly"
        ],
        [
          "eye abnormalities"
        ],
        [
          "central nervous system dysfunction"
        ]
      ]
    },
    {
      "id": "66302090187cba990d00002a",
      "type": "list",
      "body": "Which are the key transcription factors known to drive glioma progression and therapy resistance?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35409080",
        "http://www.ncbi.nlm.nih.gov/pubmed/20414333",
        "http://www.ncbi.nlm.nih.gov/pubmed/36817051",
        "http://www.ncbi.nlm.nih.gov/pubmed/37821870",
        "http://www.ncbi.nlm.nih.gov/pubmed/32573857",
        "http://www.ncbi.nlm.nih.gov/pubmed/37087499",
        "http://www.ncbi.nlm.nih.gov/pubmed/30542695",
        "http://www.ncbi.nlm.nih.gov/pubmed/29467892",
        "http://www.ncbi.nlm.nih.gov/pubmed/33720698",
        "http://www.ncbi.nlm.nih.gov/pubmed/31900920"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37087499",
          "text": "Chronic inflammation is a key driver of glioma progression as it promotes aberrant activation of inflammatory pathways such as NF-κB signalling, which drives cancer cell invasion and angiogenesis. NF-κB factors typically dimerise with its own family members, but emerging evidence of their promiscuous interactions with other oncogenic factors has been reported to promote transcription of new target genes and function.",
          "beginSection": "abstract",
          "offsetInBeginSection": 90,
          "endSection": "abstract",
          "offsetInEndSection": 510
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37087499",
          "text": "Chronic inflammation is a key driver of glioma progression as it promotes aberrant activation of inflammatory pathways such as NF-κB signalling, which drives cancer cell invasion and angiogenesis. NF-κB factors typically dimerise with its own family members, but emerging evidence of their promiscuous interactions with other oncogenic factors has been reported to promote transcription of new target genes and function. Here, we show that non-canonical NF-κB activation directly regulates p52 at the ETS1 promoter, activating its expression.",
          "beginSection": "abstract",
          "offsetInBeginSection": 90,
          "endSection": "abstract",
          "offsetInEndSection": 632
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32573857",
          "text": "Transcription factors that normally regulate neural progenitors and glial development are aberrantly coexpressed in GBM, conferring cancer stem-like properties to drive tumor progression and therapeutic resistance. However, the functional role of individual transcription factors in GBMs in vivo remains elusive.",
          "beginSection": "abstract",
          "offsetInBeginSection": 116,
          "endSection": "abstract",
          "offsetInEndSection": 428
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32573857",
          "text": "Transcription factors that normally regulate neural progenitors and glial development are aberrantly coexpressed in GBM, conferring cancer stem-like properties to drive tumor progression and therapeutic resistance.",
          "beginSection": "abstract",
          "offsetInBeginSection": 116,
          "endSection": "abstract",
          "offsetInEndSection": 330
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37087499",
          "text": "Chronic inflammation is a key driver of glioma progression as it promotes aberrant activation of inflammatory pathways such as NF-κB signalling, which drives cancer cell invasion and angiogenesis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 90,
          "endSection": "abstract",
          "offsetInEndSection": 286
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37087499",
          "text": "Gliomas are highly invasive and chemoresistant cancers, making them challenging to treat. Chronic inflammation is a key driver of glioma progression as it promotes aberrant activation of inflammatory pathways such as NF-κB signalling, which drives cancer cell invasion and angiogenesis. NF-κB factors typically dimerise with its own family members, but emerging evidence of their promiscuous interactions with other oncogenic factors has been reported to promote transcription of new target genes and function.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 510
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36817051",
          "text": "HNF4G accelerates glioma progression by facilitating NRP1 transcription.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 72
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32573857",
          "text": "Transcription factors that normally regulate neural progenitors and glial development are aberrantly coexpressed in GBM, conferring cancer stem-like properties to drive tumor progression and therapeutic resistance. However, the functional role of individual transcription factors in GBMs in vivo remains elusive. Here, we demonstrate that the basic-helix-loop-helix transcription factor ASCL1 regulates transcriptional targets that are central to GBM development, including neural stem cell and glial transcription factors, oncogenic signaling molecules, chromatin modifying genes, and cell cycle and mitotic genes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 116,
          "endSection": "abstract",
          "offsetInEndSection": 731
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37821870",
          "text": "Forkhead box transcription factors (FOXOs and FOXM1) in glioma: from molecular mechanisms to therapeutics.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 106
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37821870",
          "text": "FOXM1 and FOXOs have been recognized as crucial transcription factors in tumor cells, including glioma cells.",
          "beginSection": "abstract",
          "offsetInBeginSection": 541,
          "endSection": "abstract",
          "offsetInEndSection": 650
        }
      ],
      "ideal_answer": "NF-κB, p52, HNF4G, ASCL1, FOXM1, and FOXOs are key transcription factors known to drive glioma progression and therapy resistance.",
      "exact_answer": [
        [
          "NF-κB"
        ],
        [
          "p52"
        ],
        [
          "HNF4G"
        ],
        [
          "ASCL1"
        ],
        [
          "FOXM1"
        ],
        [
          "FOXOs"
        ]
      ]
    },
    {
      "id": "662e29f9187cba990d00000a",
      "type": "list",
      "body": "What are the genotypes of Japanese Encephalitis Virus (JEV)?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36450570",
        "http://www.ncbi.nlm.nih.gov/pubmed/25884184",
        "http://www.ncbi.nlm.nih.gov/pubmed/30207876",
        "http://www.ncbi.nlm.nih.gov/pubmed/38076463",
        "http://www.ncbi.nlm.nih.gov/pubmed/22407526",
        "http://www.ncbi.nlm.nih.gov/pubmed/27986564",
        "http://www.ncbi.nlm.nih.gov/pubmed/29487230",
        "http://www.ncbi.nlm.nih.gov/pubmed/34777278",
        "http://www.ncbi.nlm.nih.gov/pubmed/6279773",
        "http://www.ncbi.nlm.nih.gov/pubmed/18976565"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38076463",
          "text": "The Japanese encephalitis virus (JEV) is classified into five distinct genotypes, with genotypes 1 and 3 historically showing higher activity. These genotypes are the primary agents of viral encephalitis in the Asian continent. Genotypes 4 and 5 have remained silent in low-latitude tropical regions since their discovery.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 322
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38076463",
          "text": "The Japanese encephalitis virus (JEV) is classified into five distinct genotypes, with genotypes 1 and 3 historically showing higher activity. These genotypes are the primary agents of viral encephalitis in the Asian continent.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 227
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38076463",
          "text": "The Japanese encephalitis virus (JEV) is classified into five distinct genotypes, with genotypes 1 and 3 historically showing higher activity.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 142
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25884184",
          "text": "BACKGROUND\nJapanese encephalitis virus (JEV) is the etiological agent of Japanese encephalitis (JE), one of the most serious viral encephalitis worldwide. Five genotypes have been classified based on phylogenetic analysis of the viral envelope gene or the complete genome. Previous studies based on four genotypes have reported that in evolutionary terms, genotype 1 JEV is the most recent lineage.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 398
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25884184",
          "text": "BACKGROUND\nJapanese encephalitis virus (JEV) is the etiological agent of Japanese encephalitis (JE), one of the most serious viral encephalitis worldwide. Five genotypes have been classified based on phylogenetic analysis of the viral envelope gene or the complete genome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 272
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30207876",
          "text": "Japanese encephalitis virus (JEV) is a representative virus of the JEV serogroup in genus Flavivirus, family Flaviviridae. JEV is a mosquito-borne virus that causes Japanese encephalitis (JE), one of the most severe viral encephalitis diseases in the world. JEV is divided into five genotypes (G1-G5), and each genotype has its own distribution pattern.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 353
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25884184",
          "text": "Insights into the evolutionary history of Japanese encephalitis virus (JEV) based on whole-genome sequences comprising the five genotypes.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 138
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30207876",
          "text": "JEV is a mosquito-borne virus that causes Japanese encephalitis (JE), one of the most severe viral encephalitis diseases in the world. JEV is divided into five genotypes (G1-G5), and each genotype has its own distribution pattern. However, the distribution of different JEV genotypes has changed markedly in recent years.",
          "beginSection": "abstract",
          "offsetInBeginSection": 123,
          "endSection": "abstract",
          "offsetInEndSection": 444
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30207876",
          "text": "Japanese encephalitis virus (JEV) is a representative virus of the JEV serogroup in genus Flavivirus, family Flaviviridae.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 122
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30207876",
          "text": "JEV is a mosquito-borne virus that causes Japanese encephalitis (JE), one of the most severe viral encephalitis diseases in the world. JEV is divided into five genotypes (G1-G5), and each genotype has its own distribution pattern.",
          "beginSection": "abstract",
          "offsetInBeginSection": 123,
          "endSection": "abstract",
          "offsetInEndSection": 353
        }
      ],
      "ideal_answer": "The genotypes of Japanese Encephalitis Virus (JEV) are G1, G2, G3, G4, and G5.",
      "exact_answer": [
        [
          "G1"
        ],
        [
          "G2"
        ],
        [
          "G3"
        ],
        [
          "G4"
        ],
        [
          "G5"
        ]
      ]
    },
    {
      "id": "65d373151930410b13000048",
      "type": "list",
      "body": "What medication were tested in the TRICOTEL trial?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35940183",
        "http://www.ncbi.nlm.nih.gov/pubmed/37459873",
        "http://www.ncbi.nlm.nih.gov/pubmed/32535646",
        "http://www.ncbi.nlm.nih.gov/pubmed/27699179",
        "http://www.ncbi.nlm.nih.gov/pubmed/17287150",
        "http://www.ncbi.nlm.nih.gov/pubmed/28254084",
        "http://www.ncbi.nlm.nih.gov/pubmed/7246558",
        "http://www.ncbi.nlm.nih.gov/pubmed/25741871",
        "http://www.ncbi.nlm.nih.gov/pubmed/24326536",
        "http://www.ncbi.nlm.nih.gov/pubmed/19785727"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32535646",
          "text": "RESULTS\nEight thousand sixteen patients were enrolled, of whom 4902 received trial medication.",
          "beginSection": "abstract",
          "offsetInBeginSection": 865,
          "endSection": "abstract",
          "offsetInEndSection": 959
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17287150",
          "text": "To date, no other such trial has been published in which objective measures of adherence (electronic pill bottles) were used to assess the effectiveness of these behavioral interventions for hypertension. This study tested a combination of commercially-available interventions that can be easily accessed by health care providers and patients, and therefore may provide a real-world solution to the problem of non-adherence among hypertensives. The aim of the ABC Trial was to test the effectiveness of a stepped care intervention in improving both medication adherence to an antihypertensive medication regimen and BP control.",
          "beginSection": "abstract",
          "offsetInBeginSection": 282,
          "endSection": "abstract",
          "offsetInEndSection": 909
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17287150",
          "text": "This study tested a combination of commercially-available interventions that can be easily accessed by health care providers and patients, and therefore may provide a real-world solution to the problem of non-adherence among hypertensives. The aim of the ABC Trial was to test the effectiveness of a stepped care intervention in improving both medication adherence to an antihypertensive medication regimen and BP control.",
          "beginSection": "abstract",
          "offsetInBeginSection": 487,
          "endSection": "abstract",
          "offsetInEndSection": 909
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17287150",
          "text": "The aim of the ABC Trial was to test the effectiveness of a stepped care intervention in improving both medication adherence to an antihypertensive medication regimen and BP control.",
          "beginSection": "abstract",
          "offsetInBeginSection": 727,
          "endSection": "abstract",
          "offsetInEndSection": 909
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17287150",
          "text": "The aim of the ABC Trial was to test the effectiveness of a stepped care intervention in improving both medication adherence to an antihypertensive medication regimen and BP control. Step 1 of the intervention employed home Self-BP Monitoring (SBPM); at this stage, there were two arms: (1) Usual Care (UC) and (2) Intervention.",
          "beginSection": "abstract",
          "offsetInBeginSection": 727,
          "endSection": "abstract",
          "offsetInEndSection": 1055
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17287150",
          "text": "The medication Adherence and Blood Pressure Control (ABC) trial: a multi-site randomized controlled trial in a hypertensive, multi-cultural, economically disadvantaged population.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 179
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17287150",
          "text": "This study tested a combination of commercially-available interventions that can be easily accessed by health care providers and patients, and therefore may provide a real-world solution to the problem of non-adherence among hypertensives. The aim of the ABC Trial was to test the effectiveness of a stepped care intervention in improving both medication adherence to an antihypertensive medication regimen and BP control. Step 1 of the intervention employed home Self-BP Monitoring (SBPM); at this stage, there were two arms: (1) Usual Care (UC) and (2) Intervention.",
          "beginSection": "abstract",
          "offsetInBeginSection": 487,
          "endSection": "abstract",
          "offsetInEndSection": 1055
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17287150",
          "text": "The Medication Adherence and BP Control Trial (ABC Trial) is a randomized, controlled, multi-site, medication adherence and blood pressure (BP) control trial in an economically disadvantaged and multi-cultural population of hypertensive patients followed in primary care practices. To date, no other such trial has been published in which objective measures of adherence (electronic pill bottles) were used to assess the effectiveness of these behavioral interventions for hypertension. This study tested a combination of commercially-available interventions that can be easily accessed by health care providers and patients, and therefore may provide a real-world solution to the problem of non-adherence among hypertensives.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 726
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17287150",
          "text": "The Medication Adherence and BP Control Trial (ABC Trial) is a randomized, controlled, multi-site, medication adherence and blood pressure (BP) control trial in an economically disadvantaged and multi-cultural population of hypertensive patients followed in primary care practices. To date, no other such trial has been published in which objective measures of adherence (electronic pill bottles) were used to assess the effectiveness of these behavioral interventions for hypertension.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 486
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27699179",
          "text": "This trial is registered with ClinicalTrials.gov NCT01296633.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1298,
          "endSection": "abstract",
          "offsetInEndSection": 1359
        }
      ],
      "ideal_answer": "The TRICOTEL trial tested a combination of commercially-available interventions that can be easily accessed by health care providers and patients to improve medication adherence to an antihypertensive medication regimen and blood pressure control. The specific medications used in the trial are not mentioned in the context.",
      "exact_answer": []
    },
    {
      "id": "66214ff0b9f8b89d7e000006",
      "type": "list",
      "body": "What are the most frequent side effects of regorafenib?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35716310",
        "http://www.ncbi.nlm.nih.gov/pubmed/26327919",
        "http://www.ncbi.nlm.nih.gov/pubmed/26594725",
        "http://www.ncbi.nlm.nih.gov/pubmed/25907508",
        "http://www.ncbi.nlm.nih.gov/pubmed/30069758",
        "http://www.ncbi.nlm.nih.gov/pubmed/29783729",
        "http://www.ncbi.nlm.nih.gov/pubmed/24756792",
        "http://www.ncbi.nlm.nih.gov/pubmed/36076618",
        "http://www.ncbi.nlm.nih.gov/pubmed/29291014",
        "http://www.ncbi.nlm.nih.gov/pubmed/23959464"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26594725",
          "text": "Regorafenib had no impact on overall survival in a placebo-controlled trial in 199 patients, but adverse effects were frequent and serious. Symptomatic care is a more reasonable choice.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 185
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26594725",
          "text": "Regorafenib had no impact on overall survival in a placebo-controlled trial in 199 patients, but adverse effects were frequent and serious.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 139
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26594725",
          "text": "Regorafenib (Stivarga) and gastrointestinal stromal tumours after treatment failure. Radiological improvement but major adverse effects.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 136
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30069758",
          "text": "Regorafenib.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 12
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30069758",
          "text": "Regorafenib (BAY 73-4506, Stivarga®) is an oral diphenylurea multi-kinase inhibitor that targets angiogenic (VEGFR1-3, TIE2), stromal (PDGFR-β, FGFR), and oncogenic receptor tyrosine kinases (KIT, RET, and RAF).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 211
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24756792",
          "text": "Regorafenib (BAY 73-4506, Stivarga®) is an oral diphenylurea multikinase inhibitor that targets angiogenic (VEGFR1-3, TIE2), stromal (PDGFR-β, FGFR), and oncogenic receptor tyrosine kinases (KIT, RET, and RAF).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 210
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30069758",
          "text": "Regorafenib (BAY 73-4506, Stivarga®) is an oral diphenylurea multi-kinase inhibitor that targets angiogenic (VEGFR1-3, TIE2), stromal (PDGFR-β, FGFR), and oncogenic receptor tyrosine kinases (KIT, RET, and RAF). Regorafenib is the first small-molecule multi-kinase inhibitor to achieve survival benefits in metastatic colorectal cancer that has progressed after all standard therapies.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 385
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24756792",
          "text": "Consequently, regorafenib was FDA approved for this indication.",
          "beginSection": "abstract",
          "offsetInBeginSection": 384,
          "endSection": "abstract",
          "offsetInEndSection": 447
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24756792",
          "text": "Regorafenib (BAY 73-4506, Stivarga®) is an oral diphenylurea multikinase inhibitor that targets angiogenic (VEGFR1-3, TIE2), stromal (PDGFR-β, FGFR), and oncogenic receptor tyrosine kinases (KIT, RET, and RAF). Regorafenib is the first small-molecule multikinase inhibitor to achieve survival benefits in metastatic colorectal cancer that has progressed after all standard therapies.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 383
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30069758",
          "text": "Regorafenib (BAY 73-4506, Stivarga®) is an oral diphenylurea multi-kinase inhibitor that targets angiogenic (VEGFR1-3, TIE2), stromal (PDGFR-β, FGFR), and oncogenic receptor tyrosine kinases (KIT, RET, and RAF). Regorafenib is the first small-molecule multi-kinase inhibitor to achieve survival benefits in metastatic colorectal cancer that has progressed after all standard therapies. Consequently, Regorafenib was FDA approved for this indication in 2012.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 457
        }
      ],
      "ideal_answer": "The most frequent side effects of regorafenib are hand-foot skin reaction, diarrhea, fatigue, hypertension, and anorexia.",
      "exact_answer": [
        [
          "hand-foot skin reaction"
        ],
        [
          "diarrhea"
        ],
        [
          "fatigue"
        ],
        [
          "hypertension"
        ],
        [
          "anorexia"
        ]
      ]
    },
    {
      "id": "662cf8db187cba990d000003",
      "type": "yesno",
      "body": "Is Periostin a novel biomarker of TH2-driven asthma?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36753209",
        "http://www.ncbi.nlm.nih.gov/pubmed/36763690",
        "http://www.ncbi.nlm.nih.gov/pubmed/37260069",
        "http://www.ncbi.nlm.nih.gov/pubmed/24247042",
        "http://www.ncbi.nlm.nih.gov/pubmed/24759559",
        "http://www.ncbi.nlm.nih.gov/pubmed/29879994",
        "http://www.ncbi.nlm.nih.gov/pubmed/27054127",
        "http://www.ncbi.nlm.nih.gov/pubmed/31496317",
        "http://www.ncbi.nlm.nih.gov/pubmed/27582399",
        "http://www.ncbi.nlm.nih.gov/pubmed/25037608"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24247042",
          "text": "Periostin, a novel biomarker of TH2-driven asthma.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 50
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24247042",
          "text": "This review focuses on the emerging data surrounding the use of one such biomarker for T helper 2 (TH2)-driven asthma: periostin. RECENT FINDINGS\nPeriostin is an extracellular matrix protein that is induced by interleukin (IL)-4 and IL-13 in airway epithelial cells and lung fibroblasts. It has proven to be an important biomarker of TH2-associated airway inflammation and a potential predictor of airway eosinophilia.",
          "beginSection": "abstract",
          "offsetInBeginSection": 244,
          "endSection": "abstract",
          "offsetInEndSection": 664
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24247042",
          "text": "This review focuses on the emerging data surrounding the use of one such biomarker for T helper 2 (TH2)-driven asthma: periostin. RECENT FINDINGS\nPeriostin is an extracellular matrix protein that is induced by interleukin (IL)-4 and IL-13 in airway epithelial cells and lung fibroblasts.",
          "beginSection": "abstract",
          "offsetInBeginSection": 244,
          "endSection": "abstract",
          "offsetInEndSection": 533
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24247042",
          "text": "This review focuses on the emerging data surrounding the use of one such biomarker for T helper 2 (TH2)-driven asthma: periostin.",
          "beginSection": "abstract",
          "offsetInBeginSection": 244,
          "endSection": "abstract",
          "offsetInEndSection": 373
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29879994",
          "text": "Since periostin is associated with Th2 driven inflammation and inhaled corticosteroid (ICS)-response in asthma, it could function as a biomarker in COPD.",
          "beginSection": "abstract",
          "offsetInBeginSection": 116,
          "endSection": "abstract",
          "offsetInEndSection": 269
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24247042",
          "text": "Biomarkers are currently being investigated to better characterize the disease phenotypes and to identify the responders to specific targeted therapies. This review focuses on the emerging data surrounding the use of one such biomarker for T helper 2 (TH2)-driven asthma: periostin. RECENT FINDINGS\nPeriostin is an extracellular matrix protein that is induced by interleukin (IL)-4 and IL-13 in airway epithelial cells and lung fibroblasts.",
          "beginSection": "abstract",
          "offsetInBeginSection": 91,
          "endSection": "abstract",
          "offsetInEndSection": 533
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29879994",
          "text": "Although Th2 driven inflammation is present in COPD, it is not clearly elucidated which COPD patients are affected. Since periostin is associated with Th2 driven inflammation and inhaled corticosteroid (ICS)-response in asthma, it could function as a biomarker in COPD.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 269
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24247042",
          "text": "Biomarkers are currently being investigated to better characterize the disease phenotypes and to identify the responders to specific targeted therapies. This review focuses on the emerging data surrounding the use of one such biomarker for T helper 2 (TH2)-driven asthma: periostin.",
          "beginSection": "abstract",
          "offsetInBeginSection": 91,
          "endSection": "abstract",
          "offsetInEndSection": 373
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24759559",
          "text": "Serum periostin: a novel biomarker for asthma management.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 57
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27054127",
          "text": "Serum periostin is a biomarker which aid in understanding Th2 high eosinophilic asthma.",
          "beginSection": "abstract",
          "offsetInBeginSection": 154,
          "endSection": "abstract",
          "offsetInEndSection": 241
        }
      ],
      "ideal_answer": "Yes, periostin is a novel biomarker of TH2-driven asthma.",
      "exact_answer": "yes"
    },
    {
      "id": "66168a89fdcbea915f000054",
      "type": "summary",
      "body": "Burkitt lymphoma and Epstein-Barr virus.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19165855",
        "http://www.ncbi.nlm.nih.gov/pubmed/19874382",
        "http://www.ncbi.nlm.nih.gov/pubmed/37046794",
        "http://www.ncbi.nlm.nih.gov/pubmed/232190",
        "http://www.ncbi.nlm.nih.gov/pubmed/25418195",
        "http://www.ncbi.nlm.nih.gov/pubmed/8824493",
        "http://www.ncbi.nlm.nih.gov/pubmed/23747673",
        "http://www.ncbi.nlm.nih.gov/pubmed/18042696",
        "http://www.ncbi.nlm.nih.gov/pubmed/18716017",
        "http://www.ncbi.nlm.nih.gov/pubmed/24731550"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18042696",
          "text": "Epstein-Barr virus and Burkitt lymphoma.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 40
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18716017",
          "text": "Epstein-Barr virus and Burkitt lymphoma.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 40
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25418195",
          "text": "Epstein-Barr virus and Burkitt lymphoma.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 40
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24731550",
          "text": "More than 90% of endemic Burkitt lymphoma carry latent Epstein-Barr virus, whereas only 20% of sporadic Burkitt lymphoma are associated with Epstein-Barr infection. Although the Epstein-Barr virus is highly related with the endemic form, how and whether the virus participates in its pathogenesis remains to be fully elucidated.",
          "beginSection": "abstract",
          "offsetInBeginSection": 148,
          "endSection": "abstract",
          "offsetInEndSection": 476
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8824493",
          "text": "Epstein-Barr virus associated Burkitt lymphoma in a heart transplant recipient.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 79
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24731550",
          "text": "More than 90% of endemic Burkitt lymphoma carry latent Epstein-Barr virus, whereas only 20% of sporadic Burkitt lymphoma are associated with Epstein-Barr infection. Although the Epstein-Barr virus is highly related with the endemic form, how and whether the virus participates in its pathogenesis remains to be fully elucidated. In particular, the virus may impair cellular gene expression by its own encoded microRNAs.",
          "beginSection": "abstract",
          "offsetInBeginSection": 148,
          "endSection": "abstract",
          "offsetInEndSection": 567
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24731550",
          "text": "More than 90% of endemic Burkitt lymphoma carry latent Epstein-Barr virus, whereas only 20% of sporadic Burkitt lymphoma are associated with Epstein-Barr infection.",
          "beginSection": "abstract",
          "offsetInBeginSection": 148,
          "endSection": "abstract",
          "offsetInEndSection": 312
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23747673",
          "text": "The significance of Epstein-Barr virus detection in the cerebrospinal fluid of patients with Burkitt lymphoma is poorly studied.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 128
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24731550",
          "text": "BACKGROUND\nBurkitt lymphoma is an aggressive B-cell lymphoma presenting in three clinical forms: endemic, sporadic and immunodeficiency-associated. More than 90% of endemic Burkitt lymphoma carry latent Epstein-Barr virus, whereas only 20% of sporadic Burkitt lymphoma are associated with Epstein-Barr infection. Although the Epstein-Barr virus is highly related with the endemic form, how and whether the virus participates in its pathogenesis remains to be fully elucidated.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 476
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8824493",
          "text": "This report describes a case of Epstein-Barr [correction of Epstein Barr] Virus related post-transplantation B lymphoproliferative disease of unusual Burkitt lymphoma (BL) type in which combined cytotoxic agents (PACE BOM) successfully produced complete and long-term tumor remission.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 284
        }
      ],
      "ideal_answer": "Epstein-Barr virus is associated with more than 90% of endemic Burkitt lymphoma cases, but only 20% of sporadic Burkitt lymphoma cases. The virus's role in the pathogenesis of Burkitt lymphoma is not yet fully understood, but it may impair cellular gene expression.",
      "exact_answer": "n/a"
    },
    {
      "id": "663020de187cba990d00002c",
      "type": "list",
      "body": "What tumor suppressor genes are commonly affected by glioblastoma mutations or deletions?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30899826",
        "http://www.ncbi.nlm.nih.gov/pubmed/8548755",
        "http://www.ncbi.nlm.nih.gov/pubmed/18726148",
        "http://www.ncbi.nlm.nih.gov/pubmed/10079373",
        "http://www.ncbi.nlm.nih.gov/pubmed/11776785",
        "http://www.ncbi.nlm.nih.gov/pubmed/12085961",
        "http://www.ncbi.nlm.nih.gov/pubmed/25521327",
        "http://www.ncbi.nlm.nih.gov/pubmed/15820312",
        "http://www.ncbi.nlm.nih.gov/pubmed/28762582",
        "http://www.ncbi.nlm.nih.gov/pubmed/18381405"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25521327",
          "text": "In this study, to elucidate potential tumor suppressor genes involved in gastric cancer (GC), we analyzed the entire set of large homozygous deletions in six human GC cell lines through genome- and transcriptome-wide approaches. We identified 51 genes in homozygous deletion regions of chromosomes and confirmed the deletion frequency in tumor tissues of 219 GC patients from The Cancer Genome Atlas database. We evaluated the effect of homozygous deletions on the mRNA level and found significantly affected genes in chromosome bands 9p21, 3p22, 5p14, and 6q15.",
          "beginSection": "abstract",
          "offsetInBeginSection": 278,
          "endSection": "abstract",
          "offsetInEndSection": 840
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28762582",
          "text": "Tumor-suppressor genes can be inactivated by several mechanisms and, in a majority of cases, both alleles need to be affected. One of the mechanisms of inactivation is due to deletions ranging from dozen to hundreds of nucleotides; such deletions are often missed by variant callers.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 283
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25521327",
          "text": "In this study, to elucidate potential tumor suppressor genes involved in gastric cancer (GC), we analyzed the entire set of large homozygous deletions in six human GC cell lines through genome- and transcriptome-wide approaches. We identified 51 genes in homozygous deletion regions of chromosomes and confirmed the deletion frequency in tumor tissues of 219 GC patients from The Cancer Genome Atlas database.",
          "beginSection": "abstract",
          "offsetInBeginSection": 278,
          "endSection": "abstract",
          "offsetInEndSection": 687
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12085961",
          "text": "In addition to their location in a region with frequent deletion, there are functional and/or genetic evidence supporting the candidacy of these genes. Thus far PTEN is the most frequently mutated gene in prostate cancer, and KLF5 showed the most frequent hemizygous deletion and loss of expression. A tumor suppressor role has been demonstrated for NKX3.1, PTEN, and p27/Kip1 in knockout mice models.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1111,
          "endSection": "abstract",
          "offsetInEndSection": 1512
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28762582",
          "text": "Tumor-suppressor genes can be inactivated by several mechanisms and, in a majority of cases, both alleles need to be affected. One of the mechanisms of inactivation is due to deletions ranging from dozen to hundreds of nucleotides; such deletions are often missed by variant callers. HomDelDetect is a method to detect such homozygous deletions in cancer models, such as cancer cell lines and potentially patient tumor-derived xenografts.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 438
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11776785",
          "text": "[Mutations of several tumor suppressor genes in primary retinoblastoma].",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 72
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25521327",
          "text": "In this study, to elucidate potential tumor suppressor genes involved in gastric cancer (GC), we analyzed the entire set of large homozygous deletions in six human GC cell lines through genome- and transcriptome-wide approaches.",
          "beginSection": "abstract",
          "offsetInBeginSection": 278,
          "endSection": "abstract",
          "offsetInEndSection": 506
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25521327",
          "text": "In addition, we observed that homozygous focal deletions generated truncated transcripts of TGFBR2, CTNNA1, and STXBP5. Ectopic expression of two kinds of TGFBR2-reverse GADL1 fusion genes suppressed TGF-β signaling, which may lead to the loss of sensitivity to TGF-β tumor suppressive activity. In conclusion, our findings suggest that novel tumor suppressor genes that are aberrantly expressed through homozygous deletions may play important roles in gastric tumorigenesis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1066,
          "endSection": "abstract",
          "offsetInEndSection": 1541
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12085961",
          "text": "Chromosomal deletions and tumor suppressor genes in prostate cancer.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 68
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25521327",
          "text": "Homozygous deletions at 3p22, 5p14, 6q15, and 9p21 result in aberrant expression of tumor suppressor genes in gastric cancer.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 125
        }
      ],
      "ideal_answer": "PTEN, KLF5, NKX3.1, p27/Kip1, TGFBR2, CTNNA1, and STXBP5 are commonly affected tumor suppressor genes in glioblastoma.",
      "exact_answer": [
        [
          "PTEN"
        ],
        [
          "KLF5"
        ],
        [
          "NKX3.1"
        ],
        [
          "p27/Kip1"
        ],
        [
          "TGFBR2"
        ],
        [
          "CTNNA1"
        ],
        [
          "STXBP5"
        ]
      ]
    },
    {
      "id": "6630211d187cba990d00002d",
      "type": "yesno",
      "body": "Is there an association between specific genotypes and the risk of ASD for Duchenne Muscular Dystrophy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36565132",
        "http://www.ncbi.nlm.nih.gov/pubmed/16417872",
        "http://www.ncbi.nlm.nih.gov/pubmed/2730379",
        "http://www.ncbi.nlm.nih.gov/pubmed/32571459",
        "http://www.ncbi.nlm.nih.gov/pubmed/34677095",
        "http://www.ncbi.nlm.nih.gov/pubmed/11929208",
        "http://www.ncbi.nlm.nih.gov/pubmed/8128406",
        "http://www.ncbi.nlm.nih.gov/pubmed/7454431",
        "http://www.ncbi.nlm.nih.gov/pubmed/1994843",
        "http://www.ncbi.nlm.nih.gov/pubmed/7322666"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16417872",
          "text": "We rejected the hypothesis that Duchenne muscular dystrophy and autism spectrum disorder co-occurrence was likely to be explained by chance (P = .006). We identify a previously unrecognized association of Duchenne muscular dystrophy with autism spectrum disorder. Further work might elucidate the level of association between these two conditions, either at the genetic or at the protein level, and might clarify, at least partially, the neurobiologic mechanisms associated with autism spectrum disorder.",
          "beginSection": "abstract",
          "offsetInBeginSection": 770,
          "endSection": "abstract",
          "offsetInEndSection": 1274
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16417872",
          "text": "We identify a previously unrecognized association of Duchenne muscular dystrophy with autism spectrum disorder. Further work might elucidate the level of association between these two conditions, either at the genetic or at the protein level, and might clarify, at least partially, the neurobiologic mechanisms associated with autism spectrum disorder.",
          "beginSection": "abstract",
          "offsetInBeginSection": 922,
          "endSection": "abstract",
          "offsetInEndSection": 1274
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16417872",
          "text": "We rejected the hypothesis that Duchenne muscular dystrophy and autism spectrum disorder co-occurrence was likely to be explained by chance (P = .006). We identify a previously unrecognized association of Duchenne muscular dystrophy with autism spectrum disorder.",
          "beginSection": "abstract",
          "offsetInBeginSection": 770,
          "endSection": "abstract",
          "offsetInEndSection": 1033
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16417872",
          "text": "We identify a previously unrecognized association of Duchenne muscular dystrophy with autism spectrum disorder.",
          "beginSection": "abstract",
          "offsetInBeginSection": 922,
          "endSection": "abstract",
          "offsetInEndSection": 1033
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34677095",
          "text": "The adjusted risk of receiving any respiratory intervention among preterm males with Duchenne muscular dystrophy was 87% higher than among the corresponding full-term males with Duchenne muscular dystrophy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 452,
          "endSection": "abstract",
          "offsetInEndSection": 658
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16417872",
          "text": "Association of Duchenne muscular dystrophy with autism spectrum disorder.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 73
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34677095",
          "text": "The adjusted risk of receiving any respiratory intervention among preterm males with Duchenne muscular dystrophy was 87% higher than among the corresponding full-term males with Duchenne muscular dystrophy. The adjusted risks for ambulation cessation and left ventricular dysfunction were modestly elevated among preterm compared to full-term males, but the 95% confidence intervals contained the null.",
          "beginSection": "abstract",
          "offsetInBeginSection": 452,
          "endSection": "abstract",
          "offsetInEndSection": 854
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16417872",
          "text": "We rejected the hypothesis that Duchenne muscular dystrophy and autism spectrum disorder co-occurrence was likely to be explained by chance (P = .006).",
          "beginSection": "abstract",
          "offsetInBeginSection": 770,
          "endSection": "abstract",
          "offsetInEndSection": 921
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11929208",
          "text": "Duchenne muscular dystrophy is an X-linked disease of muscle caused by an absence of the protein dystrophin.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 108
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34677095",
          "text": "The adjusted risk of receiving any respiratory intervention among preterm males with Duchenne muscular dystrophy was 87% higher than among the corresponding full-term males with Duchenne muscular dystrophy. The adjusted risks for ambulation cessation and left ventricular dysfunction were modestly elevated among preterm compared to full-term males, but the 95% confidence intervals contained the null. No difference in the start of corticosteroid use between preterm and full-term Duchenne muscular dystrophy males was observed.",
          "beginSection": "abstract",
          "offsetInBeginSection": 452,
          "endSection": "abstract",
          "offsetInEndSection": 981
        }
      ],
      "ideal_answer": "Yes, there is an association between specific genotypes and the risk of ASD for Duchenne Muscular Dystrophy.",
      "exact_answer": "yes"
    },
    {
      "id": "65d144b81930410b13000041",
      "type": "factoid",
      "body": "Coffee Bean Sign is characteristic to which disease?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36263824",
        "http://www.ncbi.nlm.nih.gov/pubmed/35859918",
        "http://www.ncbi.nlm.nih.gov/pubmed/37761402",
        "http://www.ncbi.nlm.nih.gov/pubmed/35773776",
        "http://www.ncbi.nlm.nih.gov/pubmed/36779459",
        "http://www.ncbi.nlm.nih.gov/pubmed/36168370",
        "http://www.ncbi.nlm.nih.gov/pubmed/33088563",
        "http://www.ncbi.nlm.nih.gov/pubmed/3302307",
        "http://www.ncbi.nlm.nih.gov/pubmed/18322966",
        "http://www.ncbi.nlm.nih.gov/pubmed/23606585"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33088563",
          "text": "The presence of the coffee bean sign is pathognomonic of sigmoid volvulus.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 74
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36263824",
          "text": "A 66-year-old man presented with abdominal distension. A plain radiograph showed the coffee bean sign, suggesting sigmoid volvulus (SV).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 136
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23606585",
          "text": "The sonographic \"coffee bean\" sign helps distinguish an axillary neurofibroma from a lymphadenopathy.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 101
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3302307",
          "text": "The \"coffee bean\" sign in periappendiceal and peridiverticular abscess.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 71
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33088563",
          "text": "Coffee bean sign: Its meaning and importance.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 45
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36263824",
          "text": "A plain radiograph showed the coffee bean sign, suggesting sigmoid volvulus (SV).",
          "beginSection": "abstract",
          "offsetInBeginSection": 55,
          "endSection": "abstract",
          "offsetInEndSection": 136
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36263824",
          "text": "A 66-year-old man presented with abdominal distension. A plain radiograph showed the coffee bean sign, suggesting sigmoid volvulus (SV). The CT scans disclosed the steel pan sign, the whirl sign, and the beak-shaped transition point, confirming SV.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 248
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37761402",
          "text": "Common symptoms and clinical signs were abdominal pain (85%), distension (85%), tenderness (54%) and vomiting (59%). Signs of peritonitis were present in 14% and indicated a gangrenous sigmoid (X2 = 45.33; p < 0.001). A total of 183 had abdominal radiographs, and 65% showed a positive 'coffee-bean-sign'.",
          "beginSection": "abstract",
          "offsetInBeginSection": 440,
          "endSection": "abstract",
          "offsetInEndSection": 745
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18322966",
          "text": "Such nonspecific prenatal radiological signs and a low index of suspicion of a volvulus during gestation might delay appropriate surgical management and result in ischemic necrosis of the bowel. Preterm labor, specific prenatal sonographic findings (for example, the coffee bean sign) and bluish discoloration of the abdominal wall could suggest intrauterine midgut volvulus requiring prompt surgical intervention.",
          "beginSection": "abstract",
          "offsetInBeginSection": 641,
          "endSection": "abstract",
          "offsetInEndSection": 1055
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36263824",
          "text": "A plain radiograph showed the coffee bean sign, suggesting sigmoid volvulus (SV). The CT scans disclosed the steel pan sign, the whirl sign, and the beak-shaped transition point, confirming SV.",
          "beginSection": "abstract",
          "offsetInBeginSection": 55,
          "endSection": "abstract",
          "offsetInEndSection": 248
        }
      ],
      "ideal_answer": "Sigmoid volvulus is the disease that is characteristic to the Coffee Bean Sign.",
      "exact_answer": [
        "sigmoid volvulus"
      ]
    },
    {
      "id": "662fc351187cba990d000014",
      "type": "summary",
      "body": "What role does epiregulin and amphiregulin play in the use of EGFR inhibitors for colorectal cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/17664471",
        "http://www.ncbi.nlm.nih.gov/pubmed/33888518",
        "http://www.ncbi.nlm.nih.gov/pubmed/30252132",
        "http://www.ncbi.nlm.nih.gov/pubmed/27344184",
        "http://www.ncbi.nlm.nih.gov/pubmed/23885463",
        "http://www.ncbi.nlm.nih.gov/pubmed/31519572",
        "http://www.ncbi.nlm.nih.gov/pubmed/16865236",
        "http://www.ncbi.nlm.nih.gov/pubmed/25675253",
        "http://www.ncbi.nlm.nih.gov/pubmed/22409860",
        "http://www.ncbi.nlm.nih.gov/pubmed/23959273"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27344184",
          "text": "Epidermal growth factor receptor (EGFR) and its ligands amphiregulin (AREG) and epiregulin (EREG) play a central role in the development of colorectal cancer, but the prognostic values of AREG and EREG are controversial.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 220
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27344184",
          "text": "Epidermal growth factor receptor (EGFR) and its ligands amphiregulin (AREG) and epiregulin (EREG) play a central role in the development of colorectal cancer, but the prognostic values of AREG and EREG are controversial. We conducted a meta-analysis of studies that investigated AREG and/or EREG mRNA levels in primary tumors to determine their prognostic value in metastatic colorectal cancer (mCRC).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 401
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27344184",
          "text": "Epidermal growth factor receptor (EGFR) and its ligands amphiregulin (AREG) and epiregulin (EREG) play a central role in the development of colorectal cancer, but the prognostic values of AREG and EREG are controversial. We conducted a meta-analysis of studies that investigated AREG and/or EREG mRNA levels in primary tumors to determine their prognostic value in metastatic colorectal cancer (mCRC). In addition, RAS status was assessed.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 439
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30252132",
          "text": "Expression of the epidermal growth factor ligands amphiregulin (AREG) and epiregulin (EREG) is positively correlated with a response to EGFR-targeted therapies in colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 181
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23885463",
          "text": "The proteins Amphiregulin and Epiregulin belong to the Epidermal growth factors family (EGF, that act through the EGFR. Over-expression of these proteins has been seen in a variety of malignancies and non-malignant pathologies. These proteins can be detected in samples from colorectal malignancies and inflammatory bowel disease by immunohistochemical staining.",
          "beginSection": "abstract",
          "offsetInBeginSection": 503,
          "endSection": "abstract",
          "offsetInEndSection": 865
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30252132",
          "text": "Expression of the epidermal growth factor ligands amphiregulin (AREG) and epiregulin (EREG) is positively correlated with a response to EGFR-targeted therapies in colorectal cancer. Gene-body methylation sites, which show a strong inverse correlation with AREG and EREG gene expression, were identified in cell lines using targeted 454 FLX-bisulfite sequencing and SIRPH analyses for AREG/EREG promoters and intragenic CpGs.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 424
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30252132",
          "text": "Epigenetic regulation of Amphiregulin and Epiregulin in colorectal cancer.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 74
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30252132",
          "text": "Expression of the epidermal growth factor ligands amphiregulin (AREG) and epiregulin (EREG) is positively correlated with a response to EGFR-targeted therapies in colorectal cancer. Gene-body methylation sites, which show a strong inverse correlation with AREG and EREG gene expression, were identified in cell lines using targeted 454 FLX-bisulfite sequencing and SIRPH analyses for AREG/EREG promoters and intragenic CpGs. Upon treatment of colorectal cancer cells with 5-aza-2'-desoxycytidine, methylation decreases at specific intragenic CpGs accompanied by upregulation of AREG and EREG gene expression.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 608
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23885463",
          "text": "Correlation has been found between the presence of mutations in the K-ras gene and resistance to treatment with Cetuximab.New guidelines require K-ras mutation analysis before anti-EGFR treatment is provided. The proteins Amphiregulin and Epiregulin belong to the Epidermal growth factors family (EGF, that act through the EGFR. Over-expression of these proteins has been seen in a variety of malignancies and non-malignant pathologies.",
          "beginSection": "abstract",
          "offsetInBeginSection": 294,
          "endSection": "abstract",
          "offsetInEndSection": 730
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31519572",
          "text": "BACKGROUND/AIM\nAmphiregulin (AREG) and epiregulin (EREG) mRNA expression levels are predictors of response to anti-EGFR antibody therapy. Left-sided colon cancer is more sensitive to anti-EGFR antibodies than right-sided, although the mechanism is unclear.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 256
        }
      ],
      "ideal_answer": "Epiregulin and amphiregulin are ligands of the epidermal growth factor receptor (EGFR) that play a central role in the development of colorectal cancer. They are positively correlated with a response to EGFR-targeted therapies in colorectal cancer. However, their prognostic value is controversial and their expression may be influenced by gene-body methylation and 5-aza-2'-desoxycytidine treatment.",
      "exact_answer": "n/a"
    },
    {
      "id": "662cfc88187cba990d000008",
      "type": "factoid",
      "body": "What process does tRNA nucleotidyl transferase 1 (TRNT1)  catalyze?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25652405",
        "http://www.ncbi.nlm.nih.gov/pubmed/37239403",
        "http://www.ncbi.nlm.nih.gov/pubmed/36121781",
        "http://www.ncbi.nlm.nih.gov/pubmed/179457",
        "http://www.ncbi.nlm.nih.gov/pubmed/884105",
        "http://www.ncbi.nlm.nih.gov/pubmed/28390992",
        "http://www.ncbi.nlm.nih.gov/pubmed/30758723",
        "http://www.ncbi.nlm.nih.gov/pubmed/32471101",
        "http://www.ncbi.nlm.nih.gov/pubmed/27370603",
        "http://www.ncbi.nlm.nih.gov/pubmed/1774153"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32471101",
          "text": "tRNA nucleotidyl transferase 1 (TRNT1) is an essential enzyme catalyzing the addition of terminal cytosine-cytosine-adenosine (CCA) trinucleotides to all mature tRNAs, which is necessary for aminoacylation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 206
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32471101",
          "text": "tRNA nucleotidyl transferase 1 (TRNT1) is an essential enzyme catalyzing the addition of terminal cytosine-cytosine-adenosine (CCA) trinucleotides to all mature tRNAs, which is necessary for aminoacylation. It was recently discovered that partial loss-of-function mutations in TRNT1 are associated with various, seemingly unrelated human diseases including sideroblastic anemia with B-cell immunodeficiency, periodic fevers and developmental delay (SIFD), retinitis pigmentosa with erythrocyte microcytosis, and progressive B-cell immunodeficiency.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 548
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32471101",
          "text": "tRNA nucleotidyl transferase 1 (TRNT1) is an essential enzyme catalyzing the addition of terminal cytosine-cytosine-adenosine (CCA) trinucleotides to all mature tRNAs, which is necessary for aminoacylation. It was recently discovered that partial loss-of-function mutations in TRNT1 are associated with various, seemingly unrelated human diseases including sideroblastic anemia with B-cell immunodeficiency, periodic fevers and developmental delay (SIFD), retinitis pigmentosa with erythrocyte microcytosis, and progressive B-cell immunodeficiency. In addition, even within the same disease, the severity and range of the symptoms vary greatly, suggesting a broad, pleiotropic impact of imparting TRNT1 function on diverse cellular systems.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 740
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25652405",
          "text": "Addition of the trinucleotide cytosine/cytosine/adenine (CCA) to the 3' end of transfer RNAs (tRNAs) is essential for translation and is catalyzed by the enzyme TRNT1 (tRNA nucleotidyl transferase), which functions in both the cytoplasm and mitochondria. Exome sequencing revealed TRNT1 mutations in two unrelated subjects with different clinical features.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 356
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25652405",
          "text": "Addition of the trinucleotide cytosine/cytosine/adenine (CCA) to the 3' end of transfer RNAs (tRNAs) is essential for translation and is catalyzed by the enzyme TRNT1 (tRNA nucleotidyl transferase), which functions in both the cytoplasm and mitochondria.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 254
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25652405",
          "text": "Addition of the trinucleotide cytosine/cytosine/adenine (CCA) to the 3' end of transfer RNAs (tRNAs) is essential for translation and is catalyzed by the enzyme TRNT1 (tRNA nucleotidyl transferase), which functions in both the cytoplasm and mitochondria. ",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 255
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/884105",
          "text": "The enzyme tRNA nucleotidyl transferase (EC 2.7.7.25) has been highly purified from whole adult houseflies.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 107
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/179457",
          "text": "This incorporation is catalyzed by E. coli and yeast tRNA nucleotidyl transferases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 81,
          "endSection": "abstract",
          "offsetInEndSection": 164
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/884105",
          "text": "The enzyme tRNA nucleotidyl transferase (EC 2.7.7.25) has been highly purified from whole adult houseflies. A molecular weight of 30 000 has been determined.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 157
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/884105",
          "text": "The enzyme tRNA nucleotidyl transferase (EC 2.7.7.25) has been highly purified from whole adult houseflies. A molecular weight of 30 000 has been determined. The enzyme requires Mg2+ and tRNA deprived of the 3' terminal sequence CCA for activity in the incorporation of AMP and CMP onto the tRNA.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 296
        }
      ],
      "ideal_answer": "tRNA nucleotidyl transferase 1 (TRNT1) catalyzes the addition of terminal cytosine-cytosine-adenosine (CCA) trinucleotides to all mature tRNAs, which is necessary for aminoacylation.",
      "exact_answer": [
        ""
      ]
    },
    {
      "id": "6614f810fdcbea915f000043",
      "type": "list",
      "body": "What are the causes for heart and lung transplantation in children?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34991964",
        "http://www.ncbi.nlm.nih.gov/pubmed/33849770",
        "http://www.ncbi.nlm.nih.gov/pubmed/32067330",
        "http://www.ncbi.nlm.nih.gov/pubmed/8344042",
        "http://www.ncbi.nlm.nih.gov/pubmed/2624781",
        "http://www.ncbi.nlm.nih.gov/pubmed/16815380",
        "http://www.ncbi.nlm.nih.gov/pubmed/3150119",
        "http://www.ncbi.nlm.nih.gov/pubmed/20216165",
        "http://www.ncbi.nlm.nih.gov/pubmed/2056404",
        "http://www.ncbi.nlm.nih.gov/pubmed/8843521"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20216165",
          "text": "This is a review of the current literature and our own experience with lung and heart-lung transplantation for children with pulmonary hypertension of a variety of causes. I reviewed the pertinent literature and our lung transplant database to acquire information and data regarding this subject. The patients include those at St. Louis Children's Hospital as well as those reported from other institutions.",
          "beginSection": "abstract",
          "offsetInBeginSection": 116,
          "endSection": "abstract",
          "offsetInEndSection": 523
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3150119",
          "text": "Heart-lung transplantation is usually performed in children for heart disease (congenital cardiopathies with left-right shunt); pulmonary or cardio-pulmonary lesions are less frequent indications. Factors that limit that type of surgery are the small number of suitable donors, the need for a favourable social and familial environment and certain ethical problems.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 365
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16815380",
          "text": "Heart and lung transplantation in children.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 43
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2624781",
          "text": "Heart- and heart-lung transplantation in children.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 50
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3150119",
          "text": "[Heart-lung transplantation in children].",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 41
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3150119",
          "text": "Heart-lung transplantation is usually performed in children for heart disease (congenital cardiopathies with left-right shunt); pulmonary or cardio-pulmonary lesions are less frequent indications.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 196
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20216165",
          "text": "Lung and heart-lung transplantation are accepted treatments for children with end-stage pulmonary vascular disease. This is a review of the current literature and our own experience with lung and heart-lung transplantation for children with pulmonary hypertension of a variety of causes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 287
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20216165",
          "text": "This is a review of the current literature and our own experience with lung and heart-lung transplantation for children with pulmonary hypertension of a variety of causes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 116,
          "endSection": "abstract",
          "offsetInEndSection": 287
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8344042",
          "text": "Heart, heart-lung, and lung transplantation have become accepted modalities for treatment in children with serious cardiopulmonary disease. Although early deaths secondary to infection and/or acute rejection have been reduced dramatically, there is still an early mortality related to cardiac complications and a late mortality related to rejection and infection.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 363
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20216165",
          "text": "Lung and heart-lung transplantation are accepted treatments for children with end-stage pulmonary vascular disease. This is a review of the current literature and our own experience with lung and heart-lung transplantation for children with pulmonary hypertension of a variety of causes. I reviewed the pertinent literature and our lung transplant database to acquire information and data regarding this subject.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 412
        }
      ],
      "ideal_answer": "The causes for heart and lung transplantation in children include congenital cardiopathies with left-right shunt, pulmonary hypertension, and end-stage pulmonary vascular disease.",
      "exact_answer": [
        [
          "congenital cardiopathies with left-right shunt"
        ],
        [
          "pulmonary hypertension"
        ],
        [
          "end-stage pulmonary vascular disease"
        ]
      ]
    },
    {
      "id": "662edc6f187cba990d00000c",
      "type": "yesno",
      "body": "Can enhancer-promoter interactions form independently of genomic distance?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38084924",
        "http://www.ncbi.nlm.nih.gov/pubmed/25340767",
        "http://www.ncbi.nlm.nih.gov/pubmed/37430091",
        "http://www.ncbi.nlm.nih.gov/pubmed/28881991",
        "http://www.ncbi.nlm.nih.gov/pubmed/35418676",
        "http://www.ncbi.nlm.nih.gov/pubmed/27064255",
        "http://www.ncbi.nlm.nih.gov/pubmed/31514731",
        "http://www.ncbi.nlm.nih.gov/pubmed/19923429",
        "http://www.ncbi.nlm.nih.gov/pubmed/28461980",
        "http://www.ncbi.nlm.nih.gov/pubmed/34246183"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38084924",
          "text": "Enhancer-promoter interactions can form independently of genomic distance and be functional across TAD boundaries",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 113
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38084924",
          "text": "Enhancer-promoter interactions can form independently of genomic distance and be functional across TAD boundaries.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 114
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38084924",
          "text": "Furthermore, contrary to intra-TAD interactions, the formation of inter-TAD enhancer-promoter interactions is not solely driven by genomic distance, with distal interactions sometimes favored over proximal ones. These observations suggest that other general mechanisms must exist to establish and maintain specific enhancer-promoter interactions across large distances.",
          "beginSection": "abstract",
          "offsetInBeginSection": 827,
          "endSection": "abstract",
          "offsetInEndSection": 1196
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38084924",
          "text": "Furthermore, contrary to intra-TAD interactions, the formation of inter-TAD enhancer-promoter interactions is not solely driven by genomic distance, with distal interactions sometimes favored over proximal ones.",
          "beginSection": "abstract",
          "offsetInBeginSection": 827,
          "endSection": "abstract",
          "offsetInEndSection": 1038
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38084924",
          "text": "While this developmental gene can establish inter-TAD interactions with its enhancer, the functionality of these interactions remains limited, highlighting the existence of topological constraints. Furthermore, contrary to intra-TAD interactions, the formation of inter-TAD enhancer-promoter interactions is not solely driven by genomic distance, with distal interactions sometimes favored over proximal ones. These observations suggest that other general mechanisms must exist to establish and maintain specific enhancer-promoter interactions across large distances.",
          "beginSection": "abstract",
          "offsetInBeginSection": 629,
          "endSection": "abstract",
          "offsetInEndSection": 1196
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28881991",
          "text": "MOTIVATION\nA large number of distal enhancers and proximal promoters form enhancer-promoter interactions to regulate target genes in the human genome. Although recent high-throughput genome-wide mapping approaches have allowed us to more comprehensively recognize potential enhancer-promoter interactions, it is still largely unknown whether sequence-based features alone are sufficient to predict such interactions. RESULTS\nHere, we develop a new computational method (named PEP) to predict enhancer-promoter interactions based on sequence-based features only, when the locations of putative enhancers and promoters in a particular cell type are given.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 655
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28881991",
          "text": "MOTIVATION\nA large number of distal enhancers and proximal promoters form enhancer-promoter interactions to regulate target genes in the human genome. Although recent high-throughput genome-wide mapping approaches have allowed us to more comprehensively recognize potential enhancer-promoter interactions, it is still largely unknown whether sequence-based features alone are sufficient to predict such interactions.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 416
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37430091",
          "text": "How enhancers control target gene expression over long genomic distances remains an important unsolved problem. Here we investigated enhancer-promoter communication by integrating data from nucleosome-resolution genomic contact maps, nascent transcription and perturbations affecting either RNA polymerase II (Pol II) dynamics or the activity of thousands of candidate enhancers. Integration of new Micro-C experiments with published CRISPRi data demonstrated that enhancers spend more time in close proximity to their target promoters in functional enhancer-promoter pairs compared to nonfunctional pairs, which can be attributed in part to factors unrelated to genomic position.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 680
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38084924",
          "text": "While this developmental gene can establish inter-TAD interactions with its enhancer, the functionality of these interactions remains limited, highlighting the existence of topological constraints. Furthermore, contrary to intra-TAD interactions, the formation of inter-TAD enhancer-promoter interactions is not solely driven by genomic distance, with distal interactions sometimes favored over proximal ones.",
          "beginSection": "abstract",
          "offsetInBeginSection": 629,
          "endSection": "abstract",
          "offsetInEndSection": 1038
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28881991",
          "text": "The results across six different cell types demonstrate that our method is effective in predicting enhancer-promoter interactions as compared to the state-of-the-art methods that use functional genomic signals. Our work demonstrates that sequence-based features alone can reliably predict enhancer-promoter interactions genome-wide, which could potentially facilitate the discovery of important sequence determinants for long-range gene regulation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 805,
          "endSection": "abstract",
          "offsetInEndSection": 1253
        }
      ],
      "ideal_answer": "Yes, enhancer-promoter interactions can form independently of genomic distance.",
      "exact_answer": "yes"
    },
    {
      "id": "66300d3e187cba990d00001b",
      "type": "factoid",
      "body": "What is the prevalence of intellectual developmental disorders in Becker Muscular Dystrophy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36440509",
        "http://www.ncbi.nlm.nih.gov/pubmed/1673177",
        "http://www.ncbi.nlm.nih.gov/pubmed/18056690",
        "http://www.ncbi.nlm.nih.gov/pubmed/3993293",
        "http://www.ncbi.nlm.nih.gov/pubmed/34782199",
        "http://www.ncbi.nlm.nih.gov/pubmed/37968431",
        "http://www.ncbi.nlm.nih.gov/pubmed/1389764",
        "http://www.ncbi.nlm.nih.gov/pubmed/7485232",
        "http://www.ncbi.nlm.nih.gov/pubmed/7194435",
        "http://www.ncbi.nlm.nih.gov/pubmed/15269471"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18056690",
          "text": "Males with Becker muscular dystrophy have a high incidence of learning difficulties. Autism and behavioral and attention problems are also more common in Becker muscular dystrophy than in the general population.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1803,
          "endSection": "abstract",
          "offsetInEndSection": 2014
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1673177",
          "text": "Prevalence and incidence of Becker muscular dystrophy.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 54
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18056690",
          "text": "The frequency of total behavioral problems in the clinical range was 67%, and the frequency of autism was 8.3%. Patients with Becker muscular dystrophy demonstrate a less homogeneous cognitive phenotype than that seen in Duchenne muscular dystrophy. Males with Becker muscular dystrophy have a high incidence of learning difficulties.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1553,
          "endSection": "abstract",
          "offsetInEndSection": 1887
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34782199",
          "text": "BACKGROUND\nDevelopmental disorders associated with Becker muscular dystrophy (BMD), possibly resulting from a lack of dystrophin in the brain, have been reported, but their importance is not fully understood. We report a case of a BMD patient who had been socially withdrawn due to mental retardation and autism spectrum disorder and could not receive appropriate medical services, resulting in delayed detection of severe cardiomyopathy and embolic strokes which developed as complications of BMD.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 498
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34782199",
          "text": "BACKGROUND\nDevelopmental disorders associated with Becker muscular dystrophy (BMD), possibly resulting from a lack of dystrophin in the brain, have been reported, but their importance is not fully understood. We report a case of a BMD patient who had been socially withdrawn due to mental retardation and autism spectrum disorder and could not receive appropriate medical services, resulting in delayed detection of severe cardiomyopathy and embolic strokes which developed as complications of BMD. CASE REPORT\nThe case is a 41-year-old male.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 544
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18056690",
          "text": "Patients with Becker muscular dystrophy demonstrate a less homogeneous cognitive phenotype than that seen in Duchenne muscular dystrophy. Males with Becker muscular dystrophy have a high incidence of learning difficulties. Autism and behavioral and attention problems are also more common in Becker muscular dystrophy than in the general population.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1665,
          "endSection": "abstract",
          "offsetInEndSection": 2014
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34782199",
          "text": "BACKGROUND\nDevelopmental disorders associated with Becker muscular dystrophy (BMD), possibly resulting from a lack of dystrophin in the brain, have been reported, but their importance is not fully understood.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 208
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1673177",
          "text": "73 patients alive and resident in the Northern Health Region were identified, giving a prevalence rate of 2.38/100,000. This compares with a prevalence of Duchenne muscular dystrophy of 2.48/100,000. The cumulative birth incidence of Becker muscular dystrophy (at least 1 in 18 450 male live births) was about one third that of Duchenne muscular dystrophy (1 in 5618 male live births), suggesting that the disorder is more common than previously thought.",
          "beginSection": "abstract",
          "offsetInBeginSection": 501,
          "endSection": "abstract",
          "offsetInEndSection": 955
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18056690",
          "text": "Autism and behavioral and attention problems are also more common in Becker muscular dystrophy than in the general population.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1888,
          "endSection": "abstract",
          "offsetInEndSection": 2014
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1673177",
          "text": "This compares with a prevalence of Duchenne muscular dystrophy of 2.48/100,000. The cumulative birth incidence of Becker muscular dystrophy (at least 1 in 18 450 male live births) was about one third that of Duchenne muscular dystrophy (1 in 5618 male live births), suggesting that the disorder is more common than previously thought.",
          "beginSection": "abstract",
          "offsetInBeginSection": 621,
          "endSection": "abstract",
          "offsetInEndSection": 955
        }
      ],
      "ideal_answer": "The prevalence of intellectual developmental disorders in Becker Muscular Dystrophy is high, with 67% of patients having total behavioral problems in the clinical range and 8.3% having autism. The cumulative birth incidence of Becker Muscular Dystrophy is about one third that of Duchenne Muscular Dystrophy, suggesting that the disorder is more common than previously thought.",
      "exact_answer": [
        "high incidence"
      ]
    },
    {
      "id": "65cfdf1c1930410b13000028",
      "type": "factoid",
      "body": "Mutation of which gene was implicated in Disabling pansclerotic morphea?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37256972",
        "http://www.ncbi.nlm.nih.gov/pubmed/16021158",
        "http://www.ncbi.nlm.nih.gov/pubmed/7356347",
        "http://www.ncbi.nlm.nih.gov/pubmed/20108512",
        "http://www.ncbi.nlm.nih.gov/pubmed/24891683",
        "http://www.ncbi.nlm.nih.gov/pubmed/23716826",
        "http://www.ncbi.nlm.nih.gov/pubmed/28543434",
        "http://www.ncbi.nlm.nih.gov/pubmed/11843172",
        "http://www.ncbi.nlm.nih.gov/pubmed/19250408",
        "http://www.ncbi.nlm.nih.gov/pubmed/6372700"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28543434",
          "text": "Disabling pansclerotic morphea of childhood (DPMC) is a rare disorder that confers a risk of developing ulcer-related squamous cell carcinoma (SCC).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 148
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28543434",
          "text": "Disabling pansclerotic morphea of childhood (DPMC) is a rare disorder that confers a risk of developing ulcer-related squamous cell carcinoma (SCC). We describe a young man with long-standing DPMC and SCC with lung metastasis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 226
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11843172",
          "text": "Disabling pansclerotic morphea of childhood and hypogammaglobulinemia: a curious association.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 93
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7356347",
          "text": "Disabling pansclerotic morphea of children.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 43
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7356347",
          "text": "Laboratory data were characterized by a polyclonal elevation of gamma-globulin level and by peripheral eosinophilia. Pulmonary changes in five patients and esophageal changes in one imply that acral pansclerotic morphea may be assoicated with mild nonprogressive visceral change. Although cyclophosphamide may retard the process, no satisfactory treatment for progressive, mutilating acral pansclerotic morphea has been found.",
          "beginSection": "abstract",
          "offsetInBeginSection": 311,
          "endSection": "abstract",
          "offsetInEndSection": 737
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16021158",
          "text": "We describe adult-onset disabling pansclerotic morphea in two previously healthy young men. In both cases, the onset of disease was explosive, with rapid progression, widespread cutaneous involvement, and severe disablement caused by mutilating contracture deformities.",
          "beginSection": "abstract",
          "offsetInBeginSection": 290,
          "endSection": "abstract",
          "offsetInEndSection": 559
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7356347",
          "text": "Although cyclophosphamide may retard the process, no satisfactory treatment for progressive, mutilating acral pansclerotic morphea has been found.",
          "beginSection": "abstract",
          "offsetInBeginSection": 591,
          "endSection": "abstract",
          "offsetInEndSection": 737
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24891683",
          "text": "Adult-onset unilateral disabling pansclerotic morphea.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 54
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16021158",
          "text": "We describe adult-onset disabling pansclerotic morphea in two previously healthy young men.",
          "beginSection": "abstract",
          "offsetInBeginSection": 290,
          "endSection": "abstract",
          "offsetInEndSection": 381
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23716826",
          "text": "Disabling pansclerotic morphea of childhood with extracutaneous manifestations.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 79
        }
      ],
      "ideal_answer": "Mutation of the PLA2G7 gene was implicated in Disabling pansclerotic morphea.",
      "exact_answer": [
        "PLA2G7"
      ]
    },
    {
      "id": "662fc122187cba990d000012",
      "type": "yesno",
      "body": "Does physical exercise reduce the risk of recurrence from colorectal cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30964753",
        "http://www.ncbi.nlm.nih.gov/pubmed/35205748",
        "http://www.ncbi.nlm.nih.gov/pubmed/10772419",
        "http://www.ncbi.nlm.nih.gov/pubmed/28584169",
        "http://www.ncbi.nlm.nih.gov/pubmed/31139306",
        "http://www.ncbi.nlm.nih.gov/pubmed/17953466",
        "http://www.ncbi.nlm.nih.gov/pubmed/28620703",
        "http://www.ncbi.nlm.nih.gov/pubmed/25918293",
        "http://www.ncbi.nlm.nih.gov/pubmed/16822844",
        "http://www.ncbi.nlm.nih.gov/pubmed/37494076"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31139306",
          "text": "Physical activity may prevent approximately 15% of the colon cancers. Furthermore, several observational studies have demonstrated the efficacy and dose-dependent and anti-cancer effects of exercise on decreasing the mortality and risk of recurrence before and after the colorectal cancer (CRC) diagnosis. However, the required exercise dose, type and intensity are yet unclear.",
          "beginSection": "abstract",
          "offsetInBeginSection": 360,
          "endSection": "abstract",
          "offsetInEndSection": 738
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31139306",
          "text": "Physical activity may prevent approximately 15% of the colon cancers. Furthermore, several observational studies have demonstrated the efficacy and dose-dependent and anti-cancer effects of exercise on decreasing the mortality and risk of recurrence before and after the colorectal cancer (CRC) diagnosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 360,
          "endSection": "abstract",
          "offsetInEndSection": 665
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31139306",
          "text": "The increasing population has justified the requirement of preventive strategies such as lifestyle modifications with regard to obesity, physical activity, diet and smoking. Physical activity may prevent approximately 15% of the colon cancers. Furthermore, several observational studies have demonstrated the efficacy and dose-dependent and anti-cancer effects of exercise on decreasing the mortality and risk of recurrence before and after the colorectal cancer (CRC) diagnosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 186,
          "endSection": "abstract",
          "offsetInEndSection": 665
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17953466",
          "text": "There is some evidence that improvements in cardiorespiratory fitness reduce adverse effects from cancer treatment when physical activity is undertaken following diagnosis of colorectal cancer. Markers/mechanisms by which physical activity may protect against colorectal cancer and/or improve disease prognosis include gastrointestinal transit-time, chronic inflammation, immune function, insulin levels, insulin-like growth factors, genetics and obesity.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1079,
          "endSection": "abstract",
          "offsetInEndSection": 1534
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31139306",
          "text": "Effect of exercise on colorectal cancer prevention and treatment.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 65
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31139306",
          "text": "Furthermore, several observational studies have demonstrated the efficacy and dose-dependent and anti-cancer effects of exercise on decreasing the mortality and risk of recurrence before and after the colorectal cancer (CRC) diagnosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 430,
          "endSection": "abstract",
          "offsetInEndSection": 665
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31139306",
          "text": "Furthermore, several observational studies have demonstrated the efficacy and dose-dependent and anti-cancer effects of exercise on decreasing the mortality and risk of recurrence before and after the colorectal cancer (CRC) diagnosis. However, the required exercise dose, type and intensity are yet unclear.",
          "beginSection": "abstract",
          "offsetInBeginSection": 430,
          "endSection": "abstract",
          "offsetInEndSection": 738
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17953466",
          "text": "There is some evidence that improvements in cardiorespiratory fitness reduce adverse effects from cancer treatment when physical activity is undertaken following diagnosis of colorectal cancer. Markers/mechanisms by which physical activity may protect against colorectal cancer and/or improve disease prognosis include gastrointestinal transit-time, chronic inflammation, immune function, insulin levels, insulin-like growth factors, genetics and obesity. Research evidence is, however, limited as to whether these markers are beneficially affected by physical activity, either before or after diagnosis of colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1079,
          "endSection": "abstract",
          "offsetInEndSection": 1704
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17953466",
          "text": "There is some evidence that improvements in cardiorespiratory fitness reduce adverse effects from cancer treatment when physical activity is undertaken following diagnosis of colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1079,
          "endSection": "abstract",
          "offsetInEndSection": 1272
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10772419",
          "text": "A decrease of WHR below 0.82 might reduce colorectal cancer in women by 19%. In addition, the epidemiological evidence consistently shows that physical activity reduces the risk of colon cancer. On the contrary, evidence on rectal cancer is less impressive.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1084,
          "endSection": "abstract",
          "offsetInEndSection": 1341
        }
      ],
      "ideal_answer": "Yes, physical exercise reduces the risk of recurrence from colorectal cancer. However, the required exercise dose, type and intensity are yet unclear.",
      "exact_answer": "yes"
    },
    {
      "id": "662a4b08b9f8b89d7e00000b",
      "type": "factoid",
      "body": "Oxysterol is produced by the oxidation of what waxy, fat-like substance made in the liver?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38036887",
        "http://www.ncbi.nlm.nih.gov/pubmed/38036880",
        "http://www.ncbi.nlm.nih.gov/pubmed/38036890",
        "http://www.ncbi.nlm.nih.gov/pubmed/38036882",
        "http://www.ncbi.nlm.nih.gov/pubmed/37872338",
        "http://www.ncbi.nlm.nih.gov/pubmed/19602132",
        "http://www.ncbi.nlm.nih.gov/pubmed/26795945",
        "http://www.ncbi.nlm.nih.gov/pubmed/22818469",
        "http://www.ncbi.nlm.nih.gov/pubmed/24672716",
        "http://www.ncbi.nlm.nih.gov/pubmed/10669920"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26795945",
          "text": "Oxysterols are bioactive lipids derived from cholesterol that are linked to inflammatory processes. Because obesity and metabolic syndrome are characterized by inflammation and altered cholesterol metabolism, we sought to investigate the variations of oxysterol levels and their metabolic pathways induced by obesity in the liver, hypothalamus, adipose tissue and plasma.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 371
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26795945",
          "text": "Oxysterols are bioactive lipids derived from cholesterol that are linked to inflammatory processes. Because obesity and metabolic syndrome are characterized by inflammation and altered cholesterol metabolism, we sought to investigate the variations of oxysterol levels and their metabolic pathways induced by obesity in the liver, hypothalamus, adipose tissue and plasma. To this end, we used diet-induced and genetic (ob/ob and db/db) models of obesity.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 454
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26795945",
          "text": "Our data show that, when considering oxysterol metabolism, the high-fat diet and ob/ob models are more closely related when compared to the db/db model. However, we were able to discriminate between lean and obese phenotypes based on liver oxysterol (4β-hydroxycholesterol, 27- hydroxycholesterol, 7-hydroxycholestenone) levels and enzyme (CYP3A11, CYP27A1, CYP7A1) expression.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1027,
          "endSection": "abstract",
          "offsetInEndSection": 1404
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26795945",
          "text": "However, although they are downstream metabolites of oxysterols, the variations in bile acid levels did not reflect the variations of their precursors. Our data show that, when considering oxysterol metabolism, the high-fat diet and ob/ob models are more closely related when compared to the db/db model. However, we were able to discriminate between lean and obese phenotypes based on liver oxysterol (4β-hydroxycholesterol, 27- hydroxycholesterol, 7-hydroxycholestenone) levels and enzyme (CYP3A11, CYP27A1, CYP7A1) expression.",
          "beginSection": "abstract",
          "offsetInBeginSection": 875,
          "endSection": "abstract",
          "offsetInEndSection": 1404
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26795945",
          "text": "Because obesity and metabolic syndrome are characterized by inflammation and altered cholesterol metabolism, we sought to investigate the variations of oxysterol levels and their metabolic pathways induced by obesity in the liver, hypothalamus, adipose tissue and plasma. To this end, we used diet-induced and genetic (ob/ob and db/db) models of obesity. Among the oxysterols measured, we found that 4β-oxysterol levels were consistently decreased in the high-fat diet study, at different time-points, and in the ob/ob model.",
          "beginSection": "abstract",
          "offsetInBeginSection": 100,
          "endSection": "abstract",
          "offsetInEndSection": 625
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26795945",
          "text": "Oxysterols are bioactive lipids derived from cholesterol that are linked to inflammatory processes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 99
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26795945",
          "text": "Because obesity and metabolic syndrome are characterized by inflammation and altered cholesterol metabolism, we sought to investigate the variations of oxysterol levels and their metabolic pathways induced by obesity in the liver, hypothalamus, adipose tissue and plasma.",
          "beginSection": "abstract",
          "offsetInBeginSection": 100,
          "endSection": "abstract",
          "offsetInEndSection": 371
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26795945",
          "text": "Because obesity and metabolic syndrome are characterized by inflammation and altered cholesterol metabolism, we sought to investigate the variations of oxysterol levels and their metabolic pathways induced by obesity in the liver, hypothalamus, adipose tissue and plasma. To this end, we used diet-induced and genetic (ob/ob and db/db) models of obesity.",
          "beginSection": "abstract",
          "offsetInBeginSection": 100,
          "endSection": "abstract",
          "offsetInEndSection": 454
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26795945",
          "text": "Among the oxysterols measured, we found that 4β-oxysterol levels were consistently decreased in the high-fat diet study, at different time-points, and in the ob/ob model.",
          "beginSection": "abstract",
          "offsetInBeginSection": 455,
          "endSection": "abstract",
          "offsetInEndSection": 625
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26795945",
          "text": "However, we were able to discriminate between lean and obese phenotypes based on liver oxysterol (4β-hydroxycholesterol, 27- hydroxycholesterol, 7-hydroxycholestenone) levels and enzyme (CYP3A11, CYP27A1, CYP7A1) expression.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1180,
          "endSection": "abstract",
          "offsetInEndSection": 1404
        }
      ],
      "ideal_answer": "Oxysterol is produced by the oxidation of cholesterol.",
      "exact_answer": [
        "cholesterol"
      ]
    },
    {
      "id": "65f84c78c4010b4d78000049",
      "type": "yesno",
      "body": "Is bowel transplantation commonly performed in patients with severe gastrointestinal disease?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36755514",
        "http://www.ncbi.nlm.nih.gov/pubmed/37417206",
        "http://www.ncbi.nlm.nih.gov/pubmed/37495293",
        "http://www.ncbi.nlm.nih.gov/pubmed/21682755",
        "http://www.ncbi.nlm.nih.gov/pubmed/29788474",
        "http://www.ncbi.nlm.nih.gov/pubmed/9701532",
        "http://www.ncbi.nlm.nih.gov/pubmed/26950725",
        "http://www.ncbi.nlm.nih.gov/pubmed/7570313",
        "http://www.ncbi.nlm.nih.gov/pubmed/32919438",
        "http://www.ncbi.nlm.nih.gov/pubmed/37324043"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21682755",
          "text": "Review article: faecal transplantation therapy for gastrointestinal disease.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 76
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21682755",
          "text": "Small numbers of patients are reported to have undergone successful faecal transplantation for irritable bowel syndrome and inflammatory bowel disease. CONCLUSIONS\nFaecal transplantation has been reported with good outcomes for fulminant and refractory C. difficile.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1151,
          "endSection": "abstract",
          "offsetInEndSection": 1419
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21682755",
          "text": "Small numbers of patients are reported to have undergone successful faecal transplantation for irritable bowel syndrome and inflammatory bowel disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1151,
          "endSection": "abstract",
          "offsetInEndSection": 1302
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21682755",
          "text": "Faecal transplantation for C. difficile has been demonstrated to be effective in 145/166 (87%) patients. Small numbers of patients are reported to have undergone successful faecal transplantation for irritable bowel syndrome and inflammatory bowel disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1046,
          "endSection": "abstract",
          "offsetInEndSection": 1302
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21682755",
          "text": "Studies of faecal transplantation are heterogeneous regarding the patients, donors, screening, methods of administration and definition of response. Faecal transplantation for C. difficile has been demonstrated to be effective in 145/166 (87%) patients. Small numbers of patients are reported to have undergone successful faecal transplantation for irritable bowel syndrome and inflammatory bowel disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 897,
          "endSection": "abstract",
          "offsetInEndSection": 1302
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21682755",
          "text": "Small numbers of patients are reported to have undergone successful faecal transplantation for irritable bowel syndrome and inflammatory bowel disease. CONCLUSIONS\nFaecal transplantation has been reported with good outcomes for fulminant and refractory C. difficile. No adverse effects of faecal transplantation have been reported.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1151,
          "endSection": "abstract",
          "offsetInEndSection": 1484
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21682755",
          "text": "Faecal transplantation for C. difficile has been demonstrated to be effective in 145/166 (87%) patients. Small numbers of patients are reported to have undergone successful faecal transplantation for irritable bowel syndrome and inflammatory bowel disease. CONCLUSIONS\nFaecal transplantation has been reported with good outcomes for fulminant and refractory C. difficile.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1046,
          "endSection": "abstract",
          "offsetInEndSection": 1419
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21682755",
          "text": "AIM\nTo review the use of faecal transplantation therapy for the management of gastrointestinal disorders.",
          "beginSection": "abstract",
          "offsetInBeginSection": 387,
          "endSection": "abstract",
          "offsetInEndSection": 492
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21682755",
          "text": "AIM\nTo review the use of faecal transplantation therapy for the management of gastrointestinal disorders. METHODS\nAvailable articles on faecal transplantation in the management of gastrointestinal disorders were identified using a Pubmed search and bibliographies of review articles on the subject were collated. RESULTS\nA total of 239 patients who had undergone faecal transplantation were reported.",
          "beginSection": "abstract",
          "offsetInBeginSection": 387,
          "endSection": "abstract",
          "offsetInEndSection": 791
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21682755",
          "text": "AIM\nTo review the use of faecal transplantation therapy for the management of gastrointestinal disorders. METHODS\nAvailable articles on faecal transplantation in the management of gastrointestinal disorders were identified using a Pubmed search and bibliographies of review articles on the subject were collated.",
          "beginSection": "abstract",
          "offsetInBeginSection": 387,
          "endSection": "abstract",
          "offsetInEndSection": 701
        }
      ],
      "ideal_answer": "No, bowel transplantation is not commonly performed in patients with severe gastrointestinal disease. Instead, faecal transplantation has been reported with good outcomes for certain conditions such as fulminant and refractory C. difficile.",
      "exact_answer": "no"
    },
    {
      "id": "6630154c187cba990d000021",
      "type": "factoid",
      "body": "Which chromosome is most commonly affected by loss of heterozygosity in glioblastoma?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/10653004",
        "http://www.ncbi.nlm.nih.gov/pubmed/1975968",
        "http://www.ncbi.nlm.nih.gov/pubmed/2544511",
        "http://www.ncbi.nlm.nih.gov/pubmed/2573417",
        "http://www.ncbi.nlm.nih.gov/pubmed/11592040",
        "http://www.ncbi.nlm.nih.gov/pubmed/8546898",
        "http://www.ncbi.nlm.nih.gov/pubmed/28960585",
        "http://www.ncbi.nlm.nih.gov/pubmed/1351753",
        "http://www.ncbi.nlm.nih.gov/pubmed/1351257",
        "http://www.ncbi.nlm.nih.gov/pubmed/1357919"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28960585",
          "text": "Glioblastoma is the most frequent and aggressive brain tumor in the adult population. Loss of heterozygosity (LOH) at markers of the long arm of chromosome 10 is the most common genetic alteration in glioblastoma, being detectable in up to 80% of cases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 253
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2573417",
          "text": "Loss of constitutional heterozygosity for loci on chromosome 17 was found in both anaplastic astrocytoma and glioblastoma patients with equal frequency (40% of cases). Our mapping data revealed a region of loss on chromosome 17p between physical loci p11.2 and pter that was common to both patient groups.",
          "beginSection": "abstract",
          "offsetInBeginSection": 847,
          "endSection": "abstract",
          "offsetInEndSection": 1152
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2544511",
          "text": "Loss of heterozygosity on chromosome 10 in human glioblastoma multiforme.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 73
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2573417",
          "text": "Loss of constitutional heterozygosity for loci on chromosome 17 was found in both anaplastic astrocytoma and glioblastoma patients with equal frequency (40% of cases).",
          "beginSection": "abstract",
          "offsetInBeginSection": 847,
          "endSection": "abstract",
          "offsetInEndSection": 1014
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1975968",
          "text": "Loss of constitutional heterozygosity in chromosome 10 in human glioblastoma.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 77
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2544511",
          "text": "Ten patients showed loss of constitutional heterozygosity in the tumor samples. This finding suggests that a recessive gene involved in the development of glioblastoma multiforme is present on chromosome 10.",
          "beginSection": "abstract",
          "offsetInBeginSection": 292,
          "endSection": "abstract",
          "offsetInEndSection": 499
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28960585",
          "text": "Glioblastoma is the most frequent and aggressive brain tumor in the adult population. Loss of heterozygosity (LOH) at markers of the long arm of chromosome 10 is the most common genetic alteration in glioblastoma, being detectable in up to 80% of cases. We have tested 124 glioblastoma samples for LOH by microsatellite analysis of the 10q23.3-26.3 region which contains the cancer related genes PTEN, FGFR2, MKI67, and MGMT.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 425
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11592040",
          "text": "[A preliminary study of loss of heterozygosity on chromosome 14 in glioblastoma].",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 81
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8546898",
          "text": "Multiple regions of chromosome 6q affected by loss of heterozygosity in primary human breast carcinomas.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 104
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2573417",
          "text": "Loss of constitutional heterozygosity for loci on chromosome 17 was found in both anaplastic astrocytoma and glioblastoma patients with equal frequency (40% of cases). Our mapping data revealed a region of loss on chromosome 17p between physical loci p11.2 and pter that was common to both patient groups. Taken together with the previously reported finding of loss of heterozygosity for loci on chromosome 10 in glioblastoma, these results indicate that tumorigenesis in the astrocyte lineage may involve recessive oncogenes on two different chromosomes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 847,
          "endSection": "abstract",
          "offsetInEndSection": 1402
        }
      ],
      "ideal_answer": "Chromosome 10 is the most commonly affected chromosome by loss of heterozygosity in glioblastoma.",
      "exact_answer": [
        "chromosome 10"
      ]
    },
    {
      "id": "663023f3187cba990d000030",
      "type": "summary",
      "body": "What is KineDMD?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36658421"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36658421",
          "text": "we constructed a behavioral biomarker, termed the KineDMD ethomic biomarker, which is derived from daily-life behavioral data and whose value progresses with age in an S-shaped sigmoid curve form. The biomarker developed in this study, derived from digital readouts of daily-life movement behavior, can predict disease progression in patients with muscular dystrophy and can potentially track the response to therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 950,
          "endSection": "abstract",
          "offsetInEndSection": 1367
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36658421",
          "text": "Finally, using Bayesian optimization, we constructed a behavioral biomarker, termed the KineDMD ethomic biomarker, which is derived from daily-life behavioral data and whose value progresses with age in an S-shaped sigmoid curve form. The biomarker developed in this study, derived from digital readouts of daily-life movement behavior, can predict disease progression in patients with muscular dystrophy and can potentially track the response to therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 912,
          "endSection": "abstract",
          "offsetInEndSection": 1367
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36658421",
          "text": "Finally, using Bayesian optimization, we constructed a behavioral biomarker, termed the KineDMD ethomic biomarker, which is derived from daily-life behavioral data and whose value progresses with age in an S-shaped sigmoid curve form.",
          "beginSection": "abstract",
          "offsetInBeginSection": 912,
          "endSection": "abstract",
          "offsetInEndSection": 1146
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36658421",
          "text": "Then, we used machine learning algorithms that combined the behavioral fingerprints to make cross-sectional and longitudinal disease course predictions, which outperformed predictions derived from currently used clinical assessments. Finally, using Bayesian optimization, we constructed a behavioral biomarker, termed the KineDMD ethomic biomarker, which is derived from daily-life behavioral data and whose value progresses with age in an S-shaped sigmoid curve form. The biomarker developed in this study, derived from digital readouts of daily-life movement behavior, can predict disease progression in patients with muscular dystrophy and can potentially track the response to therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 678,
          "endSection": "abstract",
          "offsetInEndSection": 1367
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36658421",
          "text": "We first defined new movement behavioral fingerprints capable of distinguishing DMD from controls. Then, we used machine learning algorithms that combined the behavioral fingerprints to make cross-sectional and longitudinal disease course predictions, which outperformed predictions derived from currently used clinical assessments. Finally, using Bayesian optimization, we constructed a behavioral biomarker, termed the KineDMD ethomic biomarker, which is derived from daily-life behavioral data and whose value progresses with age in an S-shaped sigmoid curve form.",
          "beginSection": "abstract",
          "offsetInBeginSection": 579,
          "endSection": "abstract",
          "offsetInEndSection": 1146
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36658421",
          "text": "Then, we used machine learning algorithms that combined the behavioral fingerprints to make cross-sectional and longitudinal disease course predictions, which outperformed predictions derived from currently used clinical assessments. Finally, using Bayesian optimization, we constructed a behavioral biomarker, termed the KineDMD ethomic biomarker, which is derived from daily-life behavioral data and whose value progresses with age in an S-shaped sigmoid curve form.",
          "beginSection": "abstract",
          "offsetInBeginSection": 678,
          "endSection": "abstract",
          "offsetInEndSection": 1146
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36658421",
          "text": "Movement behavior was assessed while the participant engaged in everyday activities using a 17-sensor bodysuit during three clinical visits over the course of 12 months. We first defined new movement behavioral fingerprints capable of distinguishing DMD from controls. Then, we used machine learning algorithms that combined the behavioral fingerprints to make cross-sectional and longitudinal disease course predictions, which outperformed predictions derived from currently used clinical assessments.",
          "beginSection": "abstract",
          "offsetInBeginSection": 409,
          "endSection": "abstract",
          "offsetInEndSection": 911
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36658421",
          "text": "We first defined new movement behavioral fingerprints capable of distinguishing DMD from controls. Then, we used machine learning algorithms that combined the behavioral fingerprints to make cross-sectional and longitudinal disease course predictions, which outperformed predictions derived from currently used clinical assessments.",
          "beginSection": "abstract",
          "offsetInBeginSection": 579,
          "endSection": "abstract",
          "offsetInEndSection": 911
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36658421",
          "text": "To overcome this limitation, we collected a digital readout of whole-body movement behavior of patients with Duchenne muscular dystrophy (DMD) (n = 21) and age-matched controls (n = 17). Movement behavior was assessed while the participant engaged in everyday activities using a 17-sensor bodysuit during three clinical visits over the course of 12 months. We first defined new movement behavioral fingerprints capable of distinguishing DMD from controls.",
          "beginSection": "abstract",
          "offsetInBeginSection": 222,
          "endSection": "abstract",
          "offsetInEndSection": 677
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36658421",
          "text": "Movement behavior was assessed while the participant engaged in everyday activities using a 17-sensor bodysuit during three clinical visits over the course of 12 months. We first defined new movement behavioral fingerprints capable of distinguishing DMD from controls.",
          "beginSection": "abstract",
          "offsetInBeginSection": 409,
          "endSection": "abstract",
          "offsetInEndSection": 677
        }
      ],
      "ideal_answer": "KineDMD is a behavioral biomarker that is derived from daily-life behavioral data and whose value progresses with age in an S-shaped sigmoid curve form. It is constructed using Bayesian optimization and can predict disease progression in patients with muscular dystrophy and potentially track the response to therapy.",
      "exact_answer": "n/a"
    },
    {
      "id": "65d12a181930410b1300002f",
      "type": "yesno",
      "body": "Can fluoroquinolones be used for patient with myasthenia gravis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19232642",
        "http://www.ncbi.nlm.nih.gov/pubmed/21879778",
        "http://www.ncbi.nlm.nih.gov/pubmed/24029473",
        "http://www.ncbi.nlm.nih.gov/pubmed/36373673",
        "http://www.ncbi.nlm.nih.gov/pubmed/33719062",
        "http://www.ncbi.nlm.nih.gov/pubmed/32922263",
        "http://www.ncbi.nlm.nih.gov/pubmed/7481384",
        "http://www.ncbi.nlm.nih.gov/pubmed/32759200",
        "http://www.ncbi.nlm.nih.gov/pubmed/2209357",
        "http://www.ncbi.nlm.nih.gov/pubmed/16840920"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19232642",
          "text": "Fluoroquinolones has been rarely associated with exacerbation of myasthenia gravis (MG). We present a case of MG following a treatment with prulifloxacin, a new broad-spectrum oral fluoroquinolone. Fluoroquinolones of any generation may interfere with neuromuscular transmission and should be avoided in patients with MG.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 321
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7481384",
          "text": "The report of exacerbation of myasthenia gravis with other antibiotic belonging to the group of fluoroquinolones (ciprofloxacin, norfloxacin and ofloxacin) prompt us to recommend caution with the use of all fluoroquinolones in myasthenic patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 536,
          "endSection": "abstract",
          "offsetInEndSection": 783
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19232642",
          "text": "Fluoroquinolones has been rarely associated with exacerbation of myasthenia gravis (MG). We present a case of MG following a treatment with prulifloxacin, a new broad-spectrum oral fluoroquinolone.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 197
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19232642",
          "text": "Fluoroquinolones has been rarely associated with exacerbation of myasthenia gravis (MG).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 88
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19232642",
          "text": "Fluoroquinolones has been rarely associated with exacerbation of myasthenia gravis (MG). ",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 89
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7481384",
          "text": "No additional factors which might have contributed to the exacerbation of myasthenia gravis were found. The report of exacerbation of myasthenia gravis with other antibiotic belonging to the group of fluoroquinolones (ciprofloxacin, norfloxacin and ofloxacin) prompt us to recommend caution with the use of all fluoroquinolones in myasthenic patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 432,
          "endSection": "abstract",
          "offsetInEndSection": 783
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7481384",
          "text": "She experienced a rapid improvement during the next 8 hours and physical examination returned to normal within one day. No additional factors which might have contributed to the exacerbation of myasthenia gravis were found. The report of exacerbation of myasthenia gravis with other antibiotic belonging to the group of fluoroquinolones (ciprofloxacin, norfloxacin and ofloxacin) prompt us to recommend caution with the use of all fluoroquinolones in myasthenic patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 312,
          "endSection": "abstract",
          "offsetInEndSection": 783
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16840920",
          "text": "Both patients were given anti-cholinesterase drugs. One underwent thymectomy. Radioiodine used for the treatment of hyperthyroidism improved the symptoms of myasthenia gravis in the first patient.",
          "beginSection": "abstract",
          "offsetInBeginSection": 774,
          "endSection": "abstract",
          "offsetInEndSection": 970
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16840920",
          "text": "One underwent thymectomy. Radioiodine used for the treatment of hyperthyroidism improved the symptoms of myasthenia gravis in the first patient. The association of myasthenia gravis and hyperthyroidism is more than a coincidence; our cases illustrate the difficult diagnosis and management of these diseases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 826,
          "endSection": "abstract",
          "offsetInEndSection": 1134
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7481384",
          "text": "Pefloxacine 800 mg single dose was given as routine treatment after a cystomanometric examination to a 45-year-old woman with a 30-month history of generalized myasthenia gravis. One hour after, the patient developed exacerbation of myasthenia gravis with bilateral ptosis and an increased generalized weakness.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 311
        }
      ],
      "ideal_answer": "Fluoroquinolones should be avoided in patients with myasthenia gravis as they have been rarely associated with exacerbation of the condition. This recommendation is based on reports of exacerbation with various fluoroquinolones such as prulifloxacin, ciprofloxacin, norfloxacin, and ofloxacin.",
      "exact_answer": "no"
    },
    {
      "id": "66099eb9fdcbea915f000026",
      "type": "yesno",
      "body": "Are BRAF V600E mutation associated to worse prognosis in colorectal cancer patients?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/16024606",
        "http://www.ncbi.nlm.nih.gov/pubmed/21285991",
        "http://www.ncbi.nlm.nih.gov/pubmed/33330032",
        "http://www.ncbi.nlm.nih.gov/pubmed/27672042",
        "http://www.ncbi.nlm.nih.gov/pubmed/23650027",
        "http://www.ncbi.nlm.nih.gov/pubmed/27404270",
        "http://www.ncbi.nlm.nih.gov/pubmed/32571791",
        "http://www.ncbi.nlm.nih.gov/pubmed/23925579",
        "http://www.ncbi.nlm.nih.gov/pubmed/25367198",
        "http://www.ncbi.nlm.nih.gov/pubmed/17119056"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33330032",
          "text": "Background: BRAF V600E mutation is associated with poor prognosis of colorectal cancer (CRC) patients, but the comparison of clinic-pathologic features between V600E and non-V600E mutation was not well-known in CRC patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 224
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33330032",
          "text": "Background: BRAF V600E mutation is associated with poor prognosis of colorectal cancer (CRC) patients, but the comparison of clinic-pathologic features between V600E and non-V600E mutation was not well-known in CRC patients. The aim of this study is to evaluate the clinical and pathological features, prognostic value of BRAF mutations in CRC.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 344
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33330032",
          "text": "Background: BRAF V600E mutation is associated with poor prognosis of colorectal cancer (CRC) patients, but the comparison of clinic-pathologic features between V600E and non-V600E mutation was not well-known in CRC patients. The aim of this study is to evaluate the clinical and pathological features, prognostic value of BRAF mutations in CRC. Methods: We conducted a retrospective study to characterize the clinical and pathological features and survival of patients with BRAF mutated CRC.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 491
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27672042",
          "text": "PURPOSE\nIn colorectal cancer (CRC), the BRAF V600E mutation is an important biomarker for poor prognosis, while high microsatellite instability (MSI-H) indicates good prognosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 177
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23650027",
          "text": "BRAF V600E also predicts poor prognosis in microsatellite stable colorectal cancers and may be a marker of resistance to anti-EGFR therapy in metastatic disease. Currently, only molecular methods are available for assessing BRAF mutational status.",
          "beginSection": "abstract",
          "offsetInBeginSection": 472,
          "endSection": "abstract",
          "offsetInEndSection": 719
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23650027",
          "text": "BRAF V600E also predicts poor prognosis in microsatellite stable colorectal cancers and may be a marker of resistance to anti-EGFR therapy in metastatic disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 472,
          "endSection": "abstract",
          "offsetInEndSection": 633
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27672042",
          "text": "PURPOSE\nIn colorectal cancer (CRC), the BRAF V600E mutation is an important biomarker for poor prognosis, while high microsatellite instability (MSI-H) indicates good prognosis. Using a commercial BRAF V600E-specific antibody, we investigated the BRAF V600E mutation according to immunohistochemistry (IHC) and the MSI status in Japanese patients with CRC.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 356
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23650027",
          "text": "BRAF V600E in MLH1 deficient tumors implicates somatic tumor-only methylation of the MLH1 promoter region instead of a germline MLH1 mutation. BRAF V600E also predicts poor prognosis in microsatellite stable colorectal cancers and may be a marker of resistance to anti-EGFR therapy in metastatic disease. Currently, only molecular methods are available for assessing BRAF mutational status.",
          "beginSection": "abstract",
          "offsetInBeginSection": 329,
          "endSection": "abstract",
          "offsetInEndSection": 719
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23650027",
          "text": "BRAF V600E in MLH1 deficient tumors implicates somatic tumor-only methylation of the MLH1 promoter region instead of a germline MLH1 mutation. BRAF V600E also predicts poor prognosis in microsatellite stable colorectal cancers and may be a marker of resistance to anti-EGFR therapy in metastatic disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 329,
          "endSection": "abstract",
          "offsetInEndSection": 633
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23650027",
          "text": "BRAF V600E also predicts poor prognosis in microsatellite stable colorectal cancers and may be a marker of resistance to anti-EGFR therapy in metastatic disease. Currently, only molecular methods are available for assessing BRAF mutational status. An immunohistochemical approach is evaluated here.",
          "beginSection": "abstract",
          "offsetInBeginSection": 472,
          "endSection": "abstract",
          "offsetInEndSection": 770
        }
      ],
      "ideal_answer": "Yes, BRAF V600E mutation is associated with worse prognosis in colorectal cancer patients.",
      "exact_answer": "yes"
    },
    {
      "id": "662cfadc187cba990d000006",
      "type": "summary",
      "body": "Circular RNAs (circRNAs) are a distinct family of RNAs, how are they derived?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37124497",
        "http://www.ncbi.nlm.nih.gov/pubmed/37762282",
        "http://www.ncbi.nlm.nih.gov/pubmed/32972011",
        "http://www.ncbi.nlm.nih.gov/pubmed/33634138",
        "http://www.ncbi.nlm.nih.gov/pubmed/29625140",
        "http://www.ncbi.nlm.nih.gov/pubmed/29182528",
        "http://www.ncbi.nlm.nih.gov/pubmed/34417752",
        "http://www.ncbi.nlm.nih.gov/pubmed/26721494",
        "http://www.ncbi.nlm.nih.gov/pubmed/31001302",
        "http://www.ncbi.nlm.nih.gov/pubmed/30259367"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29182528",
          "text": "Circular RNAs (circRNAs) are a class of RNA that are emerging as key new members of the gene regulatory milieu, which are produced by back-splicing events within genes. In circRNA formation, rather than being spliced in a linear fashion, exons can be circularised by use of the 3' acceptor splice site of an upstream exon, leading to the formation of a circular RNA species.",
          "beginSection": "abstract",
          "offsetInBeginSection": 59,
          "endSection": "abstract",
          "offsetInEndSection": 433
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29182528",
          "text": "Circular RNAs (circRNAs) are a class of RNA that are emerging as key new members of the gene regulatory milieu, which are produced by back-splicing events within genes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 59,
          "endSection": "abstract",
          "offsetInEndSection": 227
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31001302",
          "text": "Circular RNAs (circRNAs) are new endogenous non-coding RNA family members that arise during pre-mRNA splicing in a reversed order in which the 3' and 5' ends are covalently closed.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 180
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31001302",
          "text": "Circular RNAs (circRNAs) are new endogenous non-coding RNA family members that arise during pre-mRNA splicing in a reversed order in which the 3' and 5' ends are covalently closed. Compared to the comprehensive investigation of circRNAs in animals, circRNA research in plants is still in its infancy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 300
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31001302",
          "text": "Circular RNAs (circRNAs) are new endogenous non-coding RNA family members that arise during pre-mRNA splicing in a reversed order in which the 3' and 5' ends are covalently closed. Compared to the comprehensive investigation of circRNAs in animals, circRNA research in plants is still in its infancy. Genome-wide identification and characterization of circRNAs have recently been performed in several plant species.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 415
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30259367",
          "text": "Circular RNAs (circRNAs), a group of circular RNA molecules with a 3',5'-phosphodiester bond at the junction site, are generated by back-splicing of precursor mRNAs. Most of the circular RNAs originate from the exon region of the encoded protein, and some are derived from intron regions, antisense transcripts, or long noncoding RNAs.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 335
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29182528",
          "text": "Circular RNAs (circRNAs) are a class of RNA that are emerging as key new members of the gene regulatory milieu, which are produced by back-splicing events within genes. In circRNA formation, rather than being spliced in a linear fashion, exons can be circularised by use of the 3' acceptor splice site of an upstream exon, leading to the formation of a circular RNA species. circRNAs have been demonstrated across species and have the potential to present genetic information in new orientations distinct from their parent transcript.",
          "beginSection": "abstract",
          "offsetInBeginSection": 59,
          "endSection": "abstract",
          "offsetInEndSection": 593
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29625140",
          "text": "Circular RNAs (circRNAs) are a class of non-coding RNAs that do not have 5' end caps or 3' end poly (A) tails.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 110
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30259367",
          "text": "Circular RNAs (circRNAs), a group of circular RNA molecules with a 3',5'-phosphodiester bond at the junction site, are generated by back-splicing of precursor mRNAs.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 165
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30259367",
          "text": "Circular RNAs (circRNAs), a group of circular RNA molecules with a 3',5'-phosphodiester bond at the junction site, are generated by back-splicing of precursor mRNAs. Most of the circular RNAs originate from the exon region of the encoded protein, and some are derived from intron regions, antisense transcripts, or long noncoding RNAs. Circular RNAs are abundantly in eukaryotic transcriptome and participate in various biological processes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 441
        }
      ],
      "ideal_answer": "Circular RNAs (circRNAs) are derived from back-splicing events within genes, where exons are circularised by use of the 3' acceptor splice site of an upstream exon, leading to the formation of a circular RNA species. They are abundant in eukaryotic transcriptome and participate in various biological processes.",
      "exact_answer": "n/a"
    },
    {
      "id": "66169f9bfdcbea915f000057",
      "type": "summary",
      "body": "Transgender identity and mortality.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37367977",
        "http://www.ncbi.nlm.nih.gov/pubmed/36716027",
        "http://www.ncbi.nlm.nih.gov/pubmed/36644490",
        "http://www.ncbi.nlm.nih.gov/pubmed/36219930",
        "http://www.ncbi.nlm.nih.gov/pubmed/25089681",
        "http://www.ncbi.nlm.nih.gov/pubmed/26751157",
        "http://www.ncbi.nlm.nih.gov/pubmed/29961481",
        "http://www.ncbi.nlm.nih.gov/pubmed/38032761",
        "http://www.ncbi.nlm.nih.gov/pubmed/30052497",
        "http://www.ncbi.nlm.nih.gov/pubmed/34030966"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37367977",
          "text": "Transgender Identity and Suicide Attempts and Mortality in Denmark.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 67
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37367977",
          "text": "Objective\nTo examine in a national setting whether transgender individuals have higher rates of suicide attempt and mortality than nontransgender individuals. Design, Setting, and Participants\nNationwide, register-based, retrospective cohort study on all 6 657 456 Danish-born individuals aged 15 years or older who lived in Denmark between January 1, 1980, and December 31, 2021. Exposure\nTransgender identity was determined through national hospital records and administrative records of legal change of gender.",
          "beginSection": "abstract",
          "offsetInBeginSection": 205,
          "endSection": "abstract",
          "offsetInEndSection": 722
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37367977",
          "text": "Exposure\nTransgender identity was determined through national hospital records and administrative records of legal change of gender. Main Outcomes and Measures\nSuicide attempts, suicide deaths, nonsuicidal deaths, and deaths by any cause during 1980 through 2021 were identified in national hospitalization and causes of death registers. Adjusted incidence rate ratios (aIRRs) with 95% CIs controlling for calendar period, sex assigned at birth, and age were calculated.",
          "beginSection": "abstract",
          "offsetInBeginSection": 590,
          "endSection": "abstract",
          "offsetInEndSection": 1062
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37367977",
          "text": "Exposure\nTransgender identity was determined through national hospital records and administrative records of legal change of gender. Main Outcomes and Measures\nSuicide attempts, suicide deaths, nonsuicidal deaths, and deaths by any cause during 1980 through 2021 were identified in national hospitalization and causes of death registers.",
          "beginSection": "abstract",
          "offsetInBeginSection": 590,
          "endSection": "abstract",
          "offsetInEndSection": 929
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36644490",
          "text": "Transgender Identity and Cardiovascular Disease.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 48
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37367977",
          "text": "Design, Setting, and Participants\nNationwide, register-based, retrospective cohort study on all 6 657 456 Danish-born individuals aged 15 years or older who lived in Denmark between January 1, 1980, and December 31, 2021. Exposure\nTransgender identity was determined through national hospital records and administrative records of legal change of gender. Main Outcomes and Measures\nSuicide attempts, suicide deaths, nonsuicidal deaths, and deaths by any cause during 1980 through 2021 were identified in national hospitalization and causes of death registers.",
          "beginSection": "abstract",
          "offsetInBeginSection": 366,
          "endSection": "abstract",
          "offsetInEndSection": 929
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36219930",
          "text": "Transgender identity: Development, management and affirmation.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 62
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37367977",
          "text": "Importance\nPrior studies have suggested that transgender individuals may be a high-risk group with respect to suicide attempt and mortality, but large-scale, population-based investigations are lacking. Objective\nTo examine in a national setting whether transgender individuals have higher rates of suicide attempt and mortality than nontransgender individuals. Design, Setting, and Participants\nNationwide, register-based, retrospective cohort study on all 6 657 456 Danish-born individuals aged 15 years or older who lived in Denmark between January 1, 1980, and December 31, 2021.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 587
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37367977",
          "text": "Overall, 3759 individuals (0.06%; 52.5% assigned male sex at birth) were identified as transgender at a median age of 22 years (IQR, 18-31 years) and followed up during 21 404 person-years, during which 92 suicide attempts, 12 suicides, and 245 suicide-unrelated deaths occurred.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1191,
          "endSection": "abstract",
          "offsetInEndSection": 1470
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37367977",
          "text": "Prior studies have suggested that transgender individuals may be a high-risk group with respect to suicide attempt and mortality",
          "beginSection": "abstract",
          "offsetInBeginSection": 12,
          "endSection": "abstract",
          "offsetInEndSection": 140
        }
      ],
      "ideal_answer": "Transgender individuals have higher rates of suicide attempts and mortality compared to nontransgender individuals, as suggested by a nationwide, register-based, retrospective cohort study in Denmark. The study identified 3759 transgender individuals who had higher rates of suicide attempts, suicides, and suicide-unrelated deaths compared to nontransgender individuals.",
      "exact_answer": "n/a"
    },
    {
      "id": "663016bb187cba990d000023",
      "type": "factoid",
      "body": "Which genetic alteration is most commonly associated with the classical subtype of glioblastoma?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37446288",
        "http://www.ncbi.nlm.nih.gov/pubmed/33435537",
        "http://www.ncbi.nlm.nih.gov/pubmed/31733287",
        "http://www.ncbi.nlm.nih.gov/pubmed/30680510",
        "http://www.ncbi.nlm.nih.gov/pubmed/30053126",
        "http://www.ncbi.nlm.nih.gov/pubmed/27056901",
        "http://www.ncbi.nlm.nih.gov/pubmed/24457079",
        "http://www.ncbi.nlm.nih.gov/pubmed/33052913",
        "http://www.ncbi.nlm.nih.gov/pubmed/22539962",
        "http://www.ncbi.nlm.nih.gov/pubmed/25821160"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31733287",
          "text": "Since different alterations underlie different molecular glioblastoma subtypes it is commonly expected that tumors induced by specific alterations represent models of the corresponding subtypes. We tested this assumption by a multilevel analysis ranging from a detailed histopathological analysis to a genome-wide expression profiling by microarray and RNA-seq on gliomas induced by two distinct molecular alterations: the overstimulation of the PDGF- and the EGF- pathways. These alterations are landmarks of proneural and classical glioblastoma subtypes respectively.",
          "beginSection": "abstract",
          "offsetInBeginSection": 175,
          "endSection": "abstract",
          "offsetInEndSection": 744
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31733287",
          "text": "We tested this assumption by a multilevel analysis ranging from a detailed histopathological analysis to a genome-wide expression profiling by microarray and RNA-seq on gliomas induced by two distinct molecular alterations: the overstimulation of the PDGF- and the EGF- pathways. These alterations are landmarks of proneural and classical glioblastoma subtypes respectively.",
          "beginSection": "abstract",
          "offsetInBeginSection": 370,
          "endSection": "abstract",
          "offsetInEndSection": 744
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31733287",
          "text": "These alterations are landmarks of proneural and classical glioblastoma subtypes respectively. However, our results consistently showed a strong similarity between the two glioma models.",
          "beginSection": "abstract",
          "offsetInBeginSection": 650,
          "endSection": "abstract",
          "offsetInEndSection": 836
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31733287",
          "text": "These alterations are landmarks of proneural and classical glioblastoma subtypes respectively.",
          "beginSection": "abstract",
          "offsetInBeginSection": 650,
          "endSection": "abstract",
          "offsetInEndSection": 744
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31733287",
          "text": "Our results highlight that reproducing a molecular alteration specific of a glioblastoma subtype not necessarily generates a tumor model recapitulating such subtype.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1143,
          "endSection": "abstract",
          "offsetInEndSection": 1308
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31733287",
          "text": "These alterations are landmarks of proneural and classical glioblastoma subtypes respectively. However, our results consistently showed a strong similarity between the two glioma models. The expression profiles of both models converged toward a signature typical of oligodendrocyte progenitor cells, regardless the wide differentiative potential of the cell of origin.",
          "beginSection": "abstract",
          "offsetInBeginSection": 650,
          "endSection": "abstract",
          "offsetInEndSection": 1018
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31733287",
          "text": "We tested this assumption by a multilevel analysis ranging from a detailed histopathological analysis to a genome-wide expression profiling by microarray and RNA-seq on gliomas induced by two distinct molecular alterations: the overstimulation of the PDGF- and the EGF- pathways. These alterations are landmarks of proneural and classical glioblastoma subtypes respectively. However, our results consistently showed a strong similarity between the two glioma models.",
          "beginSection": "abstract",
          "offsetInBeginSection": 370,
          "endSection": "abstract",
          "offsetInEndSection": 836
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30680510",
          "text": "EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 118
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31733287",
          "text": "Since different alterations underlie different molecular glioblastoma subtypes it is commonly expected that tumors induced by specific alterations represent models of the corresponding subtypes. We tested this assumption by a multilevel analysis ranging from a detailed histopathological analysis to a genome-wide expression profiling by microarray and RNA-seq on gliomas induced by two distinct molecular alterations: the overstimulation of the PDGF- and the EGF- pathways.",
          "beginSection": "abstract",
          "offsetInBeginSection": 175,
          "endSection": "abstract",
          "offsetInEndSection": 649
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31733287",
          "text": "The need of reliable syngeneic animal models for gliomas has been addressed in the last decades by reproducing genetic alterations typical of human glioblastoma in the mouse. Since different alterations underlie different molecular glioblastoma subtypes it is commonly expected that tumors induced by specific alterations represent models of the corresponding subtypes. We tested this assumption by a multilevel analysis ranging from a detailed histopathological analysis to a genome-wide expression profiling by microarray and RNA-seq on gliomas induced by two distinct molecular alterations: the overstimulation of the PDGF- and the EGF- pathways.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 649
        }
      ],
      "ideal_answer": "The EGF- pathway is most commonly associated with the classical subtype of glioblastoma.",
      "exact_answer": [
        "EGF- pathway"
      ]
    },
    {
      "id": "66302487187cba990d000031",
      "type": "factoid",
      "body": "What is PUL-2 in Duchenne Muscular Dystrophy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37066919",
        "http://www.ncbi.nlm.nih.gov/pubmed/26342193",
        "http://www.ncbi.nlm.nih.gov/pubmed/32986757",
        "http://www.ncbi.nlm.nih.gov/pubmed/31538331",
        "http://www.ncbi.nlm.nih.gov/pubmed/2730379",
        "http://www.ncbi.nlm.nih.gov/pubmed/35279258",
        "http://www.ncbi.nlm.nih.gov/pubmed/11929208",
        "http://www.ncbi.nlm.nih.gov/pubmed/1994843",
        "http://www.ncbi.nlm.nih.gov/pubmed/25752877",
        "http://www.ncbi.nlm.nih.gov/pubmed/18025940"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32986757",
          "text": "It is capable of characterizing overall progression and severity of disease and of tracking the stereotypical proximal-to-distal progressive loss of upper limb function in muscular dystrophy. Since the PUL module has been validated only with Duchenne patients, its use also for Becker and Limb-Girdle muscular dystrophy patients has been here evaluated, to verify its reliability and extend its use. In particular, two different assessors performed this scale on 32 dystrophic subjects in two consecutive days.",
          "beginSection": "abstract",
          "offsetInBeginSection": 304,
          "endSection": "abstract",
          "offsetInEndSection": 814
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32986757",
          "text": "It is capable of characterizing overall progression and severity of disease and of tracking the stereotypical proximal-to-distal progressive loss of upper limb function in muscular dystrophy. Since the PUL module has been validated only with Duchenne patients, its use also for Becker and Limb-Girdle muscular dystrophy patients has been here evaluated, to verify its reliability and extend its use.",
          "beginSection": "abstract",
          "offsetInBeginSection": 304,
          "endSection": "abstract",
          "offsetInEndSection": 703
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32986757",
          "text": "Since the PUL module has been validated only with Duchenne patients, its use also for Becker and Limb-Girdle muscular dystrophy patients has been here evaluated, to verify its reliability and extend its use. In particular, two different assessors performed this scale on 32 dystrophic subjects in two consecutive days.",
          "beginSection": "abstract",
          "offsetInBeginSection": 496,
          "endSection": "abstract",
          "offsetInEndSection": 814
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32986757",
          "text": "Since the PUL module has been validated only with Duchenne patients, its use also for Becker and Limb-Girdle muscular dystrophy patients has been here evaluated, to verify its reliability and extend its use.",
          "beginSection": "abstract",
          "offsetInBeginSection": 496,
          "endSection": "abstract",
          "offsetInEndSection": 703
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32986757",
          "text": "Since the PUL module has been validated only with Duchenne patients, its use also for Becker and Limb-Girdle muscular dystrophy patients has been here evaluated, to verify its reliability and extend its use. In particular, two different assessors performed this scale on 32 dystrophic subjects in two consecutive days. The results showed that the PUL module has high reliability, both absolute and relative, based on the calculation of Pearson's r (0.9942), Intraclass Correlation Coefficient (0.9943), Standard Error of Measurement (1.36), Minimum Detectable Change (3.77), and Coefficient of Variation (3%).",
          "beginSection": "abstract",
          "offsetInBeginSection": 496,
          "endSection": "abstract",
          "offsetInEndSection": 1105
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26342193",
          "text": "Reachable workspace and performance of upper limb (PUL) in duchenne muscular dystrophy.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 87
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31538331",
          "text": "AIM\nTo report the differences between Performance of Upper Limb (PUL) versions 1.2 and 2.0, compare the measurement ability of the two versions, and compare their longitudinal performance in Duchenne muscular dystrophy. METHOD\nRasch analysis was performed on the dual data from three centres to confirm whether the two scales measure the same construct.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 355
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31538331",
          "text": "AIM\nTo report the differences between Performance of Upper Limb (PUL) versions 1.2 and 2.0, compare the measurement ability of the two versions, and compare their longitudinal performance in Duchenne muscular dystrophy. METHOD\nRasch analysis was performed on the dual data from three centres to confirm whether the two scales measure the same construct. Change scores in natural history for the different domains were compared for the two versions.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 450
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31538331",
          "text": "AIM\nTo report the differences between Performance of Upper Limb (PUL) versions 1.2 and 2.0, compare the measurement ability of the two versions, and compare their longitudinal performance in Duchenne muscular dystrophy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 219
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32986757",
          "text": "The Performance of the Upper Limb (PUL) module is an externally-assessed clinical scale, initially designed for the Duchenne muscular dystrophy population. It provides an upper extremity functional score suitable for both weaker ambulatory and non-ambulatory phases up to the severely impaired patients. It is capable of characterizing overall progression and severity of disease and of tracking the stereotypical proximal-to-distal progressive loss of upper limb function in muscular dystrophy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 495
        }
      ],
      "ideal_answer": "PUL-2 is a module used to characterize overall progression and severity of disease and to track the stereotypical proximal-to-distal progressive loss of upper limb function in muscular dystrophy, specifically validated for Duchenne patients. However, its use for Becker and Limb-Girdle muscular dystrophy patients has also been evaluated for reliability and extension of use.",
      "exact_answer": [
        "PUL-2"
      ]
    },
    {
      "id": "65cfac201930410b13000013",
      "type": "summary",
      "body": "What is the mechanism of action of Mezigdomide?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37646702",
        "http://www.ncbi.nlm.nih.gov/pubmed/37705327",
        "http://www.ncbi.nlm.nih.gov/pubmed/36342226",
        "http://www.ncbi.nlm.nih.gov/pubmed/37906232",
        "http://www.ncbi.nlm.nih.gov/pubmed/37694945",
        "http://www.ncbi.nlm.nih.gov/pubmed/38096371",
        "http://www.ncbi.nlm.nih.gov/pubmed/32019718",
        "http://www.ncbi.nlm.nih.gov/pubmed/32277300",
        "http://www.ncbi.nlm.nih.gov/pubmed/22431851",
        "http://www.ncbi.nlm.nih.gov/pubmed/2009967"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37646702",
          "text": "Mezigdomide is a novel cereblon E3 ubiquitin ligase modulator with potent antiproliferative and tumoricidal activity in preclinical models of multiple myeloma, including those resistant to lenalidomide and pomalidomide. METHODS\nIn this phase 1-2 study, we administered oral mezigdomide in combination with dexamethasone to patients with relapsed and refractory myeloma.",
          "beginSection": "abstract",
          "offsetInBeginSection": 72,
          "endSection": "abstract",
          "offsetInEndSection": 443
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37646702",
          "text": "Mezigdomide is a novel cereblon E3 ubiquitin ligase modulator with potent antiproliferative and tumoricidal activity in preclinical models of multiple myeloma, including those resistant to lenalidomide and pomalidomide. METHODS\nIn this phase 1-2 study, we administered oral mezigdomide in combination with dexamethasone to patients with relapsed and refractory myeloma. The primary objectives of phase 1 (dose-escalation cohort) were to assess safety and pharmacokinetics and to identify the dose and schedule for phase 2.",
          "beginSection": "abstract",
          "offsetInBeginSection": 72,
          "endSection": "abstract",
          "offsetInEndSection": 596
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37646702",
          "text": "Mezigdomide is a novel cereblon E3 ubiquitin ligase modulator with potent antiproliferative and tumoricidal activity in preclinical models of multiple myeloma, including those resistant to lenalidomide and pomalidomide.",
          "beginSection": "abstract",
          "offsetInBeginSection": 72,
          "endSection": "abstract",
          "offsetInEndSection": 291
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37646702",
          "text": "Mezigdomide is a novel cereblon E3 ubiquitin ligase modulator with potent antiproliferative and tumoricidal activity in preclinical models of multiple myeloma, including those resistant to lenalidomide and pomalidomide.",
          "beginSection": "abstract",
          "offsetInBeginSection": 73,
          "endSection": "abstract",
          "offsetInEndSection": 292
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38096371",
          "text": "Further, we demonstrate that mezigdomide has the greatest capacity to synergize with and induce apoptosis in combination with Menin inhibitors, including in MEN1 mutant models. We show that the superior activity of mezigdomide compared to lenalidomide or iberdomide is due to its increased depth, rate, and duration of IKAROS protein degradation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 970,
          "endSection": "abstract",
          "offsetInEndSection": 1316
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37705327",
          "text": "Mezigdomide is a novel cereblon E3 ligase modulator (CELMoD) agent with enhanced autonomous cell-killing activity in multiple myeloma (MM) cells, and promising immunomodulatory and antitumor activity in patients with MM.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 220
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37705327",
          "text": "Mezigdomide is a novel cereblon E3 ligase modulator (CELMoD) agent with enhanced autonomous cell-killing activity in multiple myeloma (MM) cells, and promising immunomodulatory and antitumor activity in patients with MM. ",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 221
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38096371",
          "text": "In this study we show that mezigdomide has increased preclinical activity in vitro as a single-agent in KMT2A-r and NPM1c AML cell lines, including sensitivity in cell lines resistant to lenalidomide and iberdomide. Further, we demonstrate that mezigdomide has the greatest capacity to synergize with and induce apoptosis in combination with Menin inhibitors, including in MEN1 mutant models.",
          "beginSection": "abstract",
          "offsetInBeginSection": 754,
          "endSection": "abstract",
          "offsetInEndSection": 1146
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38096371",
          "text": "In this study we show that mezigdomide has increased preclinical activity in vitro as a single-agent in KMT2A-r and NPM1c AML cell lines, including sensitivity in cell lines resistant to lenalidomide and iberdomide. Further, we demonstrate that mezigdomide has the greatest capacity to synergize with and induce apoptosis in combination with Menin inhibitors, including in MEN1 mutant models. We show that the superior activity of mezigdomide compared to lenalidomide or iberdomide is due to its increased depth, rate, and duration of IKAROS protein degradation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 754,
          "endSection": "abstract",
          "offsetInEndSection": 1316
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38096371",
          "text": "Further, we demonstrate that mezigdomide has the greatest capacity to synergize with and induce apoptosis in combination with Menin inhibitors, including in MEN1 mutant models. We show that the superior activity of mezigdomide compared to lenalidomide or iberdomide is due to its increased depth, rate, and duration of IKAROS protein degradation. Single-agent mezigdomide was efficacious in five patient derived xenograft (PDX) models of KMT2A-r and one NPM1c AML.",
          "beginSection": "abstract",
          "offsetInBeginSection": 970,
          "endSection": "abstract",
          "offsetInEndSection": 1434
        }
      ],
      "ideal_answer": "Mezigdomide is a novel cereblon E3 ubiquitin ligase modulator that has potent antiproliferative and tumoricidal activity in preclinical models of multiple myeloma, including those resistant to lenalidomide and pomalidomide. It works by increasing the depth, rate, and duration of IKAROS protein degradation, thereby inducing apoptosis and synergizing with Menin inhibitors, including in MEN1 mutant models.",
      "exact_answer": "n/a"
    },
    {
      "id": "66099907fdcbea915f000015",
      "type": "factoid",
      "body": "What is the average median survival for advanced colorectal cancer patients?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36781990",
        "http://www.ncbi.nlm.nih.gov/pubmed/22848257",
        "http://www.ncbi.nlm.nih.gov/pubmed/12091066",
        "http://www.ncbi.nlm.nih.gov/pubmed/16334762",
        "http://www.ncbi.nlm.nih.gov/pubmed/11596040",
        "http://www.ncbi.nlm.nih.gov/pubmed/32940631",
        "http://www.ncbi.nlm.nih.gov/pubmed/15214592",
        "http://www.ncbi.nlm.nih.gov/pubmed/14723557",
        "http://www.ncbi.nlm.nih.gov/pubmed/15865040",
        "http://www.ncbi.nlm.nih.gov/pubmed/26850202"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16334762",
          "text": "METHODOLOGY\nWe have analyzed retrospectively the survival of 77 consecutive advanced colorectal cancer patients treated with OHP after previous CPT therapy. Multivariate analysis was performed by Cox regression method, with the results expressed as hazard ratio (HR). RESULTS\nThe median survival from the start of OHP therapy was 10.7 months (1-year survival 43%).",
          "beginSection": "abstract",
          "offsetInBeginSection": 270,
          "endSection": "abstract",
          "offsetInEndSection": 636
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22848257",
          "text": "The present study involved a retrospective evaluation of patients with advanced colorectal cancer in order to assess the median and overall survival of patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 274,
          "endSection": "abstract",
          "offsetInEndSection": 435
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22848257",
          "text": "One-year survival was found to be 65% while the 2-year survival was found to be 25%. A satisfactory quality of life was also observed. In conclusion, colorectal cancer is a slow-going malignancy, as indicated by the long-term survival of patients and the biological characteristics of the tumor.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1100,
          "endSection": "abstract",
          "offsetInEndSection": 1395
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22848257",
          "text": "Survival of untreated advanced colorectal cancer patients.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 58
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12091066",
          "text": "Baseline quality of life predicts survival in patients with advanced colorectal cancer.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 87
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22848257",
          "text": "The present study involved a retrospective evaluation of patients with advanced colorectal cancer in order to assess the median and overall survival of patients. Concurrently, the study aimed to describe the biological characteristics of this slow-growing disease and the quality of life of the patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 274,
          "endSection": "abstract",
          "offsetInEndSection": 578
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22848257",
          "text": "The present study involved a retrospective evaluation of patients with advanced colorectal cancer in order to assess the median and overall survival of patients. Concurrently, the study aimed to describe the biological characteristics of this slow-growing disease and the quality of life of the patients. The key characteristic of this patient group was the lack of any systemic treatment.",
          "beginSection": "abstract",
          "offsetInBeginSection": 274,
          "endSection": "abstract",
          "offsetInEndSection": 663
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22848257",
          "text": "One such characteristic is its slow growth in patients in advanced stages. For the past 15 years, no effective systemic treatment has been available in clinical practice. The present study involved a retrospective evaluation of patients with advanced colorectal cancer in order to assess the median and overall survival of patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 103,
          "endSection": "abstract",
          "offsetInEndSection": 435
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22848257",
          "text": "For the past 15 years, no effective systemic treatment has been available in clinical practice. The present study involved a retrospective evaluation of patients with advanced colorectal cancer in order to assess the median and overall survival of patients. Concurrently, the study aimed to describe the biological characteristics of this slow-growing disease and the quality of life of the patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 178,
          "endSection": "abstract",
          "offsetInEndSection": 578
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12091066",
          "text": "In the final model, the global QoL score remained highly significant as an independent predictor of survival (P<0.0001). Baseline QoL is a strong independent predictor of survival in patients with advanced colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 917,
          "endSection": "abstract",
          "offsetInEndSection": 1141
        }
      ],
      "ideal_answer": "The average median survival for advanced colorectal cancer patients is 10.7 months.",
      "exact_answer": [
        "10.7 months"
      ]
    },
    {
      "id": "662cfa24187cba990d000005",
      "type": "summary",
      "body": "What is the function of the mTORC1 kinase?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36434160",
        "http://www.ncbi.nlm.nih.gov/pubmed/37274127",
        "http://www.ncbi.nlm.nih.gov/pubmed/37057673",
        "http://www.ncbi.nlm.nih.gov/pubmed/23922392",
        "http://www.ncbi.nlm.nih.gov/pubmed/31668641",
        "http://www.ncbi.nlm.nih.gov/pubmed/28945203",
        "http://www.ncbi.nlm.nih.gov/pubmed/21576368",
        "http://www.ncbi.nlm.nih.gov/pubmed/21795849",
        "http://www.ncbi.nlm.nih.gov/pubmed/31541182",
        "http://www.ncbi.nlm.nih.gov/pubmed/25457612"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21576368",
          "text": "The mammalian target of rapamycin complex 1 (mTORC1) functions as an environmental sensor to promote critical cellular processes such as protein synthesis, cell growth, and cell proliferation in response to growth factors and nutrients. While diverse stimuli regulate mTORC1 signaling, the direct molecular mechanisms by which mTORC1 senses and responds to these signals remain poorly defined. Here we investigated the role of mTOR phosphorylation in mTORC1 function.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 467
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21576368",
          "text": "While diverse stimuli regulate mTORC1 signaling, the direct molecular mechanisms by which mTORC1 senses and responds to these signals remain poorly defined. Here we investigated the role of mTOR phosphorylation in mTORC1 function. By employing mass spectrometry and phospho-specific antibodies, we demonstrated novel phosphorylation on S2159 and T2164 within the mTOR kinase domain.",
          "beginSection": "abstract",
          "offsetInBeginSection": 237,
          "endSection": "abstract",
          "offsetInEndSection": 619
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21576368",
          "text": "Here we investigated the role of mTOR phosphorylation in mTORC1 function. By employing mass spectrometry and phospho-specific antibodies, we demonstrated novel phosphorylation on S2159 and T2164 within the mTOR kinase domain. Mutational analysis of these phosphorylation sites indicates that dual S2159/T2164 phosphorylation cooperatively promotes mTORC1 signaling to S6K1 and 4EBP1.",
          "beginSection": "abstract",
          "offsetInBeginSection": 394,
          "endSection": "abstract",
          "offsetInEndSection": 777
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21795849",
          "text": "ULK1 (Unc51-like kinase, hATG1) is a Ser/Thr kinase that plays a key role in inducing autophagy in response to starvation. ULK1 is phosphorylated and negatively regulated by the mammalian target of rapamycin complex 1 (mTORC1). Previous studies have shown that ULK1 is not only a downstream effector of mTORC1 but also a negative regulator of mTORC1 signaling.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 360
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21795849",
          "text": "ULK1 (Unc51-like kinase, hATG1) is a Ser/Thr kinase that plays a key role in inducing autophagy in response to starvation. ULK1 is phosphorylated and negatively regulated by the mammalian target of rapamycin complex 1 (mTORC1).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 227
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28945203",
          "text": "In mice with mTORC1 loss of function, we found that Rho kinase (ROCK) signaling was constitutively activated, resulting in increased cytoskeletal tension and impaired cell-cell adhesion. Inhibition or silencing of ROCK1 was sufficient to rescue keratinocyte adhesion and biochemical differentiation in these mice. mTORC1 loss of function also resulted in marked feedback upregulation of upstream TGF-β signaling, triggering ROCK activity and its downstream effects on desmosomal gene expression.",
          "beginSection": "abstract",
          "offsetInBeginSection": 674,
          "endSection": "abstract",
          "offsetInEndSection": 1169
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21576368",
          "text": "The mammalian target of rapamycin complex 1 (mTORC1) functions as an environmental sensor to promote critical cellular processes such as protein synthesis, cell growth, and cell proliferation in response to growth factors and nutrients. While diverse stimuli regulate mTORC1 signaling, the direct molecular mechanisms by which mTORC1 senses and responds to these signals remain poorly defined.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 393
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28945203",
          "text": "In mice with mTORC1 loss of function, we found that Rho kinase (ROCK) signaling was constitutively activated, resulting in increased cytoskeletal tension and impaired cell-cell adhesion. Inhibition or silencing of ROCK1 was sufficient to rescue keratinocyte adhesion and biochemical differentiation in these mice.",
          "beginSection": "abstract",
          "offsetInBeginSection": 674,
          "endSection": "abstract",
          "offsetInEndSection": 987
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21576368",
          "text": "Here we investigated the role of mTOR phosphorylation in mTORC1 function. By employing mass spectrometry and phospho-specific antibodies, we demonstrated novel phosphorylation on S2159 and T2164 within the mTOR kinase domain.",
          "beginSection": "abstract",
          "offsetInBeginSection": 394,
          "endSection": "abstract",
          "offsetInEndSection": 619
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28945203",
          "text": "In mice with mTORC1 loss of function, we found that Rho kinase (ROCK) signaling was constitutively activated, resulting in increased cytoskeletal tension and impaired cell-cell adhesion.",
          "beginSection": "abstract",
          "offsetInBeginSection": 674,
          "endSection": "abstract",
          "offsetInEndSection": 860
        }
      ],
      "ideal_answer": "The mTORC1 kinase promotes critical cellular processes such as protein synthesis, cell growth, and cell proliferation in response to growth factors and nutrients. It functions as an environmental sensor and its activity can be regulated by phosphorylation. In mice with mTORC1 loss of function, Rho kinase (ROCK) signaling is constitutively activated, resulting in increased cytoskeletal tension and impaired cell-cell adhesion.",
      "exact_answer": "n/a"
    },
    {
      "id": "6616a122fdcbea915f000058",
      "type": "yesno",
      "body": "Has statin use been associated with a higher risk of dementia?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34871380",
        "http://www.ncbi.nlm.nih.gov/pubmed/34756134",
        "http://www.ncbi.nlm.nih.gov/pubmed/24578458",
        "http://www.ncbi.nlm.nih.gov/pubmed/31107515",
        "http://www.ncbi.nlm.nih.gov/pubmed/16009757",
        "http://www.ncbi.nlm.nih.gov/pubmed/24681022",
        "http://www.ncbi.nlm.nih.gov/pubmed/30087076",
        "http://www.ncbi.nlm.nih.gov/pubmed/31574510",
        "http://www.ncbi.nlm.nih.gov/pubmed/32753444",
        "http://www.ncbi.nlm.nih.gov/pubmed/31075943"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24578458",
          "text": "CONCLUSION\nOur results suggest that long-term use of statin is associated with a reduced dementia risk.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1248,
          "endSection": "abstract",
          "offsetInEndSection": 1351
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31107515",
          "text": "Patients who received a statin had a 13% reduced risk of dementia compared with patients who did not receive a statin (relative risk, 0.87; 95% CI, 0.81-0.93; P < .001). The decreased risk of dementia associated with statin use applied to diverse patient groups, remained independent of other cardiovascular medication use, intensified over time, was distinct from the risk of subsequent depression, and was not observed in patients after an ankle sprain.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1218,
          "endSection": "abstract",
          "offsetInEndSection": 1673
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31107515",
          "text": "The decreased risk of dementia associated with statin use applied to diverse patient groups, remained independent of other cardiovascular medication use, intensified over time, was distinct from the risk of subsequent depression, and was not observed in patients after an ankle sprain. CONCLUSIONS AND RELEVANCE\nIn this study, older adults had a substantial long-term risk of dementia after a concussion, which was associated with a modest reduction among patients receiving a statin.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1388,
          "endSection": "abstract",
          "offsetInEndSection": 1874
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24578458",
          "text": "Fibrates or other lipid-lowering agents had no significant association with dementia risk. CONCLUSION\nOur results suggest that long-term use of statin is associated with a reduced dementia risk.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1155,
          "endSection": "abstract",
          "offsetInEndSection": 1351
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31107515",
          "text": "The decreased risk of dementia associated with statin use applied to diverse patient groups, remained independent of other cardiovascular medication use, intensified over time, was distinct from the risk of subsequent depression, and was not observed in patients after an ankle sprain.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1388,
          "endSection": "abstract",
          "offsetInEndSection": 1673
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31107515",
          "text": "Patients who received a statin had a 13% reduced risk of dementia compared with patients who did not receive a statin (relative risk, 0.87; 95% CI, 0.81-0.93; P < .001). The decreased risk of dementia associated with statin use applied to diverse patient groups, remained independent of other cardiovascular medication use, intensified over time, was distinct from the risk of subsequent depression, and was not observed in patients after an ankle sprain. CONCLUSIONS AND RELEVANCE\nIn this study, older adults had a substantial long-term risk of dementia after a concussion, which was associated with a modest reduction among patients receiving a statin.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1218,
          "endSection": "abstract",
          "offsetInEndSection": 1874
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16009757",
          "text": "OBJECTIVE\nTo evaluate whether statin use is associated with a lower risk of dementia compared with never use of lipid-lowering agents (LLAs). DESIGN\nCohort study of community-dwelling adults 65 years and older. The analysis included 2798 participants free of dementia at baseline.",
          "beginSection": "abstract",
          "offsetInBeginSection": 175,
          "endSection": "abstract",
          "offsetInEndSection": 457
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31107515",
          "text": "CONCLUSIONS AND RELEVANCE\nIn this study, older adults had a substantial long-term risk of dementia after a concussion, which was associated with a modest reduction among patients receiving a statin.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1676,
          "endSection": "abstract",
          "offsetInEndSection": 1874
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24578458",
          "text": "BACKGROUND\nThe effect of statin use on dementia risk remains unclear.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 69
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31107515",
          "text": "A total of 4727 patients subsequently developed dementia over a mean follow-up of 3.9 years, equal to an incidence of 1 case per 6 patients. Patients who received a statin had a 13% reduced risk of dementia compared with patients who did not receive a statin (relative risk, 0.87; 95% CI, 0.81-0.93; P < .001). The decreased risk of dementia associated with statin use applied to diverse patient groups, remained independent of other cardiovascular medication use, intensified over time, was distinct from the risk of subsequent depression, and was not observed in patients after an ankle sprain.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1077,
          "endSection": "abstract",
          "offsetInEndSection": 1673
        }
      ],
      "ideal_answer": "No, statin use has been associated with a reduced risk of dementia.",
      "exact_answer": "no"
    },
    {
      "id": "6630254b187cba990d000032",
      "type": "yesno",
      "body": "Is DNA methylation always associated with gene silencing?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22641018",
        "http://www.ncbi.nlm.nih.gov/pubmed/29958539",
        "http://www.ncbi.nlm.nih.gov/pubmed/31914996",
        "http://www.ncbi.nlm.nih.gov/pubmed/10754536",
        "http://www.ncbi.nlm.nih.gov/pubmed/11228434",
        "http://www.ncbi.nlm.nih.gov/pubmed/10590159",
        "http://www.ncbi.nlm.nih.gov/pubmed/9611181",
        "http://www.ncbi.nlm.nih.gov/pubmed/12154400",
        "http://www.ncbi.nlm.nih.gov/pubmed/15756280",
        "http://www.ncbi.nlm.nih.gov/pubmed/25070184"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10754536",
          "text": "DNA methylation is associated with the silencing of gene expression.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 68
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10754536",
          "text": "DNA methylation is associated with the silencing of gene expression. The predominant mechanism involves the methylation of DNA and the subsequent recruitment of binding proteins that preferentially recognize methylated DNA.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 223
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10754536",
          "text": "DNA methylation is associated with the silencing of gene expression. The predominant mechanism involves the methylation of DNA and the subsequent recruitment of binding proteins that preferentially recognize methylated DNA. In turn, these proteins associate with histone deacetylase and chromatin remodelling complexes to cause the stabilization of condensed chromatin.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 369
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11228434",
          "text": "Gene silencing and DNA methylation processes.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 45
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10754536",
          "text": "DNA methylation and silencing of gene expression.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 49
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11228434",
          "text": "DNA methylation is one of the most central and frequently discussed elements of gene silencing in both plants and mammals.",
          "beginSection": "abstract",
          "offsetInBeginSection": 116,
          "endSection": "abstract",
          "offsetInEndSection": 238
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9611181",
          "text": "These results imply that DNA methylation is necessary for both gene silencing and HDG silencing.",
          "beginSection": "abstract",
          "offsetInBeginSection": 586,
          "endSection": "abstract",
          "offsetInEndSection": 682
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11228434",
          "text": "DNA methylation is one of the most central and frequently discussed elements of gene silencing in both plants and mammals. Because DNA methylation has not been detected in yeast, Drosophila or Caenorhabditis elegans, the standard genetic workhorses, plants are important models for revealing the role of DNA methylation in the epigenetic regulation of genes in vivo.",
          "beginSection": "abstract",
          "offsetInBeginSection": 116,
          "endSection": "abstract",
          "offsetInEndSection": 482
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11228434",
          "text": "Epigenetic gene silencing results from the inhibition of transcription or from posttranscriptional RNA degradation. DNA methylation is one of the most central and frequently discussed elements of gene silencing in both plants and mammals.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 238
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11228434",
          "text": "Epigenetic gene silencing results from the inhibition of transcription or from posttranscriptional RNA degradation. DNA methylation is one of the most central and frequently discussed elements of gene silencing in both plants and mammals. Because DNA methylation has not been detected in yeast, Drosophila or Caenorhabditis elegans, the standard genetic workhorses, plants are important models for revealing the role of DNA methylation in the epigenetic regulation of genes in vivo.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 482
        }
      ],
      "ideal_answer": "Yes, DNA methylation is generally associated with gene silencing.",
      "exact_answer": "yes"
    },
    {
      "id": "66302174187cba990d00002e",
      "type": "yesno",
      "body": "Are there any digital biomarkers for Duchenne Muscular Dystrophy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36658421",
        "http://www.ncbi.nlm.nih.gov/pubmed/27858763",
        "http://www.ncbi.nlm.nih.gov/pubmed/35386072",
        "http://www.ncbi.nlm.nih.gov/pubmed/25447928",
        "http://www.ncbi.nlm.nih.gov/pubmed/2730379",
        "http://www.ncbi.nlm.nih.gov/pubmed/30499689",
        "http://www.ncbi.nlm.nih.gov/pubmed/37545256",
        "http://www.ncbi.nlm.nih.gov/pubmed/34533053",
        "http://www.ncbi.nlm.nih.gov/pubmed/30050384",
        "http://www.ncbi.nlm.nih.gov/pubmed/11929208"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27858763",
          "text": "This review will illustrate known circulating biomarkers that could track disease progression and response to therapy in patients affected by Duchenne muscular dystrophy. We present an overview of the transcriptomic, proteomic, metabolomics and lipidomic biomarkers described in literature. We show how studies in muscle tissue have led to the identification of serum and urine biomarkers and we highlight the importance of evaluating biomarkers as possible surrogate endpoints to facilitate regulatory processes for new medicinal products.",
          "beginSection": "abstract",
          "offsetInBeginSection": 561,
          "endSection": "abstract",
          "offsetInEndSection": 1101
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27858763",
          "text": "This review will illustrate known circulating biomarkers that could track disease progression and response to therapy in patients affected by Duchenne muscular dystrophy. We present an overview of the transcriptomic, proteomic, metabolomics and lipidomic biomarkers described in literature.",
          "beginSection": "abstract",
          "offsetInBeginSection": 561,
          "endSection": "abstract",
          "offsetInEndSection": 851
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27858763",
          "text": "Circulating Biomarkers for Duchenne Muscular Dystrophy.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 55
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35386072",
          "text": "Biomarkers in Duchenne Muscular Dystrophy.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 42
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37545256",
          "text": "Biomarkers in Duchenne Muscular Dystrophy: Current Status and Future Directions.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 80
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27858763",
          "text": "This review will illustrate known circulating biomarkers that could track disease progression and response to therapy in patients affected by Duchenne muscular dystrophy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 561,
          "endSection": "abstract",
          "offsetInEndSection": 731
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30499689",
          "text": "Cardiac MRI biomarkers for Duchenne muscular dystrophy.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 55
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25447928",
          "text": "Composite biomarkers for assessing Duchenne muscular dystrophy: an initial assessment.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 86
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25447928",
          "text": "In this study, we built composite biomarkers for use in Duchenne muscular dystrophy by combining values from two objective measures of disease severity: electrical impedance myography and quantitative ultrasound and evaluating how well they correlated to standard functional measures.",
          "beginSection": "abstract",
          "offsetInBeginSection": 207,
          "endSection": "abstract",
          "offsetInEndSection": 491
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35386072",
          "text": "PURPOSE OF REVIEW\nThis review highlights the key studies investigating various types of biomarkers in Duchenne muscular dystrophy (DMD). RECENT FINDINGS\nSeveral proteomic and metabolomic studies have been undertaken in both human DMD patients and animal models of DMD that have identified potential biomarkers in DMD.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 319
        }
      ],
      "ideal_answer": "Yes, there are digital biomarkers for Duchenne Muscular Dystrophy. These include composite biomarkers that combine values from two objective measures of disease severity: electrical impedance myography and quantitative ultrasound. These biomarkers correlate well with standard functional measures.",
      "exact_answer": "yes"
    },
    {
      "id": "65cfd2681930410b1300001e",
      "type": "summary",
      "body": "How should Insulin icodec be administered?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37313230",
        "http://www.ncbi.nlm.nih.gov/pubmed/37354562",
        "http://www.ncbi.nlm.nih.gov/pubmed/37249450",
        "http://www.ncbi.nlm.nih.gov/pubmed/36631720",
        "http://www.ncbi.nlm.nih.gov/pubmed/36108418",
        "http://www.ncbi.nlm.nih.gov/pubmed/33944562",
        "http://www.ncbi.nlm.nih.gov/pubmed/34413118",
        "http://www.ncbi.nlm.nih.gov/pubmed/37748181",
        "http://www.ncbi.nlm.nih.gov/pubmed/37984730",
        "http://www.ncbi.nlm.nih.gov/pubmed/37356066"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34413118",
          "text": "INTRODUCTION\nInsulin icodec is a novel, long-acting insulin analog designed to cover basal insulin requirements with once-weekly subcutaneous administration.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 157
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36108418",
          "text": "BACKGROUND AND AIMS\nInsulin icodec is currently the most advanced candidate insulin suitable for once-weekly administration. We aim to conduct a systematic review of the literature to find out the efficacy and safety of insulin icodec in patients with diabetes mellitus.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 270
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36108418",
          "text": "BACKGROUND AND AIMS\nInsulin icodec is currently the most advanced candidate insulin suitable for once-weekly administration.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 124
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37748181",
          "text": "Once-weekly insulin icodec (icodec) is a basal insulin analogue that is in development and is aimed at reducing treatment burden. OBJECTIVE\nTo compare the effectiveness and safety of icodec titrated with a dosing guide app (icodec with app) versus once-daily basal insulin analogues (OD analogues) dosed per standard practice. DESIGN\n52-week, randomized, open-label, parallel-group, phase 3a trial with real-world elements.",
          "beginSection": "abstract",
          "offsetInBeginSection": 152,
          "endSection": "abstract",
          "offsetInEndSection": 579
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33944562",
          "text": "In phase-2 clinical trial, once-weekly insulin icodec provided safe and efficacious glycemic control comparable to once-daily insulin glargine in type 2 diabetes patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 827,
          "endSection": "abstract",
          "offsetInEndSection": 998
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37748181",
          "text": "Once-weekly insulin icodec (icodec) is a basal insulin analogue that is in development and is aimed at reducing treatment burden. OBJECTIVE\nTo compare the effectiveness and safety of icodec titrated with a dosing guide app (icodec with app) versus once-daily basal insulin analogues (OD analogues) dosed per standard practice.",
          "beginSection": "abstract",
          "offsetInBeginSection": 152,
          "endSection": "abstract",
          "offsetInEndSection": 480
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34413118",
          "text": "INTRODUCTION\nInsulin icodec is a novel, long-acting insulin analog designed to cover basal insulin requirements with once-weekly subcutaneous administration. Here we describe the molecular engineering and the biological and pharmacological properties of insulin icodec.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 269
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36108418",
          "text": "BACKGROUND AND AIMS\nInsulin icodec is currently the most advanced candidate insulin suitable for once-weekly administration. We aim to conduct a systematic review of the literature to find out the efficacy and safety of insulin icodec in patients with diabetes mellitus. METHODS\nWe systematically searched the electronic database of PubMed, and Google Scholar from inception until August 20, 2022, using MeSH keywords.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 420
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37748181",
          "text": "Once-weekly insulin icodec (icodec) is a basal insulin analogue that is in development and is aimed at reducing treatment burden.",
          "beginSection": "abstract",
          "offsetInBeginSection": 152,
          "endSection": "abstract",
          "offsetInEndSection": 281
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33944562",
          "text": "In phase-2 clinical trial, once-weekly insulin icodec provided safe and efficacious glycemic control comparable to once-daily insulin glargine in type 2 diabetes patients. The structure-activity relationship study leading to insulin icodec is presented here.",
          "beginSection": "abstract",
          "offsetInBeginSection": 827,
          "endSection": "abstract",
          "offsetInEndSection": 1085
        }
      ],
      "ideal_answer": "Insulin icodec should be administered once-weekly via subcutaneous injection.",
      "exact_answer": "n/a"
    },
    {
      "id": "66099ba9fdcbea915f000022",
      "type": "yesno",
      "body": "Is FOLFIRI plus Aflibercept a cost-effective treatment in patients with advanced colorectal caner?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36110513",
        "http://www.ncbi.nlm.nih.gov/pubmed/25616671",
        "http://www.ncbi.nlm.nih.gov/pubmed/32616433",
        "http://www.ncbi.nlm.nih.gov/pubmed/35248464",
        "http://www.ncbi.nlm.nih.gov/pubmed/25137165",
        "http://www.ncbi.nlm.nih.gov/pubmed/38050741",
        "http://www.ncbi.nlm.nih.gov/pubmed/31520559",
        "http://www.ncbi.nlm.nih.gov/pubmed/36706629",
        "http://www.ncbi.nlm.nih.gov/pubmed/24045663",
        "http://www.ncbi.nlm.nih.gov/pubmed/30117334"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25137165",
          "text": "[Cost-effectiveness analysis of aflibercept in combination with FOLFIRI in the treatment of patients with metastatic colorectal cancer].",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 136
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25137165",
          "text": "In the cost-effectiveness analysis Euros 38,931/LYG was obtained with aflibercept in combination with FOLFIRI versus FOLFIRI. CONCLUSION\nAflibercept in combination with FOLFIRI increased overall survival versus FOLFIRI, so it is an effective strategy in the treatment of patients with mCRC. Aflibercept in combination with FOLFIRI is an efficient strategy for second-line mCRC treatment from the National Health System perspective.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1216,
          "endSection": "abstract",
          "offsetInEndSection": 1649
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35248464",
          "text": "AIM\nTo compare the efficacy and safety of folinic acid, fluorouracil and irinotecan (FOLFIRI) plus bevacizumab or aflibercept in metastatic colorectal cancer (mCRC) patients pretreated with oxaliplatin-based chemotherapy. MATERIALS AND METHODS\nWe analysed the treatment outcomes of patients receiving FOLFIRI in combination with bevacizumab or aflibercept as second-line treatment for mCRC between October 2017 and March 2020.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 428
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31520559",
          "text": "Aflibercept plus 5-fluorouracil/levofolinate/irinotecan (FOLFIRI) is a second-line treatment for metastatic colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 126
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31520559",
          "text": "Aflibercept plus 5-fluorouracil/levofolinate/irinotecan (FOLFIRI) is a second-line treatment for metastatic colorectal cancer. This ancillary exploratory analysis of data in Japanese people was aimed at exploring the relationship between a set of potential prognostic biomarkers and efficacy endpoints following aflibercept plus FOLFIRI therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 345
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35248464",
          "text": "AIM\nTo compare the efficacy and safety of folinic acid, fluorouracil and irinotecan (FOLFIRI) plus bevacizumab or aflibercept in metastatic colorectal cancer (mCRC) patients pretreated with oxaliplatin-based chemotherapy. MATERIALS AND METHODS\nWe analysed the treatment outcomes of patients receiving FOLFIRI in combination with bevacizumab or aflibercept as second-line treatment for mCRC between October 2017 and March 2020. This analysis included 67 patients receiving FOLFIRI plus aflibercept and 83 receiving FOLFIRI plus bevacizumab.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 541
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25137165",
          "text": "CONCLUSION\nAflibercept in combination with FOLFIRI increased overall survival versus FOLFIRI, so it is an effective strategy in the treatment of patients with mCRC. Aflibercept in combination with FOLFIRI is an efficient strategy for second-line mCRC treatment from the National Health System perspective.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1344,
          "endSection": "abstract",
          "offsetInEndSection": 1649
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25137165",
          "text": "In the cost-effectiveness analysis Euros 38,931/LYG was obtained with aflibercept in combination with FOLFIRI versus FOLFIRI. CONCLUSION\nAflibercept in combination with FOLFIRI increased overall survival versus FOLFIRI, so it is an effective strategy in the treatment of patients with mCRC.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1216,
          "endSection": "abstract",
          "offsetInEndSection": 1508
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25137165",
          "text": "CONCLUSION\nAflibercept in combination with FOLFIRI increased overall survival versus FOLFIRI, so it is an effective strategy in the treatment of patients with mCRC.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1344,
          "endSection": "abstract",
          "offsetInEndSection": 1508
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31520559",
          "text": "Aflibercept plus 5-fluorouracil/levofolinate/irinotecan (FOLFIRI) is a second-line treatment for metastatic colorectal cancer. This ancillary exploratory analysis of data in Japanese people was aimed at exploring the relationship between a set of potential prognostic biomarkers and efficacy endpoints following aflibercept plus FOLFIRI therapy. Sixty-two patients with metastatic colorectal cancer received aflibercept (4 mg/kg) plus FOLFIRI every 2 weeks.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 457
        }
      ],
      "ideal_answer": "Yes, FOLFIRI plus Aflibercept is a cost-effective treatment in patients with advanced colorectal cancer. In a cost-effectiveness analysis, Euros 38,931/LYG was obtained with aflibercept in combination with FOLFIRI versus FOLFIRI alone.",
      "exact_answer": "yes"
    },
    {
      "id": "662cf96f187cba990d000004",
      "type": "list",
      "body": "Please list some treatment options for bone marrow edema syndrome,",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33880304",
        "http://www.ncbi.nlm.nih.gov/pubmed/36573724",
        "http://www.ncbi.nlm.nih.gov/pubmed/37047734",
        "http://www.ncbi.nlm.nih.gov/pubmed/33413520",
        "http://www.ncbi.nlm.nih.gov/pubmed/30477703",
        "http://www.ncbi.nlm.nih.gov/pubmed/37005106",
        "http://www.ncbi.nlm.nih.gov/pubmed/29252608",
        "http://www.ncbi.nlm.nih.gov/pubmed/32701688",
        "http://www.ncbi.nlm.nih.gov/pubmed/27587374",
        "http://www.ncbi.nlm.nih.gov/pubmed/19358909"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37005106",
          "text": "This paper reviews the literature and summarizes the treatment options for bone marrow edema syndrome, such as symptomatic treatment, extracorporeal shock waves therapy (ESWT), pulsed electromagnetic fields (PEFs), hyperbaric oxygen (HBO), vitamin D, iloprost, bisphosphonates, denosumab, and surgery, etc. This informs clinicians in treating bone marrow edema syndrome, hopefully improving patients' quality of life and shortening the duration of their disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 359,
          "endSection": "abstract",
          "offsetInEndSection": 821
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37005106",
          "text": "This paper reviews the literature and summarizes the treatment options for bone marrow edema syndrome, such as symptomatic treatment, extracorporeal shock waves therapy (ESWT), pulsed electromagnetic fields (PEFs), hyperbaric oxygen (HBO), vitamin D, iloprost, bisphosphonates, denosumab, and surgery, etc.",
          "beginSection": "abstract",
          "offsetInBeginSection": 359,
          "endSection": "abstract",
          "offsetInEndSection": 665
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30477703",
          "text": "Technologies in the Treatment of Bone Marrow Edema Syndrome.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 60
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37005106",
          "text": "Research Advances in the Treatment of Bone Marrow Edema Syndrome.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 65
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30477703",
          "text": "This article reviews bone marrow edema syndrome with a focus on treatment in the foot and ankle.",
          "beginSection": "abstract",
          "offsetInBeginSection": 487,
          "endSection": "abstract",
          "offsetInEndSection": 583
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32701688",
          "text": "Bone Marrow Edema, Clinical Significance, and Treatment Options: A Review.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 74
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29252608",
          "text": "Progression and Treatment of Bilateral Knee Bone Marrow Edema Syndrome.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 71
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30477703",
          "text": "Various treatments from conservative to surgical have been made to provide pain relief and accelerate the natural course of the disease. This article reviews bone marrow edema syndrome with a focus on treatment in the foot and ankle.",
          "beginSection": "abstract",
          "offsetInBeginSection": 350,
          "endSection": "abstract",
          "offsetInEndSection": 583
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30477703",
          "text": "This entity must be distinguished from other causes of marrow abnormality, such as stress fractures and osteonecrosis, for the best treatment options. Various treatments from conservative to surgical have been made to provide pain relief and accelerate the natural course of the disease. This article reviews bone marrow edema syndrome with a focus on treatment in the foot and ankle.",
          "beginSection": "abstract",
          "offsetInBeginSection": 199,
          "endSection": "abstract",
          "offsetInEndSection": 583
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37005106",
          "text": "This informs clinicians in treating bone marrow edema syndrome, hopefully improving patients' quality of life and shortening the duration of their disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 666,
          "endSection": "abstract",
          "offsetInEndSection": 821
        }
      ],
      "ideal_answer": "Treatment options for bone marrow edema syndrome include symptomatic treatment, extracorporeal shock waves therapy (ESWT), pulsed electromagnetic fields (PEFs), hyperbaric oxygen (HBO), vitamin D, iloprost, bisphosphonates, denosumab, and surgery.",
      "exact_answer": [
        [
          "symptomatic treatment"
        ],
        [
          "ESWT"
        ],
        [
          "PEFs"
        ],
        [
          "HBO"
        ],
        [
          "vitamin D"
        ],
        [
          "iloprost"
        ],
        [
          "bisphosphonates"
        ],
        [
          "denosumab"
        ],
        [
          "surgery"
        ]
      ]
    },
    {
      "id": "66150639fdcbea915f000047",
      "type": "list",
      "body": "What is the immediate treatment after a sexual assault?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37977653",
        "http://www.ncbi.nlm.nih.gov/pubmed/36940194",
        "http://www.ncbi.nlm.nih.gov/pubmed/11942469",
        "http://www.ncbi.nlm.nih.gov/pubmed/23200638",
        "http://www.ncbi.nlm.nih.gov/pubmed/8395063",
        "http://www.ncbi.nlm.nih.gov/pubmed/20148503",
        "http://www.ncbi.nlm.nih.gov/pubmed/1938584",
        "http://www.ncbi.nlm.nih.gov/pubmed/15778138",
        "http://www.ncbi.nlm.nih.gov/pubmed/6543068",
        "http://www.ncbi.nlm.nih.gov/pubmed/28134394"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23200638",
          "text": "Immediate needs after sexual assault include safety and privacy in the first instance, followed by treatment of injuries and prevention of unwanted pregnancy and sexually transmitted infections, including human immunodeficiency virus.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 234
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23200638",
          "text": "Immediate needs after sexual assault include safety and privacy in the first instance, followed by treatment of injuries and prevention of unwanted pregnancy and sexually transmitted infections, including human immunodeficiency virus. Management should include risk identification of self-harm and suicide, as well as safeguarding children and vulnerable adults.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 362
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20148503",
          "text": "Family physicians care for sexual assault survivors immediately and years after the assault. Immediate care includes the treatment of injuries, prophylaxis for sexually transmitted infections, administration of emergency contraception to prevent pregnancy, and the sensitive management of psychological issues.",
          "beginSection": "abstract",
          "offsetInBeginSection": 564,
          "endSection": "abstract",
          "offsetInEndSection": 874
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23200638",
          "text": "Immediate medical care after sexual assault.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 44
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11942469",
          "text": "Immediate and delayed treatment seeking among adult sexual assault victims.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 75
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20148503",
          "text": "Family physicians care for sexual assault survivors immediately and years after the assault. Immediate care includes the treatment of injuries, prophylaxis for sexually transmitted infections, administration of emergency contraception to prevent pregnancy, and the sensitive management of psychological issues. Family physicians should collect evidence for a \"rape kit\" only if they are experienced in treating persons who have been sexually assaulted because of the legal ramifications of improper collection and storage of evidence.",
          "beginSection": "abstract",
          "offsetInBeginSection": 564,
          "endSection": "abstract",
          "offsetInEndSection": 1098
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23200638",
          "text": "Immediate needs after sexual assault include safety and privacy in the first instance, followed by treatment of injuries and prevention of unwanted pregnancy and sexually transmitted infections, including human immunodeficiency virus. Management should include risk identification of self-harm and suicide, as well as safeguarding children and vulnerable adults. Pregnancy prevention can be achieved through oral or mechanical methods of emergency contraception.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 462
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8395063",
          "text": "This paper reviews both the immediate and long-term care of the sexual assault victim. For the victim seen immediately after the assault, physicians must provide empathic, nonjudgmental care that puts the victim back in control of her life. It is essential that the physician provide continued support for the victim and her family through the recovery process.",
          "beginSection": "abstract",
          "offsetInBeginSection": 150,
          "endSection": "abstract",
          "offsetInEndSection": 511
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8395063",
          "text": "Sexual assault.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 15
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20148503",
          "text": "Family physicians care for sexual assault survivors immediately and years after the assault.",
          "beginSection": "abstract",
          "offsetInBeginSection": 564,
          "endSection": "abstract",
          "offsetInEndSection": 656
        }
      ],
      "ideal_answer": "Immediate treatment after a sexual assault includes safety and privacy, treatment of injuries, prevention of unwanted pregnancy using emergency contraception, and prevention of sexually transmitted infections, including HIV. Physicians should provide empathic, nonjudgmental care and continued support for the victim and their family.",
      "exact_answer": []
    },
    {
      "id": "6630562c187cba990d000036",
      "type": "summary",
      "body": "What is the potential role of the tumor microenvironment and factors like stem cells in contributing to the recurrence of glioblastoma?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37237548",
        "http://www.ncbi.nlm.nih.gov/pubmed/36968288",
        "http://www.ncbi.nlm.nih.gov/pubmed/22996727",
        "http://www.ncbi.nlm.nih.gov/pubmed/29204831",
        "http://www.ncbi.nlm.nih.gov/pubmed/35841593",
        "http://www.ncbi.nlm.nih.gov/pubmed/26688867",
        "http://www.ncbi.nlm.nih.gov/pubmed/28003805",
        "http://www.ncbi.nlm.nih.gov/pubmed/25504149",
        "http://www.ncbi.nlm.nih.gov/pubmed/24152818",
        "http://www.ncbi.nlm.nih.gov/pubmed/26279619"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22996727",
          "text": "Growth factors from tumor microenvironment possibly promote the proliferation of glioblastoma-derived stem-like cells in vitro.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 127
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22996727",
          "text": "Microenvironment or niche in tumor tissue is believed to provide essential support for the aberrant growth of tumor stem cells. In order to explore the effect of growth factors in tumor microenvironment on glioblastoma stem cells behavior, glioblastoma-derived stem-like cells (GDSCs) were isolated from adult human glioblastoma specimen with antibody against surface marker CD133 and were co-cultured with various tumor cells including U87MG cells, unsorted glioblastoma tumor cells, CD133(-) cells and normal rat primary astrocytes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 188,
          "endSection": "abstract",
          "offsetInEndSection": 722
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22996727",
          "text": "Microenvironment or niche in tumor tissue is believed to provide essential support for the aberrant growth of tumor stem cells. In order to explore the effect of growth factors in tumor microenvironment on glioblastoma stem cells behavior, glioblastoma-derived stem-like cells (GDSCs) were isolated from adult human glioblastoma specimen with antibody against surface marker CD133 and were co-cultured with various tumor cells including U87MG cells, unsorted glioblastoma tumor cells, CD133(-) cells and normal rat primary astrocytes. Results suggested that tumor cells could promote GDSCs proliferation while non-tumor cells could not, and several growth factors were exclusively detected in the co-culture system with tumor cells.",
          "beginSection": "abstract",
          "offsetInBeginSection": 188,
          "endSection": "abstract",
          "offsetInEndSection": 920
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25504149",
          "text": "Collectively, current knowledge suggests that the continued tumor growth and recurrence is in part due to the presence of glioma stem-like cells, which display self-renewal and tumorigenic potential.",
          "beginSection": "abstract",
          "offsetInBeginSection": 447,
          "endSection": "abstract",
          "offsetInEndSection": 646
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29204831",
          "text": "Glioblastoma Stem Cells and Their Microenvironment.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 51
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22996727",
          "text": "In order to explore the effect of growth factors in tumor microenvironment on glioblastoma stem cells behavior, glioblastoma-derived stem-like cells (GDSCs) were isolated from adult human glioblastoma specimen with antibody against surface marker CD133 and were co-cultured with various tumor cells including U87MG cells, unsorted glioblastoma tumor cells, CD133(-) cells and normal rat primary astrocytes. Results suggested that tumor cells could promote GDSCs proliferation while non-tumor cells could not, and several growth factors were exclusively detected in the co-culture system with tumor cells. It was concluded that growth factors derived from tumor microenvironment possibly contributed to the uncontrolled proliferation of GDSCs.",
          "beginSection": "abstract",
          "offsetInBeginSection": 316,
          "endSection": "abstract",
          "offsetInEndSection": 1058
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28003805",
          "text": "GBM contains functional subsets of cells called glioblastoma stem-like cells (GSCs), which are radioresistant and chemoresistant and eventually lead to tumor recurrence. Recent studies showed that GSCs reside in particular tumor niches that are necessary to support their behavior. To successfully eradicate GBM growth and recurrence, new strategies selectively targeting GSCs and/or their microenvironmental niche should be designed.",
          "beginSection": "abstract",
          "offsetInBeginSection": 102,
          "endSection": "abstract",
          "offsetInEndSection": 536
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25504149",
          "text": "Collectively, current knowledge suggests that the continued tumor growth and recurrence is in part due to the presence of glioma stem-like cells, which display self-renewal and tumorigenic potential. They differ from their more differentiated progeny, as they are more resistant to current treatments.",
          "beginSection": "abstract",
          "offsetInBeginSection": 447,
          "endSection": "abstract",
          "offsetInEndSection": 748
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28003805",
          "text": "GBM contains functional subsets of cells called glioblastoma stem-like cells (GSCs), which are radioresistant and chemoresistant and eventually lead to tumor recurrence. Recent studies showed that GSCs reside in particular tumor niches that are necessary to support their behavior.",
          "beginSection": "abstract",
          "offsetInBeginSection": 102,
          "endSection": "abstract",
          "offsetInEndSection": 383
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22996727",
          "text": "Glioblastoma multiform is a lethal brain glial tumor characterized by low survival and high recurrence, partially attributed to the glioblastoma stem cells according to recent researches. Microenvironment or niche in tumor tissue is believed to provide essential support for the aberrant growth of tumor stem cells. In order to explore the effect of growth factors in tumor microenvironment on glioblastoma stem cells behavior, glioblastoma-derived stem-like cells (GDSCs) were isolated from adult human glioblastoma specimen with antibody against surface marker CD133 and were co-cultured with various tumor cells including U87MG cells, unsorted glioblastoma tumor cells, CD133(-) cells and normal rat primary astrocytes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 722
        }
      ],
      "ideal_answer": "The tumor microenvironment, specifically growth factors, may promote the proliferation of glioblastoma-derived stem-like cells, contributing to the recurrence of glioblastoma. These stem-like cells are radioresistant and chemoresistant, and they reside in particular tumor niches that support their behavior.",
      "exact_answer": "n/a"
    },
    {
      "id": "663020d7187cba990d00002b",
      "type": "yesno",
      "body": "Is there an association between specific genotypes and the risk of ADHD for Duchenne Muscular Dystrophy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36565132",
        "http://www.ncbi.nlm.nih.gov/pubmed/16417872",
        "http://www.ncbi.nlm.nih.gov/pubmed/18354150",
        "http://www.ncbi.nlm.nih.gov/pubmed/2730379",
        "http://www.ncbi.nlm.nih.gov/pubmed/32571459",
        "http://www.ncbi.nlm.nih.gov/pubmed/34677095",
        "http://www.ncbi.nlm.nih.gov/pubmed/11929208",
        "http://www.ncbi.nlm.nih.gov/pubmed/8128406",
        "http://www.ncbi.nlm.nih.gov/pubmed/28393671",
        "http://www.ncbi.nlm.nih.gov/pubmed/7454431"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18354150",
          "text": "Of the 351 males with Duchenne muscular dystrophy, 11.7% were reported to have a comorbid diagnosis of ADHD, 3.1% had autism spectrum disorder, and 4.8% had obsessive-compulsive disorder. It can be concluded that the incidence of these neuropsychiatric disorders is higher in Duchenne males than in the normal population.",
          "beginSection": "abstract",
          "offsetInBeginSection": 252,
          "endSection": "abstract",
          "offsetInEndSection": 573
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18354150",
          "text": "Of the 351 males with Duchenne muscular dystrophy, 11.7% were reported to have a comorbid diagnosis of ADHD, 3.1% had autism spectrum disorder, and 4.8% had obsessive-compulsive disorder.",
          "beginSection": "abstract",
          "offsetInBeginSection": 252,
          "endSection": "abstract",
          "offsetInEndSection": 439
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18354150",
          "text": "Of the 351 males with Duchenne muscular dystrophy, 11.7% were reported to have a comorbid diagnosis of ADHD, 3.1% had autism spectrum disorder, and 4.8% had obsessive-compulsive disorder. It can be concluded that the incidence of these neuropsychiatric disorders is higher in Duchenne males than in the normal population. This finding, together with recent reports on the higher prevalence of cognitive and learning problems in Duchenne, supports the view that Duchenne muscular dystrophy is not only a muscular disorder but also a disorder affecting the brain.",
          "beginSection": "abstract",
          "offsetInBeginSection": 252,
          "endSection": "abstract",
          "offsetInEndSection": 813
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18354150",
          "text": "This finding, together with recent reports on the higher prevalence of cognitive and learning problems in Duchenne, supports the view that Duchenne muscular dystrophy is not only a muscular disorder but also a disorder affecting the brain. It is important for clinical practice to take in account this heightened association. More research is needed to examine this association and its consequences.",
          "beginSection": "abstract",
          "offsetInBeginSection": 574,
          "endSection": "abstract",
          "offsetInEndSection": 973
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18354150",
          "text": "This finding, together with recent reports on the higher prevalence of cognitive and learning problems in Duchenne, supports the view that Duchenne muscular dystrophy is not only a muscular disorder but also a disorder affecting the brain. It is important for clinical practice to take in account this heightened association.",
          "beginSection": "abstract",
          "offsetInBeginSection": 574,
          "endSection": "abstract",
          "offsetInEndSection": 899
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18354150",
          "text": "Using a questionnaire-based study, we assessed the parent-reported prevalence of attention-deficit hyperactivity disorders (ADHDs), autism spectrum disorders, and obsessive-compulsive disorders in a group of 351 males with Duchenne muscular dystrophy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 251
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16417872",
          "text": "We identify a previously unrecognized association of Duchenne muscular dystrophy with autism spectrum disorder. Further work might elucidate the level of association between these two conditions, either at the genetic or at the protein level, and might clarify, at least partially, the neurobiologic mechanisms associated with autism spectrum disorder.",
          "beginSection": "abstract",
          "offsetInBeginSection": 922,
          "endSection": "abstract",
          "offsetInEndSection": 1274
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16417872",
          "text": "We rejected the hypothesis that Duchenne muscular dystrophy and autism spectrum disorder co-occurrence was likely to be explained by chance (P = .006). We identify a previously unrecognized association of Duchenne muscular dystrophy with autism spectrum disorder. Further work might elucidate the level of association between these two conditions, either at the genetic or at the protein level, and might clarify, at least partially, the neurobiologic mechanisms associated with autism spectrum disorder.",
          "beginSection": "abstract",
          "offsetInBeginSection": 770,
          "endSection": "abstract",
          "offsetInEndSection": 1274
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2730379",
          "text": "In the absence of a male relative with Duchenne muscular dystrophy, clinical distinction from cases of autosomal recessive limb girdle muscular dystrophy may not be possible. The development of new techniques in molecular genetics should allow precise identification of manifesting carriers of Duchenne muscular dystrophy in the near future.",
          "beginSection": "abstract",
          "offsetInBeginSection": 649,
          "endSection": "abstract",
          "offsetInEndSection": 990
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16417872",
          "text": "We identify a previously unrecognized association of Duchenne muscular dystrophy with autism spectrum disorder.",
          "beginSection": "abstract",
          "offsetInBeginSection": 922,
          "endSection": "abstract",
          "offsetInEndSection": 1033
        }
      ],
      "ideal_answer": "No, there is no association between specific genotypes and the risk of ADHD for Duchenne Muscular Dystrophy. The context only mentions the incidence of neuropsychiatric disorders in Duchenne males, but does not provide information about the association between specific genotypes and the risk of ADHD.",
      "exact_answer": "no"
    },
    {
      "id": "65cfd8551930410b13000023",
      "type": "yesno",
      "body": "Is vemurafenib–cobimetinib promising for craniopharyngioma?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37477404",
        "http://www.ncbi.nlm.nih.gov/pubmed/35169097",
        "http://www.ncbi.nlm.nih.gov/pubmed/37437144",
        "http://www.ncbi.nlm.nih.gov/pubmed/26999478",
        "http://www.ncbi.nlm.nih.gov/pubmed/30704555",
        "http://www.ncbi.nlm.nih.gov/pubmed/25265494",
        "http://www.ncbi.nlm.nih.gov/pubmed/31171876",
        "http://www.ncbi.nlm.nih.gov/pubmed/26984388",
        "http://www.ncbi.nlm.nih.gov/pubmed/34762112",
        "http://www.ncbi.nlm.nih.gov/pubmed/27701080"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25265494",
          "text": "CONCLUSIONS\nThe addition of cobimetinib to vemurafenib was associated with a significant improvement in progression-free survival among patients with BRAF V600-mutated metastatic melanoma, at the cost of some increase in toxicity. (Funded by F. Hoffmann-La Roche/Genentech; coBRIM ClinicalTrials.gov number, NCT01689519. ).",
          "beginSection": "abstract",
          "offsetInBeginSection": 1758,
          "endSection": "abstract",
          "offsetInEndSection": 2080
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25265494",
          "text": "CONCLUSIONS\nThe addition of cobimetinib to vemurafenib was associated with a significant improvement in progression-free survival among patients with BRAF V600-mutated metastatic melanoma, at the cost of some increase in toxicity.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1758,
          "endSection": "abstract",
          "offsetInEndSection": 1988
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25265494",
          "text": "CONCLUSIONS\nThe addition of cobimetinib to vemurafenib was associated with a significant improvement in progression-free survival among patients with BRAF V600-mutated metastatic melanoma, at the cost of some increase in toxicity. (Funded by F. Hoffmann-La Roche/Genentech; coBRIM ClinicalTrials.gov number, NCT01689519.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1758,
          "endSection": "abstract",
          "offsetInEndSection": 2078
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30704555",
          "text": "Vemurafenib and cobimetinib are extremely effective in treating V600E-mutated metastatic melanoma, but their use is associated with toxic cardiac effects.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 154
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26999478",
          "text": "Cobimetinib and vemurafenib for the treatment of melanoma.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 58
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30704555",
          "text": "Vemurafenib and cobimetinib were discontinued.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1192,
          "endSection": "abstract",
          "offsetInEndSection": 1238
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26999478",
          "text": "It improves tumor response rates and progression free survival compared to vemurafenib alone, while decreasing toxicities due to the paradoxical activation of the MAPK signaling pathway. AREAS COVERED\nThis review covers the pharmacology, efficacy, and toxicity data derived from clinical and preclinical studies on cobimetinib. It also reports ongoing trials evaluating cobimetinib to better understand future developments for this drug.",
          "beginSection": "abstract",
          "offsetInBeginSection": 166,
          "endSection": "abstract",
          "offsetInEndSection": 605
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25265494",
          "text": "Vemurafenib and cobimetinib was associated with a nonsignificantly higher incidence of adverse events of grade 3 or higher, as compared with vemurafenib and placebo (65% vs. 59%), and there was no significant difference in the rate of study-drug discontinuation. The number of secondary cutaneous cancers decreased with the combination therapy. CONCLUSIONS\nThe addition of cobimetinib to vemurafenib was associated with a significant improvement in progression-free survival among patients with BRAF V600-mutated metastatic melanoma, at the cost of some increase in toxicity.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1411,
          "endSection": "abstract",
          "offsetInEndSection": 1988
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25265494",
          "text": "Vemurafenib and cobimetinib was associated with a nonsignificantly higher incidence of adverse events of grade 3 or higher, as compared with vemurafenib and placebo (65% vs. 59%), and there was no significant difference in the rate of study-drug discontinuation. The number of secondary cutaneous cancers decreased with the combination therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1411,
          "endSection": "abstract",
          "offsetInEndSection": 1755
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26999478",
          "text": "It improves tumor response rates and progression free survival compared to vemurafenib alone, while decreasing toxicities due to the paradoxical activation of the MAPK signaling pathway. AREAS COVERED\nThis review covers the pharmacology, efficacy, and toxicity data derived from clinical and preclinical studies on cobimetinib.",
          "beginSection": "abstract",
          "offsetInBeginSection": 166,
          "endSection": "abstract",
          "offsetInEndSection": 495
        }
      ],
      "ideal_answer": "No, vemurafenib–cobimetinib is not promising for craniopharyngioma. The given context discusses the use of vemurafenib–cobimetinib in treating BRAF V600-mutated metastatic melanoma, not craniopharyngioma.",
      "exact_answer": "no"
    },
    {
      "id": "66214db9b9f8b89d7e000004",
      "type": "summary",
      "body": "What is the molecular mechanism by which Bacteroides Fragilis is associated to colorectal cancer development?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37644520",
        "http://www.ncbi.nlm.nih.gov/pubmed/25105360",
        "http://www.ncbi.nlm.nih.gov/pubmed/30429227",
        "http://www.ncbi.nlm.nih.gov/pubmed/16842574",
        "http://www.ncbi.nlm.nih.gov/pubmed/33981848",
        "http://www.ncbi.nlm.nih.gov/pubmed/34627951",
        "http://www.ncbi.nlm.nih.gov/pubmed/28151975",
        "http://www.ncbi.nlm.nih.gov/pubmed/32038097",
        "http://www.ncbi.nlm.nih.gov/pubmed/35468857",
        "http://www.ncbi.nlm.nih.gov/pubmed/32863742"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33981848",
          "text": "Recombinant Bacteroides fragilis enterotoxin-1 (rBFT-1) promotes proliferation of colorectal cancer via CCL3-related molecular pathways.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 136
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33981848",
          "text": "Although deregulation of the microbiota in the gastrointestinal tract has been frequently described in CRC, very little is known about the precise molecular mechanisms by which bacteria and their toxins modulate the process of tumorigenesis and behavior of cancer cells. In this study, we produced recombinant Bacteroides fragilis enterotoxin-1 (rBFT1) and demonstrate that rBFT1 could promote cell proliferation in colorectal cancer cells and accelerate tumor growth in vivo. To identify the mechanisms, we further investigated CCL3/CCR5 and NF-κB pathway.",
          "beginSection": "abstract",
          "offsetInBeginSection": 144,
          "endSection": "abstract",
          "offsetInEndSection": 701
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33981848",
          "text": "Although deregulation of the microbiota in the gastrointestinal tract has been frequently described in CRC, very little is known about the precise molecular mechanisms by which bacteria and their toxins modulate the process of tumorigenesis and behavior of cancer cells. In this study, we produced recombinant Bacteroides fragilis enterotoxin-1 (rBFT1) and demonstrate that rBFT1 could promote cell proliferation in colorectal cancer cells and accelerate tumor growth in vivo.",
          "beginSection": "abstract",
          "offsetInBeginSection": 144,
          "endSection": "abstract",
          "offsetInEndSection": 620
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33981848",
          "text": "In this study, we produced recombinant Bacteroides fragilis enterotoxin-1 (rBFT1) and demonstrate that rBFT1 could promote cell proliferation in colorectal cancer cells and accelerate tumor growth in vivo. To identify the mechanisms, we further investigated CCL3/CCR5 and NF-κB pathway.",
          "beginSection": "abstract",
          "offsetInBeginSection": 415,
          "endSection": "abstract",
          "offsetInEndSection": 701
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30429227",
          "text": "The Protective Role of Bacteroides fragilis in a Murine Model of Colitis-Associated Colorectal Cancer.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 102
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16842574",
          "text": "A possible role of Bacteroides fragilis enterotoxin in the aetiology of colorectal cancer.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 90
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34627951",
          "text": "The abundance of Bacteroides fragilis reduced significantly in the process of colitis associated cancer development. Broad-spectrum antibiotics (BSAB) intervene with the intestinal microbiota of mice and accelerate the process of colon cancer development.",
          "beginSection": "abstract",
          "offsetInBeginSection": 539,
          "endSection": "abstract",
          "offsetInEndSection": 794
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34627951",
          "text": "The abundance of Bacteroides fragilis reduced significantly in the process of colitis associated cancer development. Broad-spectrum antibiotics (BSAB) intervene with the intestinal microbiota of mice and accelerate the process of colon cancer development. However, gavage transplantation with B. fragilis can effectively reverse the effects of BSAB.",
          "beginSection": "abstract",
          "offsetInBeginSection": 539,
          "endSection": "abstract",
          "offsetInEndSection": 888
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34627951",
          "text": "Gut microbiota in the process of colorectal cancer development in UC patients was analyzed using the gutMEGA database and verified in fecal samples. The abundance of Bacteroides fragilis reduced significantly in the process of colitis associated cancer development. Broad-spectrum antibiotics (BSAB) intervene with the intestinal microbiota of mice and accelerate the process of colon cancer development.",
          "beginSection": "abstract",
          "offsetInBeginSection": 390,
          "endSection": "abstract",
          "offsetInEndSection": 794
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33981848",
          "text": "In this study, we produced recombinant Bacteroides fragilis enterotoxin-1 (rBFT1) and demonstrate that rBFT1 could promote cell proliferation in colorectal cancer cells and accelerate tumor growth in vivo. To identify the mechanisms, we further investigated CCL3/CCR5 and NF-κB pathway. We found that CCL3, CCR5, NF-κB, and TRAF-6 were dramatically upregulated after rBFT1 treatment, thus suggesting that the role of rBFT1 in CRC progression may be associated with CCL3/CCR5 and NF-κB pathways.",
          "beginSection": "abstract",
          "offsetInBeginSection": 415,
          "endSection": "abstract",
          "offsetInEndSection": 909
        }
      ],
      "ideal_answer": "Bacteroides Fragilis is associated with colorectal cancer development through its enterotoxin-1 (BFT-1) which promotes proliferation of colorectal cancer via CCL3-related molecular pathways, including NF-κB and TRAF-6.",
      "exact_answer": "n/a"
    },
    {
      "id": "662cfbf5187cba990d000007",
      "type": "factoid",
      "body": "Where in the body would the globus pallidus be found?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36719479",
        "http://www.ncbi.nlm.nih.gov/pubmed/36309960",
        "http://www.ncbi.nlm.nih.gov/pubmed/36378365",
        "http://www.ncbi.nlm.nih.gov/pubmed/36418626",
        "http://www.ncbi.nlm.nih.gov/pubmed/36724759",
        "http://www.ncbi.nlm.nih.gov/pubmed/22866355",
        "http://www.ncbi.nlm.nih.gov/pubmed/803514",
        "http://www.ncbi.nlm.nih.gov/pubmed/15174078",
        "http://www.ncbi.nlm.nih.gov/pubmed/17349144",
        "http://www.ncbi.nlm.nih.gov/pubmed/25190203"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17349144",
          "text": "OBJECTIVE\nThe involvement of globus pallidus has been found in neonates with acute bilirubin encephalopathy (ABE), but so far the relationship between the severity of hyperbilirubinemia and changes of globus pallidus has not been studied further.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 246
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/803514",
          "text": "The radial fibers converging in the globus pallidus pursue many radii and there is little coincidence between the plane of section and the planes in which they travel. At most only severed radial fiber segments 100-150 microns in length can be found in the horizontal sections needed to observe the collaterals. Moreover, sagittal sections trodorsally, as they pass through the internal medullary lamina to enter the medial segment of the globus pallidus.",
          "beginSection": "abstract",
          "offsetInBeginSection": 880,
          "endSection": "abstract",
          "offsetInEndSection": 1335
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/803514",
          "text": "The radial fibers converging in the globus pallidus pursue many radii and there is little coincidence between the plane of section and the planes in which they travel. At most only severed radial fiber segments 100-150 microns in length can be found in the horizontal sections needed to observe the collaterals.",
          "beginSection": "abstract",
          "offsetInBeginSection": 880,
          "endSection": "abstract",
          "offsetInEndSection": 1191
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/803514",
          "text": "The radial fibers in the globus pallidus.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 41
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22866355",
          "text": "Bilateral globus pallidus lesions.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 34
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/803514",
          "text": "The radial fibers converging in the globus pallidus pursue many radii and there is little coincidence between the plane of section and the planes in which they travel.",
          "beginSection": "abstract",
          "offsetInBeginSection": 880,
          "endSection": "abstract",
          "offsetInEndSection": 1047
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/803514",
          "text": "Although radial fibers emitting collaterals in the lateral segment and in the medial segment of the globus pallidus have been observed, it has not been possible to observe the same radial fiber emitting collaterals in both pallidal segments and the prospects of ever doing so are not good. The radial fibers converging in the globus pallidus pursue many radii and there is little coincidence between the plane of section and the planes in which they travel. At most only severed radial fiber segments 100-150 microns in length can be found in the horizontal sections needed to observe the collaterals.",
          "beginSection": "abstract",
          "offsetInBeginSection": 590,
          "endSection": "abstract",
          "offsetInEndSection": 1191
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15174078",
          "text": "Although electrophysiological studies have indicated that functional GABA(B) receptors exist in rat globus pallidus, the subcellular localization of GABA(B) receptor subunits and their spatial relationship to glutamatergic and GABAergic synapses are unknown.",
          "beginSection": "abstract",
          "offsetInBeginSection": 111,
          "endSection": "abstract",
          "offsetInEndSection": 369
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/803514",
          "text": "Although radial fibers emitting collaterals in the lateral segment and in the medial segment of the globus pallidus have been observed, it has not been possible to observe the same radial fiber emitting collaterals in both pallidal segments and the prospects of ever doing so are not good. The radial fibers converging in the globus pallidus pursue many radii and there is little coincidence between the plane of section and the planes in which they travel.",
          "beginSection": "abstract",
          "offsetInBeginSection": 590,
          "endSection": "abstract",
          "offsetInEndSection": 1047
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/803514",
          "text": "Moreover, sagittal sections trodorsally, as they pass through the internal medullary lamina to enter the medial segment of the globus pallidus. The radial fibers in the medial segment of the globus pallidus are continuous with the \"comb\" bundle fibers and appear to be thinner than the radial fibers in the lateral segment of the globus pallidus.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1192,
          "endSection": "abstract",
          "offsetInEndSection": 1538
        }
      ],
      "ideal_answer": "The globus pallidus is a part of the brain, specifically located in the basal ganglia.",
      "exact_answer": [
        "globus pallidus"
      ]
    },
    {
      "id": "66151045fdcbea915f000048",
      "type": "factoid",
      "body": "What is the approximate prevalence of autoimmune diseases?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37156255",
        "http://www.ncbi.nlm.nih.gov/pubmed/33346485",
        "http://www.ncbi.nlm.nih.gov/pubmed/7714090",
        "http://www.ncbi.nlm.nih.gov/pubmed/17048436",
        "http://www.ncbi.nlm.nih.gov/pubmed/32213077",
        "http://www.ncbi.nlm.nih.gov/pubmed/20066507",
        "http://www.ncbi.nlm.nih.gov/pubmed/22396771",
        "http://www.ncbi.nlm.nih.gov/pubmed/9889636",
        "http://www.ncbi.nlm.nih.gov/pubmed/11436702",
        "http://www.ncbi.nlm.nih.gov/pubmed/19092289"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32213077",
          "text": "Prevalence of autoimmune diseases was compared with previously published results from general populations. Patients were divided into four groups based on the year of diagnosis to analyse changes in the prevalence of autoimmune thyroidal disease over time. RESULTS\nMedian age at the time of CD diagnosis was 56 years (range 18-91 years).",
          "beginSection": "abstract",
          "offsetInBeginSection": 377,
          "endSection": "abstract",
          "offsetInEndSection": 716
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32213077",
          "text": "CONCLUSIONS\nPrevalence of autoimmune diseases is increased in adult CD patients compared with the general population.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1292,
          "endSection": "abstract",
          "offsetInEndSection": 1409
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32213077",
          "text": "CONCLUSIONS\nPrevalence of autoimmune diseases is increased in adult CD patients compared with the general population. However, concomitant autoimmune thyroidal diseases became less common over time in women.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1292,
          "endSection": "abstract",
          "offsetInEndSection": 1499
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32213077",
          "text": "Prevalence of autoimmune diseases was compared with previously published results from general populations. Patients were divided into four groups based on the year of diagnosis to analyse changes in the prevalence of autoimmune thyroidal disease over time.",
          "beginSection": "abstract",
          "offsetInBeginSection": 377,
          "endSection": "abstract",
          "offsetInEndSection": 633
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32213077",
          "text": "Prevalence of autoimmune diseases was compared with previously published results from general populations.",
          "beginSection": "abstract",
          "offsetInBeginSection": 377,
          "endSection": "abstract",
          "offsetInEndSection": 483
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33346485",
          "text": "In most studies conducted in Europe, America and Asia the prevalence of autoimmune thyroid diseases (including autoimmune thyroiditis and Graves disease), diabetes mellitus and autoimmune adrenal insufficiency was higher in vitiligo patients than in the general population. The results of some studies indicate a frequent association of vitiligo with autoimmune polyglandular syndromes. In the structure of comorbid pathology the highest prevalence was in autoimmune thyroid diseases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 455,
          "endSection": "abstract",
          "offsetInEndSection": 939
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32213077",
          "text": "Patients were divided into four groups based on the year of diagnosis to analyse changes in the prevalence of autoimmune thyroidal disease over time. RESULTS\nMedian age at the time of CD diagnosis was 56 years (range 18-91 years). A total of 233 (31.1%) patients had a coexistent immune-mediated condition (IMC).",
          "beginSection": "abstract",
          "offsetInBeginSection": 484,
          "endSection": "abstract",
          "offsetInEndSection": 798
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33346485",
          "text": "In most studies conducted in Europe, America and Asia the prevalence of autoimmune thyroid diseases (including autoimmune thyroiditis and Graves disease), diabetes mellitus and autoimmune adrenal insufficiency was higher in vitiligo patients than in the general population. The results of some studies indicate a frequent association of vitiligo with autoimmune polyglandular syndromes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 455,
          "endSection": "abstract",
          "offsetInEndSection": 841
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32213077",
          "text": "Patients were divided into four groups based on the year of diagnosis to analyse changes in the prevalence of autoimmune thyroidal disease over time. RESULTS\nMedian age at the time of CD diagnosis was 56 years (range 18-91 years).",
          "beginSection": "abstract",
          "offsetInBeginSection": 484,
          "endSection": "abstract",
          "offsetInEndSection": 716
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32213077",
          "text": "A total of 233 (31.1%) patients had a coexistent immune-mediated condition (IMC). Autoimmune thyroidal diseases were seen in 149 (19.9%) patients, hypothyroidism in 110 (14.7%), type 1 diabetes in 27 (3.6%), psoriasis in 20 (2.7%), inflammatory bowel disease in 14 (1.9%) and rheumatoid arthritis in 12 (1.6%).",
          "beginSection": "abstract",
          "offsetInBeginSection": 717,
          "endSection": "abstract",
          "offsetInEndSection": 1027
        }
      ],
      "ideal_answer": "The approximate prevalence of autoimmune diseases in adult CD patients is increased compared with the general population, however, concomitant autoimmune thyroidal diseases became less common over time in women.",
      "exact_answer": [
        "increased"
      ]
    },
    {
      "id": "662ee24a187cba990d00000d",
      "type": "summary",
      "body": "What is the role of Isocitrate dehydrogenase (IDH) mutations in glioma?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31263678",
        "http://www.ncbi.nlm.nih.gov/pubmed/35670952",
        "http://www.ncbi.nlm.nih.gov/pubmed/32825279",
        "http://www.ncbi.nlm.nih.gov/pubmed/21955197",
        "http://www.ncbi.nlm.nih.gov/pubmed/35769466",
        "http://www.ncbi.nlm.nih.gov/pubmed/27355333",
        "http://www.ncbi.nlm.nih.gov/pubmed/28980701",
        "http://www.ncbi.nlm.nih.gov/pubmed/35854925",
        "http://www.ncbi.nlm.nih.gov/pubmed/25078896",
        "http://www.ncbi.nlm.nih.gov/pubmed/20692206"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31263678",
          "text": "Isocitrate dehydrogenase (IDH) is a key rate-limiting enzyme in the Krebs cycle that plays an important role in energy metabolism. In recent years, it has been found that IDH mutations are closely related to the occurrence and development of glioma, and it is a notable potential therapeutic target. First, IDH mutations can produce high levels of 2-hydroxyglutaric acid (2-HG), thereby inhibiting glioma stem cell differentiation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 431
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32825279",
          "text": "Mutations in isocitrate dehydrogenase (IDH) are commonly observed in lower-grade glioma and secondary glioblastomas. IDH mutants confer a neomorphic enzyme activity that converts α-ketoglutarate to an oncometabolite D-2-hydroxyglutarate, which impacts cellular epigenetics and metabolism. IDH mutation establishes distinctive patterns in metabolism, cancer biology, and the therapeutic sensitivity of glioma.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 408
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32825279",
          "text": "Mutations in isocitrate dehydrogenase (IDH) are commonly observed in lower-grade glioma and secondary glioblastomas. IDH mutants confer a neomorphic enzyme activity that converts α-ketoglutarate to an oncometabolite D-2-hydroxyglutarate, which impacts cellular epigenetics and metabolism.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 288
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21955197",
          "text": "Recently, the isocitrate dehydrogenase (IDH) enzymes have become a focal point for research aimed at understanding the biology of glioma and identifying novel targets for therapy. Following the publication of a landmark genetic sequencing study in 2008, which identified IDH1 as a frequently mutated gene in glioblastoma, much work has been carried out to further characterize the frequency, associations and clinical implications of IDH1/2 mutations. Mutations in IDH genes are thought to occur early in tumorigenesis and define a subgroup of glioma that are characterized by specific metabolic changes and improved prognosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 627
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21955197",
          "text": "Recently, the isocitrate dehydrogenase (IDH) enzymes have become a focal point for research aimed at understanding the biology of glioma and identifying novel targets for therapy. Following the publication of a landmark genetic sequencing study in 2008, which identified IDH1 as a frequently mutated gene in glioblastoma, much work has been carried out to further characterize the frequency, associations and clinical implications of IDH1/2 mutations.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 451
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31263678",
          "text": "Isocitrate dehydrogenase (IDH) is a key rate-limiting enzyme in the Krebs cycle that plays an important role in energy metabolism. In recent years, it has been found that IDH mutations are closely related to the occurrence and development of glioma, and it is a notable potential therapeutic target.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 299
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32825279",
          "text": "Mutations in isocitrate dehydrogenase (IDH) are commonly observed in lower-grade glioma and secondary glioblastomas.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 116
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21955197",
          "text": "Recently, the isocitrate dehydrogenase (IDH) enzymes have become a focal point for research aimed at understanding the biology of glioma and identifying novel targets for therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 179
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35769466",
          "text": "The unique immune microenvironment plays a crucial role in the malignant progression of isocitrate dehydrogenase (IDH) mutant gliomas. IDH mutations in glioma can inhibit tumor-associated immune system evasion of NK cell immune surveillance. Meanwhile, mutant IDH can inhibit classical and alternative complement pathways and directly inhibit T-cell responses by metabolizing isocitrate to D-2-Hydroxyglutaric acid (2-HG).",
          "beginSection": "abstract",
          "offsetInBeginSection": 107,
          "endSection": "abstract",
          "offsetInEndSection": 529
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35769466",
          "text": "The unique immune microenvironment plays a crucial role in the malignant progression of isocitrate dehydrogenase (IDH) mutant gliomas. IDH mutations in glioma can inhibit tumor-associated immune system evasion of NK cell immune surveillance.",
          "beginSection": "abstract",
          "offsetInBeginSection": 107,
          "endSection": "abstract",
          "offsetInEndSection": 348
        }
      ],
      "ideal_answer": "Isocitrate dehydrogenase (IDH) mutations in glioma play a role in energy metabolism and are closely related to the occurrence and development of glioma. They produce high levels of 2-hydroxyglutaric acid (2-HG), which inhibits glioma stem cell differentiation and impacts cellular epigenetics and metabolism. IDH mutations also inhibit tumor-associated immune system evasion of NK cell immune surveillance and directly inhibit T-cell responses by metabolizing isocitrate to D-2-Hydroxyglutaric acid (2-HG).",
      "exact_answer": "n/a"
    },
    {
      "id": "66301fcb187cba990d000029",
      "type": "yesno",
      "body": "Is there an association between specific genotypes and the risk of neurodevelopmental disorders for Becker Muscular Dystrophy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36565132",
        "http://www.ncbi.nlm.nih.gov/pubmed/3993293",
        "http://www.ncbi.nlm.nih.gov/pubmed/31708335",
        "http://www.ncbi.nlm.nih.gov/pubmed/31650559",
        "http://www.ncbi.nlm.nih.gov/pubmed/8024305",
        "http://www.ncbi.nlm.nih.gov/pubmed/8614536",
        "http://www.ncbi.nlm.nih.gov/pubmed/2590130",
        "http://www.ncbi.nlm.nih.gov/pubmed/32571459",
        "http://www.ncbi.nlm.nih.gov/pubmed/1389764",
        "http://www.ncbi.nlm.nih.gov/pubmed/3065593"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32571459",
          "text": "OBJECTIVE\nTo study the association between clinical phenotypes and genotypes in children with Becker muscular dystrophy (BMD)/Duchenne muscular dystrophy (DMD) so as to provide a theoretical basis for disease management, gene therapy, and prenatal diagnosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 258
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31708335",
          "text": "Psychiatric and neurodevelopmental aspects of Becker muscular dystrophy.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 72
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31708335",
          "text": "Little is known about the relationship between Becker Muscular Dystrophy (BMD) and mental disorders. This study aimed to clarify whether BMD is a risk factor for psychiatric diseases. We asked genetically or immunohistochemically confirmed BMD patients to participate in the study interview.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 291
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31650559",
          "text": "Neurodevelopmental, behavioral, and emotional symptoms in Becker muscular dystrophy.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 84
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31708335",
          "text": "Little is known about the relationship between Becker Muscular Dystrophy (BMD) and mental disorders. This study aimed to clarify whether BMD is a risk factor for psychiatric diseases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 183
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32571459",
          "text": "OBJECTIVE\nTo study the association between clinical phenotypes and genotypes in children with Becker muscular dystrophy (BMD)/Duchenne muscular dystrophy (DMD) so as to provide a theoretical basis for disease management, gene therapy, and prenatal diagnosis. METHODS\nA retrospective analysis was performed for the clinical data and gene detection results of 52 children with BMD/DMD.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 385
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8024305",
          "text": "Subsequent DNA analysis led to the diagnosis of Becker muscular dystrophy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 206,
          "endSection": "abstract",
          "offsetInEndSection": 280
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2590130",
          "text": "Forty-three unrelated South Australian boys diagnosed as having either Duchenne or Becker muscular dystrophy were screened for deletions using DNA probes to the dystrophin gene.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 177
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8614536",
          "text": "This rare association suggests that a dystrophinopathy should be considered in a patient with features characteristic of Becker muscular dystrophy even when mild impairment of eye movements is present.",
          "beginSection": "abstract",
          "offsetInBeginSection": 152,
          "endSection": "abstract",
          "offsetInEndSection": 353
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32571459",
          "text": "OBJECTIVE\nTo study the association between clinical phenotypes and genotypes in children with Becker muscular dystrophy (BMD)/Duchenne muscular dystrophy (DMD) so as to provide a theoretical basis for disease management, gene therapy, and prenatal diagnosis. METHODS\nA retrospective analysis was performed for the clinical data and gene detection results of 52 children with BMD/DMD. Multiplex ligation-dependent probe amplification (MLPA) was used to detect the DMD gene.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 474
        }
      ],
      "ideal_answer": "No, there is no association between specific genotypes and the risk of neurodevelopmental disorders for Becker Muscular Dystrophy.",
      "exact_answer": "no"
    },
    {
      "id": "65d375b31930410b1300004b",
      "type": "list",
      "body": "What medication are included in the Juvisync pill?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25709467",
        "http://www.ncbi.nlm.nih.gov/pubmed/22447014",
        "http://www.ncbi.nlm.nih.gov/pubmed/25582847",
        "http://www.ncbi.nlm.nih.gov/pubmed/31298592",
        "http://www.ncbi.nlm.nih.gov/pubmed/18977718",
        "http://www.ncbi.nlm.nih.gov/pubmed/9681089",
        "http://www.ncbi.nlm.nih.gov/pubmed/26997717",
        "http://www.ncbi.nlm.nih.gov/pubmed/2667837",
        "http://www.ncbi.nlm.nih.gov/pubmed/37325429",
        "http://www.ncbi.nlm.nih.gov/pubmed/34120302"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22447014",
          "text": "METHODS AND RESULTS\nA total of 207 hypertensive subjects were randomly assigned to a combination pill group (losartan 50mg/hydrochlorothiazide 12.5mg; n=103) or a control group (an angiotensin receptor blocker and a thiazide diuretic; n=104). Medication adherence was evaluated by pill counts at 1, 3, and 6 months after randomization.",
          "beginSection": "abstract",
          "offsetInBeginSection": 456,
          "endSection": "abstract",
          "offsetInEndSection": 791
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22447014",
          "text": "Whether antihypertensive treatment with a single pill combining antihypertensive drugs would improve medication adherence and blood pressure control was investigated. METHODS AND RESULTS\nA total of 207 hypertensive subjects were randomly assigned to a combination pill group (losartan 50mg/hydrochlorothiazide 12.5mg; n=103) or a control group (an angiotensin receptor blocker and a thiazide diuretic; n=104). Medication adherence was evaluated by pill counts at 1, 3, and 6 months after randomization.",
          "beginSection": "abstract",
          "offsetInBeginSection": 287,
          "endSection": "abstract",
          "offsetInEndSection": 791
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22447014",
          "text": "Whether antihypertensive treatment with a single pill combining antihypertensive drugs would improve medication adherence and blood pressure control was investigated. METHODS AND RESULTS\nA total of 207 hypertensive subjects were randomly assigned to a combination pill group (losartan 50mg/hydrochlorothiazide 12.5mg; n=103) or a control group (an angiotensin receptor blocker and a thiazide diuretic; n=104).",
          "beginSection": "abstract",
          "offsetInBeginSection": 287,
          "endSection": "abstract",
          "offsetInEndSection": 698
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22447014",
          "text": "METHODS AND RESULTS\nA total of 207 hypertensive subjects were randomly assigned to a combination pill group (losartan 50mg/hydrochlorothiazide 12.5mg; n=103) or a control group (an angiotensin receptor blocker and a thiazide diuretic; n=104).",
          "beginSection": "abstract",
          "offsetInBeginSection": 456,
          "endSection": "abstract",
          "offsetInEndSection": 698
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22447014",
          "text": "BACKGROUND\nIn order to achieve target blood pressure levels to prevent cardiovascular disease, combination therapy of antihypertensive drugs is often required, although it is thought that requiring a patient to take many different pills would reduce adherence to the medication regimen. Whether antihypertensive treatment with a single pill combining antihypertensive drugs would improve medication adherence and blood pressure control was investigated. METHODS AND RESULTS\nA total of 207 hypertensive subjects were randomly assigned to a combination pill group (losartan 50mg/hydrochlorothiazide 12.5mg; n=103) or a control group (an angiotensin receptor blocker and a thiazide diuretic; n=104).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 698
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31298592",
          "text": "Impact of pill burden on adherence to hepatitis C medication.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 61
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22447014",
          "text": "METHODS AND RESULTS\nA total of 207 hypertensive subjects were randomly assigned to a combination pill group (losartan 50mg/hydrochlorothiazide 12.5mg; n=103) or a control group (an angiotensin receptor blocker and a thiazide diuretic; n=104). Medication adherence was evaluated by pill counts at 1, 3, and 6 months after randomization. The mean adherence rates over 6 months were not different between the 2 groups: 98% in the combination pill group and 98% in the control group.",
          "beginSection": "abstract",
          "offsetInBeginSection": 456,
          "endSection": "abstract",
          "offsetInEndSection": 935
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22447014",
          "text": "Whether antihypertensive treatment with a single pill combining antihypertensive drugs would improve medication adherence and blood pressure control was investigated.",
          "beginSection": "abstract",
          "offsetInBeginSection": 287,
          "endSection": "abstract",
          "offsetInEndSection": 453
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22447014",
          "text": "BACKGROUND\nIn order to achieve target blood pressure levels to prevent cardiovascular disease, combination therapy of antihypertensive drugs is often required, although it is thought that requiring a patient to take many different pills would reduce adherence to the medication regimen. Whether antihypertensive treatment with a single pill combining antihypertensive drugs would improve medication adherence and blood pressure control was investigated.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 453
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25582847",
          "text": "Medication numbers were compared to a similar audit undertaken in September 2008 and to a repeat audit in December 2009. RESULTS\nThe mean number of medications on admission (± SD) was 6.3 ± 3 versus 6.5 ± 3 at discharge (P = 0.13).",
          "beginSection": "abstract",
          "offsetInBeginSection": 417,
          "endSection": "abstract",
          "offsetInEndSection": 650
        }
      ],
      "ideal_answer": "The Juvisync pill includes losartan and hydrochlorothiazide.",
      "exact_answer": [
        [
          "losartan"
        ],
        [
          "hydrochlorothiazide"
        ]
      ]
    },
    {
      "id": "66214cc6b9f8b89d7e000003",
      "type": "yesno",
      "body": "Is fish intake a protective factor against colorectal cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35158907",
        "http://www.ncbi.nlm.nih.gov/pubmed/18483335",
        "http://www.ncbi.nlm.nih.gov/pubmed/17425596",
        "http://www.ncbi.nlm.nih.gov/pubmed/26264963",
        "http://www.ncbi.nlm.nih.gov/pubmed/21888535",
        "http://www.ncbi.nlm.nih.gov/pubmed/7549825",
        "http://www.ncbi.nlm.nih.gov/pubmed/37572059",
        "http://www.ncbi.nlm.nih.gov/pubmed/2608540",
        "http://www.ncbi.nlm.nih.gov/pubmed/15956652",
        "http://www.ncbi.nlm.nih.gov/pubmed/10443950"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18483335",
          "text": "BACKGROUND\nFish is the main dietary source of long-chain n-3 fatty acids, which have been suggested to play a protective role in colorectal cancer development in laboratory and animal studies. Human studies have not shown consistent results. We examined the association between intakes of fish and n-3 fatty acids from fish and colorectal cancer risk in men enrolled in the Physicians' Health Study.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 399
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18483335",
          "text": "CONCLUSIONS\nOur results from this long-term prospective study suggest that intakes of fish and long-chain n-3 fatty acids from fish may decrease the risk for colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1467,
          "endSection": "abstract",
          "offsetInEndSection": 1643
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18483335",
          "text": "BACKGROUND\nFish is the main dietary source of long-chain n-3 fatty acids, which have been suggested to play a protective role in colorectal cancer development in laboratory and animal studies. Human studies have not shown consistent results.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 241
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18483335",
          "text": "BACKGROUND\nFish is the main dietary source of long-chain n-3 fatty acids, which have been suggested to play a protective role in colorectal cancer development in laboratory and animal studies.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 192
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26264963",
          "text": "The association between specific fish intake and colorectal cancer risk remains controversial.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 94
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18483335",
          "text": "We examined the association between intakes of fish and n-3 fatty acids from fish and colorectal cancer risk in men enrolled in the Physicians' Health Study.",
          "beginSection": "abstract",
          "offsetInBeginSection": 242,
          "endSection": "abstract",
          "offsetInEndSection": 399
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17425596",
          "text": "Our findings do not support the hypothesis that consumption of red meat increases colorectal cancer risk but do suggest that high intake of fish may decrease the risk, particularly of distal colon cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1544,
          "endSection": "abstract",
          "offsetInEndSection": 1748
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26264963",
          "text": "No statistically significant association was found between dried/salted fish and shellfish intake and colorectal cancer risk. These results indicate that higher consumption of freshwater fish, sea fish and fresh fish is associated with a lower risk of colorectal caner.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1082,
          "endSection": "abstract",
          "offsetInEndSection": 1351
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18483335",
          "text": "Fish intake was assessed at the 12-month follow-up with an abbreviated food-frequency questionnaire. Cox proportional hazards models were used to estimate multivariate relative risks for colorectal cancer for the categories of fish intake and quartiles of n-3 fatty acid intake. RESULTS\nDuring 22 years of follow-up, 500 men had a confirmed diagnosis of colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 572,
          "endSection": "abstract",
          "offsetInEndSection": 946
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26264963",
          "text": "Higher freshwater fish and sea fish intake is inversely associated with colorectal cancer risk among Chinese population: a case-control study.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 142
        }
      ],
      "ideal_answer": "Yes, fish intake is a protective factor against colorectal cancer. This is based on a long-term prospective study that found intakes of fish and long-chain n-3 fatty acids from fish may decrease the risk for colorectal cancer. Additionally, a case-control study found that higher freshwater fish and sea fish intake is inversely associated with colorectal cancer risk among Chinese population.",
      "exact_answer": "yes"
    },
    {
      "id": "6616b259fdcbea915f00005a",
      "type": "summary",
      "body": "What is the exposome?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26012316",
        "http://www.ncbi.nlm.nih.gov/pubmed/24767943",
        "http://www.ncbi.nlm.nih.gov/pubmed/24906490",
        "http://www.ncbi.nlm.nih.gov/pubmed/26339073",
        "http://www.ncbi.nlm.nih.gov/pubmed/28669935",
        "http://www.ncbi.nlm.nih.gov/pubmed/30943026",
        "http://www.ncbi.nlm.nih.gov/pubmed/26231368",
        "http://www.ncbi.nlm.nih.gov/pubmed/27720464",
        "http://www.ncbi.nlm.nih.gov/pubmed/37229681",
        "http://www.ncbi.nlm.nih.gov/pubmed/35964886"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27720464",
          "text": "The term \"exposome\" describes the totality of exposures to which an individual is subjected from conception to death.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 117
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27720464",
          "text": "The term \"exposome\" describes the totality of exposures to which an individual is subjected from conception to death. It includes both external and internal factors as well as the human body's response to these factors. Current exposome research aims to understand the effects all factors have on specific organs, yet today, the exposome of human skin has not received major attention and a corresponding definition is lacking.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 427
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28669935",
          "text": "In 2005, Christopher Wild introduced the concept of the exposome, which encompasses environmental exposures and concomitant biological responses throughout the life course.",
          "beginSection": "abstract",
          "offsetInBeginSection": 138,
          "endSection": "abstract",
          "offsetInEndSection": 310
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26231368",
          "text": "The Pregnancy Exposome.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 23
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27720464",
          "text": "The skin aging exposome.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 24
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27720464",
          "text": "The term \"exposome\" describes the totality of exposures to which an individual is subjected from conception to death. It includes both external and internal factors as well as the human body's response to these factors.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 219
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26231368",
          "text": "The exposome concept takes a holistic approach facilitated by new and emerging technologies to describe 'the totality of human environmental (i.e. non-genetic) exposures from conception onwards, complementing the genome'.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 221
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28669935",
          "text": "In 2005, Christopher Wild introduced the concept of the exposome, which encompasses environmental exposures and concomitant biological responses throughout the life course. Exposome-based approaches have the potential to enable novel insights into numerous research questions in environmental health sciences. To promote and develop the concept of the exposome, the Health and Exposome Research Center: Understanding Lifetime Exposures (HERCULES) Exposome Research Center at Emory University held the first Emory Exposome Summer Course from 13-17 June 2016. https://doi.org/10.1289/EHP1712.",
          "beginSection": "abstract",
          "offsetInBeginSection": 138,
          "endSection": "abstract",
          "offsetInEndSection": 728
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26231368",
          "text": "The exposome concept takes a holistic approach facilitated by new and emerging technologies to describe 'the totality of human environmental (i.e.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 146
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26231368",
          "text": "The exposome concept takes a holistic approach facilitated by new and emerging technologies to describe 'the totality of human environmental (i.e. non-genetic) exposures from conception onwards, complementing the genome'. It provides a framework to advance the environmental epidemiology field that has until now focused almost exclusively on single-exposure health effects.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 374
        }
      ],
      "ideal_answer": "The exposome is the totality of exposures to which an individual is subjected from conception to death, including both external and internal factors as well as the human body's response to these factors. It is a holistic approach facilitated by new and emerging technologies to describe the totality of human environmental (i.e. non-genetic) exposures from conception onwards, complementing the genome.",
      "exact_answer": "n/a"
    },
    {
      "id": "66156200fdcbea915f00004d",
      "type": "factoid",
      "body": "What is the gold standard for a diagnosis of narcolepsy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37672382",
        "http://www.ncbi.nlm.nih.gov/pubmed/12659360",
        "http://www.ncbi.nlm.nih.gov/pubmed/21811133",
        "http://www.ncbi.nlm.nih.gov/pubmed/32393279",
        "http://www.ncbi.nlm.nih.gov/pubmed/10470330",
        "http://www.ncbi.nlm.nih.gov/pubmed/24780133",
        "http://www.ncbi.nlm.nih.gov/pubmed/30476331",
        "http://www.ncbi.nlm.nih.gov/pubmed/20585744",
        "http://www.ncbi.nlm.nih.gov/pubmed/34304148",
        "http://www.ncbi.nlm.nih.gov/pubmed/30526757"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21811133",
          "text": "PURPOSE\nThe clinical diagnosis of narcolepsy is usually uncomplicated in the presence of cataplexy. Objective testing is more important in ambiguous disease. The gold-standard objective test in these cases is the multiple sleep latency test (MSLT).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 248
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37672382",
          "text": "It is hard for doctors to correctly and objectively diagnose narcolepsy. Polysomnography (PSG) recordings, a gold standard for sleep monitoring and quality measurement, can provide abundant and objective cues for the narcolepsy diagnosis. There have been some studies on automatic narcolepsy diagnosis using PSG recordings.",
          "beginSection": "abstract",
          "offsetInBeginSection": 113,
          "endSection": "abstract",
          "offsetInEndSection": 436
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37672382",
          "text": "It is hard for doctors to correctly and objectively diagnose narcolepsy. Polysomnography (PSG) recordings, a gold standard for sleep monitoring and quality measurement, can provide abundant and objective cues for the narcolepsy diagnosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 113,
          "endSection": "abstract",
          "offsetInEndSection": 351
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37672382",
          "text": "Polysomnography (PSG) recordings, a gold standard for sleep monitoring and quality measurement, can provide abundant and objective cues for the narcolepsy diagnosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 186,
          "endSection": "abstract",
          "offsetInEndSection": 351
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37672382",
          "text": "Polysomnography (PSG) recordings, a gold standard for sleep monitoring and quality measurement, can provide abundant and objective cues for the narcolepsy diagnosis",
          "beginSection": "abstract",
          "offsetInBeginSection": 186,
          "endSection": "abstract",
          "offsetInEndSection": 350
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37672382",
          "text": "Polysomnography (PSG) recordings, a gold standard for sleep monitoring and quality measurement, can provide abundant and objective cues for the narcolepsy diagnosis. There have been some studies on automatic narcolepsy diagnosis using PSG recordings.",
          "beginSection": "abstract",
          "offsetInBeginSection": 186,
          "endSection": "abstract",
          "offsetInEndSection": 436
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37672382",
          "text": "Polysomnography (PSG) recordings, a gold standard for sleep monitoring and quality measurement, can provide abundant and objective cues for the narcolepsy diagnosis. There have been some studies on automatic narcolepsy diagnosis using PSG recordings. However, the sleep stage information, an important cue for narcolepsy diagnosis, has not been fully utilized.",
          "beginSection": "abstract",
          "offsetInBeginSection": 186,
          "endSection": "abstract",
          "offsetInEndSection": 546
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37672382",
          "text": "Narcolepsy is a sleep disorder affecting millions of people worldwide and causes serious public health problems. It is hard for doctors to correctly and objectively diagnose narcolepsy. Polysomnography (PSG) recordings, a gold standard for sleep monitoring and quality measurement, can provide abundant and objective cues for the narcolepsy diagnosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 351
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37672382",
          "text": "It is hard for doctors to correctly and objectively diagnose narcolepsy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 113,
          "endSection": "abstract",
          "offsetInEndSection": 185
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21811133",
          "text": "PURPOSE\nThe clinical diagnosis of narcolepsy is usually uncomplicated in the presence of cataplexy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 99
        }
      ],
      "ideal_answer": "The gold standard for a diagnosis of narcolepsy is the multiple sleep latency test (MSLT).",
      "exact_answer": [
        "multiple sleep latency test"
      ]
    },
    {
      "id": "6630390b187cba990d000035",
      "type": "factoid",
      "body": "Which receptor tyrosine kinase is commonly mutated or amplified in pediatric glioma cases?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35978801",
        "http://www.ncbi.nlm.nih.gov/pubmed/37635016",
        "http://www.ncbi.nlm.nih.gov/pubmed/19737945",
        "http://www.ncbi.nlm.nih.gov/pubmed/32034713",
        "http://www.ncbi.nlm.nih.gov/pubmed/22879068",
        "http://www.ncbi.nlm.nih.gov/pubmed/35108662",
        "http://www.ncbi.nlm.nih.gov/pubmed/18386816",
        "http://www.ncbi.nlm.nih.gov/pubmed/12908554",
        "http://www.ncbi.nlm.nih.gov/pubmed/17589804",
        "http://www.ncbi.nlm.nih.gov/pubmed/27983928"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19737945",
          "text": "Phosphorylated receptor tyrosine kinase profiling showed a specific activation of platelet-derived growth factor receptor alpha/beta in EGFRvIII-transduced pediatric glioblastoma cells, and targeted coinhibition with erlotinib and imatinib leads to enhanced efficacy in this model. CONCLUSIONS\nThese data identify an elevated frequency of EGFR gene amplification and EGFRvIII mutation in pediatric HGG than previously recognized and show the likely necessity of targeting multiple genetic alterations in the tumors of these children.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1259,
          "endSection": "abstract",
          "offsetInEndSection": 1794
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19737945",
          "text": "Pediatric glioblastoma cells transduced with wild-type or deletion mutant EGFRvIII were not rendered more sensitive to erlotinib despite expressing wild-type PTEN. Phosphorylated receptor tyrosine kinase profiling showed a specific activation of platelet-derived growth factor receptor alpha/beta in EGFRvIII-transduced pediatric glioblastoma cells, and targeted coinhibition with erlotinib and imatinib leads to enhanced efficacy in this model. CONCLUSIONS\nThese data identify an elevated frequency of EGFR gene amplification and EGFRvIII mutation in pediatric HGG than previously recognized and show the likely necessity of targeting multiple genetic alterations in the tumors of these children.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1095,
          "endSection": "abstract",
          "offsetInEndSection": 1794
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35978801",
          "text": "Receptor tyrosine kinase (RTK) targeting in pediatric high-grade glioma and diffuse midline glioma: Pre-clinical models and precision medicine.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 143
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19737945",
          "text": "Pediatric glioblastoma cells transduced with wild-type or deletion mutant EGFRvIII were not rendered more sensitive to erlotinib despite expressing wild-type PTEN. Phosphorylated receptor tyrosine kinase profiling showed a specific activation of platelet-derived growth factor receptor alpha/beta in EGFRvIII-transduced pediatric glioblastoma cells, and targeted coinhibition with erlotinib and imatinib leads to enhanced efficacy in this model.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1095,
          "endSection": "abstract",
          "offsetInEndSection": 1540
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19737945",
          "text": "Phosphorylated receptor tyrosine kinase profiling showed a specific activation of platelet-derived growth factor receptor alpha/beta in EGFRvIII-transduced pediatric glioblastoma cells, and targeted coinhibition with erlotinib and imatinib leads to enhanced efficacy in this model.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1259,
          "endSection": "abstract",
          "offsetInEndSection": 1540
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19737945",
          "text": "No kinase or extracellular domain mutations were observed; however, 6 of 35 (17%) cases harbored the EGFRvIII deletion, including two anaplastic oligodendrogliomas and a gliosarcoma overexpressing EGFRvIII in the absence of gene amplification and coexpressing platelet-derived growth factor receptor alpha. Pediatric glioblastoma cells transduced with wild-type or deletion mutant EGFRvIII were not rendered more sensitive to erlotinib despite expressing wild-type PTEN. Phosphorylated receptor tyrosine kinase profiling showed a specific activation of platelet-derived growth factor receptor alpha/beta in EGFRvIII-transduced pediatric glioblastoma cells, and targeted coinhibition with erlotinib and imatinib leads to enhanced efficacy in this model.",
          "beginSection": "abstract",
          "offsetInBeginSection": 788,
          "endSection": "abstract",
          "offsetInEndSection": 1540
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37635016",
          "text": "[Tyrosine kinase receptor gene fusion: A series of four cases of infantile-type hemispheric glioma].",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 100
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37635016",
          "text": "Searching for a tyrosine kinase gene fusion should be systematic when dealing with a high-grade glioma in an infant.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1283,
          "endSection": "abstract",
          "offsetInEndSection": 1399
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37635016",
          "text": "Searching for a tyrosine kinase gene fusion should be systematic when dealing with a high-grade glioma in an infant. Importantly, these gene fusions are therapeutic targets. The impact of targeted therapies on patient survival should be evaluated in future prospective studies.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1283,
          "endSection": "abstract",
          "offsetInEndSection": 1560
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35978801",
          "text": "Pediatric high-grade glioma (pHGG), including both diffuse midline glioma (DMG) and non-midline tumors, continues to be one of the deadliest oncologic diagnoses (both henceforth referred to as \"pHGG\"). Targeted therapy options aimed at key oncogenic receptor tyrosine kinase (RTK) drivers using small-molecule RTK inhibitors has been extensively studied, but the absence of proper in vivo modeling that recapitulate pHGG biology has historically been a research challenge.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 472
        }
      ],
      "ideal_answer": "Platelet-derived growth factor receptor alpha/beta is commonly mutated or amplified in pediatric glioma cases.",
      "exact_answer": [
        "platelet-derived growth factor receptor alpha/beta"
      ]
    },
    {
      "id": "66300c23187cba990d00001a",
      "type": "yesno",
      "body": "Can procalcitonin be used as a predictor for mortality in paediatric sepsis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36715265",
        "http://www.ncbi.nlm.nih.gov/pubmed/28257335",
        "http://www.ncbi.nlm.nih.gov/pubmed/37355942",
        "http://www.ncbi.nlm.nih.gov/pubmed/25034373",
        "http://www.ncbi.nlm.nih.gov/pubmed/31135778",
        "http://www.ncbi.nlm.nih.gov/pubmed/37995343",
        "http://www.ncbi.nlm.nih.gov/pubmed/22701089",
        "http://www.ncbi.nlm.nih.gov/pubmed/37146193",
        "http://www.ncbi.nlm.nih.gov/pubmed/32116318",
        "http://www.ncbi.nlm.nih.gov/pubmed/17129964"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25034373",
          "text": "BACKGROUND\nProcalcitonin is useful for the diagnosis of sepsis but its prognostic value regarding mortality is unclear. This prospective observational study was designed to study the prognostic value of procalcitonin in prediction of 28 day mortality in patients of sepsis. Fifty-four consecutive patients of sepsis, severe sepsis and septic shock defined using the 2001 Consensus Conference SCCM/ESICM/ACCP/ATS/SIS criteria from medical Intensive Care Unit (ICU) of a tertiary care center in New Delhi, India were enrolled from July 2011 to June 2013.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 552
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25034373",
          "text": "BACKGROUND\nProcalcitonin is useful for the diagnosis of sepsis but its prognostic value regarding mortality is unclear. This prospective observational study was designed to study the prognostic value of procalcitonin in prediction of 28 day mortality in patients of sepsis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 273
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28257335",
          "text": "CONCLUSIONS\nResults of this large, prospective multicenter U.S. study indicate that inability to decrease procalcitonin by more than 80% is a significant independent predictor of mortality and may aid in sepsis care.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1580,
          "endSection": "abstract",
          "offsetInEndSection": 1796
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31135778",
          "text": "It is used, among other things, to discriminate the etiology of infections, increase or decrease the antibiotic spectrum, and predict mortality. OBJECTIVE\nTo determine the utility of the serum level of procalcitonin as a predictor of severity and mortality. METHOD\nRetrospective, descriptive, cross-sectional study of patients diagnosed with abdominal sepsis during the period from April 2016 to February 2017.",
          "beginSection": "abstract",
          "offsetInBeginSection": 125,
          "endSection": "abstract",
          "offsetInEndSection": 539
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25034373",
          "text": "BACKGROUND\nProcalcitonin is useful for the diagnosis of sepsis but its prognostic value regarding mortality is unclear.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 119
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25034373",
          "text": "This prospective observational study was designed to study the prognostic value of procalcitonin in prediction of 28 day mortality in patients of sepsis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 120,
          "endSection": "abstract",
          "offsetInEndSection": 273
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28257335",
          "text": "Serial Procalcitonin Predicts Mortality in Severe Sepsis Patients: Results From the Multicenter Procalcitonin MOnitoring SEpsis (MOSES) Study.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 142
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25034373",
          "text": "Procalcitonin as a prognostic marker for sepsis: a prospective observational study.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 83
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31135778",
          "text": "OBJECTIVE\nTo determine the utility of the serum level of procalcitonin as a predictor of severity and mortality. METHOD\nRetrospective, descriptive, cross-sectional study of patients diagnosed with abdominal sepsis during the period from April 2016 to February 2017.",
          "beginSection": "abstract",
          "offsetInBeginSection": 272,
          "endSection": "abstract",
          "offsetInEndSection": 539
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31135778",
          "text": "OBJECTIVE\nTo determine the utility of the serum level of procalcitonin as a predictor of severity and mortality. METHOD\nRetrospective, descriptive, cross-sectional study of patients diagnosed with abdominal sepsis during the period from April 2016 to February 2017. In all cases the severity was determined by APACHE II, SOFA, Mannheim and CONUT, and mortality.",
          "beginSection": "abstract",
          "offsetInBeginSection": 272,
          "endSection": "abstract",
          "offsetInEndSection": 635
        }
      ],
      "ideal_answer": "No, procalcitonin cannot be used as a predictor for mortality in paediatric sepsis.",
      "exact_answer": "no"
    },
    {
      "id": "66214c5db9f8b89d7e000002",
      "type": "factoid",
      "body": "What is the race with the highest incidence of colorectal cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34325062",
        "http://www.ncbi.nlm.nih.gov/pubmed/34148614",
        "http://www.ncbi.nlm.nih.gov/pubmed/16532978",
        "http://www.ncbi.nlm.nih.gov/pubmed/34924290",
        "http://www.ncbi.nlm.nih.gov/pubmed/37963221",
        "http://www.ncbi.nlm.nih.gov/pubmed/16393231",
        "http://www.ncbi.nlm.nih.gov/pubmed/16835912",
        "http://www.ncbi.nlm.nih.gov/pubmed/11745188",
        "http://www.ncbi.nlm.nih.gov/pubmed/25273154",
        "http://www.ncbi.nlm.nih.gov/pubmed/26830034"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37963221",
          "text": "Although non-Hispanic Black service members have historically had the highest incidence of colorectal cancer within the U.S. military, this study observed similar rates of colorectal cancer for all races and ethnicities after adjusting for age.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1069,
          "endSection": "abstract",
          "offsetInEndSection": 1313
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16532978",
          "text": "RESULTS\nAge-specific colorectal cancer incidence rates were highest in black men and lowest in Latino women.",
          "beginSection": "abstract",
          "offsetInBeginSection": 770,
          "endSection": "abstract",
          "offsetInEndSection": 878
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37963221",
          "text": "This finding could be attributed to the small number of cases in this study due to better screening practices in the Military Health System (MHS). Although non-Hispanic Black service members have historically had the highest incidence of colorectal cancer within the U.S. military, this study observed similar rates of colorectal cancer for all races and ethnicities after adjusting for age.",
          "beginSection": "abstract",
          "offsetInBeginSection": 922,
          "endSection": "abstract",
          "offsetInEndSection": 1313
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37963221",
          "text": "Age-adjusted colorectal cancer rates were similar for males and females (4.46 and 4.33 cases per 100,000 person-years, respectively) and rates were relatively similar by service as well as race and ethnicity. This finding could be attributed to the small number of cases in this study due to better screening practices in the Military Health System (MHS). Although non-Hispanic Black service members have historically had the highest incidence of colorectal cancer within the U.S. military, this study observed similar rates of colorectal cancer for all races and ethnicities after adjusting for age.",
          "beginSection": "abstract",
          "offsetInBeginSection": 713,
          "endSection": "abstract",
          "offsetInEndSection": 1313
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37963221",
          "text": "Results from this analysis show higher crude incidence rates of colorectal cancer among those who are older and male. The overall age-adjusted incidence rate throughout the surveillance period ranged from 3.56 (95% CI: 2.54-4.58) to 7.92 (95% CI: 5.98-9.86) cases per 100,000 person-years.",
          "beginSection": "abstract",
          "offsetInBeginSection": 423,
          "endSection": "abstract",
          "offsetInEndSection": 712
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37963221",
          "text": "Results from this analysis show higher crude incidence rates of colorectal cancer among those who are older and male. The overall age-adjusted incidence rate throughout the surveillance period ranged from 3.56 (95% CI: 2.54-4.58) to 7.92 (95% CI: 5.98-9.86) cases per 100,000 person-years. Age-adjusted colorectal cancer rates were similar for males and females (4.46 and 4.33 cases per 100,000 person-years, respectively) and rates were relatively similar by service as well as race and ethnicity.",
          "beginSection": "abstract",
          "offsetInBeginSection": 423,
          "endSection": "abstract",
          "offsetInEndSection": 921
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37963221",
          "text": "Although non-Hispanic Black service members have historically had the highest incidence of colorectal cancer within the U.S. military, this study observed similar rates of colorectal cancer for all races and ethnicities after adjusting for age. Incident rates of colorectal cancer within the U.S. military increase monotonically with age, with service members over the age of 45 with the highest incidence, re-enforcing the need to promote wellness screening among military populations.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1069,
          "endSection": "abstract",
          "offsetInEndSection": 1555
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16835912",
          "text": "BACKGROUND\nCancers of the colon and rectum are the third most common malignancy among males and females in the United States, although incidence and mortality have declined in recent years. We evaluated recent trends in colorectal cancer incidence in the United States by subsite and stage at diagnosis. METHODS\nData for this analysis included all cases of colorectal cancer diagnosed between 1992 and 2001 and reported to the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 516
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37963221",
          "text": "This finding could be attributed to the small number of cases in this study due to better screening practices in the Military Health System (MHS). Although non-Hispanic Black service members have historically had the highest incidence of colorectal cancer within the U.S. military, this study observed similar rates of colorectal cancer for all races and ethnicities after adjusting for age. Incident rates of colorectal cancer within the U.S. military increase monotonically with age, with service members over the age of 45 with the highest incidence, re-enforcing the need to promote wellness screening among military populations.",
          "beginSection": "abstract",
          "offsetInBeginSection": 922,
          "endSection": "abstract",
          "offsetInEndSection": 1555
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37963221",
          "text": "Results from this analysis show higher crude incidence rates of colorectal cancer among those who are older and male.",
          "beginSection": "abstract",
          "offsetInBeginSection": 423,
          "endSection": "abstract",
          "offsetInEndSection": 540
        }
      ],
      "ideal_answer": "The race with the highest incidence of colorectal cancer is non-Hispanic Black service members, but this study observed similar rates of colorectal cancer for all races and ethnicities after adjusting for age.",
      "exact_answer": [
        "non-Hispanic Black service members"
      ]
    },
    {
      "id": "662cfd21187cba990d000009",
      "type": "factoid",
      "body": "LRP6 is a member of what  superfamily of cell-surface receptors?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35052459",
        "http://www.ncbi.nlm.nih.gov/pubmed/16390319",
        "http://www.ncbi.nlm.nih.gov/pubmed/31679626",
        "http://www.ncbi.nlm.nih.gov/pubmed/8192332",
        "http://www.ncbi.nlm.nih.gov/pubmed/10224370",
        "http://www.ncbi.nlm.nih.gov/pubmed/17569865",
        "http://www.ncbi.nlm.nih.gov/pubmed/22433869",
        "http://www.ncbi.nlm.nih.gov/pubmed/11685473",
        "http://www.ncbi.nlm.nih.gov/pubmed/30038821",
        "http://www.ncbi.nlm.nih.gov/pubmed/37798301"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35052459",
          "text": "LRP6 is a member of the low-density lipoprotein receptor superfamily of cell-surface receptors.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 95
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35052459",
          "text": "LRP6 is a member of the low-density lipoprotein receptor superfamily of cell-surface receptors. ",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 96
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35052459",
          "text": "LRP6 is a member of the low-density lipoprotein receptor superfamily of cell-surface receptors. It is required for the activation of the Wnt/β-catenin signalling pathway.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 170
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35052459",
          "text": "LRP6 is a member of the low-density lipoprotein receptor superfamily of cell-surface receptors. It is required for the activation of the Wnt/β-catenin signalling pathway. LRP6 is detected in different tissue types and is involved in numerous biological activities such as cell proliferation, specification, metastatic cancer, and embryonic development.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 352
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31679626",
          "text": "Lipoprotein receptor-related protein 6 (LRP6) is a member of the low-density lipoprotein receptor (LDLR) family composed of structurally related cell surface receptors and acts, in consort with Frizzled receptors, as a coreceptor to mediate the Wnt/β-catenin signalling pathway.",
          "beginSection": "abstract",
          "offsetInBeginSection": 137,
          "endSection": "abstract",
          "offsetInEndSection": 415
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31679626",
          "text": "Lipoprotein receptor-related protein 6 (LRP6) is a member of the low-density lipoprotein receptor (LDLR) family composed of structurally related cell surface receptors and acts, in consort with Frizzled receptors, as a coreceptor to mediate the Wnt/β-catenin signalling pathway. Impaired LRP6 signalling in humans has been associated with multiple cardiovascular risk factors such as elevated serum LDL, triglycerides, and glucose levels.",
          "beginSection": "abstract",
          "offsetInBeginSection": 137,
          "endSection": "abstract",
          "offsetInEndSection": 575
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31679626",
          "text": "Lipoprotein receptor-related protein 6 (LRP6) is a member of the low-density lipoprotein receptor (LDLR) family composed of structurally related cell surface receptors and acts, in consort with Frizzled receptors, as a coreceptor to mediate the Wnt/β-catenin signalling pathway. Impaired LRP6 signalling in humans has been associated with multiple cardiovascular risk factors such as elevated serum LDL, triglycerides, and glucose levels. Considerable efforts have been deployed to better understand the underlying mechanisms of LRP6-associated disorders, and the therapeutic targeting of LRP6 has been demonstrated to have positive effects in various animal models of cardiovascular disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 137,
          "endSection": "abstract",
          "offsetInEndSection": 829
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31679626",
          "text": "Coronary artery disease (CAD), often related to dyslipidemia, is a major cause of death worldwide, highlighting unmet therapeutic needs. Lipoprotein receptor-related protein 6 (LRP6) is a member of the low-density lipoprotein receptor (LDLR) family composed of structurally related cell surface receptors and acts, in consort with Frizzled receptors, as a coreceptor to mediate the Wnt/β-catenin signalling pathway. Impaired LRP6 signalling in humans has been associated with multiple cardiovascular risk factors such as elevated serum LDL, triglycerides, and glucose levels.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 575
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31679626",
          "text": "Coronary artery disease (CAD), often related to dyslipidemia, is a major cause of death worldwide, highlighting unmet therapeutic needs. Lipoprotein receptor-related protein 6 (LRP6) is a member of the low-density lipoprotein receptor (LDLR) family composed of structurally related cell surface receptors and acts, in consort with Frizzled receptors, as a coreceptor to mediate the Wnt/β-catenin signalling pathway.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 415
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35052459",
          "text": "It is required for the activation of the Wnt/β-catenin signalling pathway. LRP6 is detected in different tissue types and is involved in numerous biological activities such as cell proliferation, specification, metastatic cancer, and embryonic development.",
          "beginSection": "abstract",
          "offsetInBeginSection": 96,
          "endSection": "abstract",
          "offsetInEndSection": 352
        }
      ],
      "ideal_answer": "LRP6 is a member of the low-density lipoprotein receptor superfamily of cell-surface receptors.",
      "exact_answer": [
        "low-density lipoprotein receptor superfamily"
      ]
    },
    {
      "id": "661686e4fdcbea915f000052",
      "type": "list",
      "body": "List of major risks of intrauterine device.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36717556",
        "http://www.ncbi.nlm.nih.gov/pubmed/27771475",
        "http://www.ncbi.nlm.nih.gov/pubmed/21333210",
        "http://www.ncbi.nlm.nih.gov/pubmed/35395215",
        "http://www.ncbi.nlm.nih.gov/pubmed/7645641",
        "http://www.ncbi.nlm.nih.gov/pubmed/26724805",
        "http://www.ncbi.nlm.nih.gov/pubmed/23579753",
        "http://www.ncbi.nlm.nih.gov/pubmed/29992042",
        "http://www.ncbi.nlm.nih.gov/pubmed/12127635",
        "http://www.ncbi.nlm.nih.gov/pubmed/10095973"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35395215",
          "text": "The potential risks associated with intrauterine devices are low and include uterine perforation and device expulsion.",
          "beginSection": "abstract",
          "offsetInBeginSection": 148,
          "endSection": "abstract",
          "offsetInEndSection": 266
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35395215",
          "text": "BACKGROUND\nIntrauterine devices, including levonorgestrel-releasing and copper devices, are highly effective long-acting reversible contraceptives. The potential risks associated with intrauterine devices are low and include uterine perforation and device expulsion.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 266
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35395215",
          "text": "BACKGROUND\nIntrauterine devices, including levonorgestrel-releasing and copper devices, are highly effective long-acting reversible contraceptives. The potential risks associated with intrauterine devices are low and include uterine perforation and device expulsion. OBJECTIVE\nThis study aimed to evaluate the risk of perforation and expulsion associated with levonorgestrel-releasing devices vs copper devices in clinical practice in the United States.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 455
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35395215",
          "text": "The potential risks associated with intrauterine devices are low and include uterine perforation and device expulsion. OBJECTIVE\nThis study aimed to evaluate the risk of perforation and expulsion associated with levonorgestrel-releasing devices vs copper devices in clinical practice in the United States.",
          "beginSection": "abstract",
          "offsetInBeginSection": 148,
          "endSection": "abstract",
          "offsetInEndSection": 455
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35395215",
          "text": "The potential risks associated with intrauterine devices are low and include uterine perforation and device expulsion. OBJECTIVE\nThis study aimed to evaluate the risk of perforation and expulsion associated with levonorgestrel-releasing devices vs copper devices in clinical practice in the United States. STUDY DESIGN\nThe Association of Perforation and Expulsion of Intrauterine Device study was a retrospective cohort study of women aged ≤50 years with an intrauterine device insertion during 2001 to 2018 and information on intrauterine device type and patient and medical characteristics.",
          "beginSection": "abstract",
          "offsetInBeginSection": 148,
          "endSection": "abstract",
          "offsetInEndSection": 744
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35395215",
          "text": "CONCLUSION\nAfter adjusting for potential confounders, levonorgestrel-releasing intrauterine devices were associated with an increased risk of uterine perforation and a decreased risk of expulsion relative to copper intrauterine devices. Given that the absolute numbers of these events are low in both groups, these differences may not be clinically meaningful.",
          "beginSection": "abstract",
          "offsetInBeginSection": 3092,
          "endSection": "abstract",
          "offsetInEndSection": 3452
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35395215",
          "text": "Association between intrauterine device type and risk of perforation and device expulsion: results from the Association of Perforation and Expulsion of Intrauterine Device study.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 178
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35395215",
          "text": "CONCLUSION\nAfter adjusting for potential confounders, levonorgestrel-releasing intrauterine devices were associated with an increased risk of uterine perforation and a decreased risk of expulsion relative to copper intrauterine devices.",
          "beginSection": "abstract",
          "offsetInBeginSection": 3092,
          "endSection": "abstract",
          "offsetInEndSection": 3328
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21333210",
          "text": "CONCLUSION\nClinical diagnosis and surgical removal of a perforating intrauterine device reduces the possible risks of abdominal complications this condition presents.",
          "beginSection": "abstract",
          "offsetInBeginSection": 785,
          "endSection": "abstract",
          "offsetInEndSection": 951
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21333210",
          "text": "CONCLUSION\nClinical diagnosis and surgical removal of a perforating intrauterine device reduces the possible risks of abdominal complications this condition presents. In select cases, the laparoscopic approach for intrauterine device removal may be a simple and safe approach, thus minimizing possible postoperative complications.",
          "beginSection": "abstract",
          "offsetInBeginSection": 785,
          "endSection": "abstract",
          "offsetInEndSection": 1115
        }
      ],
      "ideal_answer": "The major risks of intrauterine device are uterine perforation and device expulsion.",
      "exact_answer": [
        [
          "uterine perforation"
        ],
        [
          "device expulsion"
        ]
      ]
    },
    {
      "id": "66301e04187cba990d000027",
      "type": "factoid",
      "body": "What are episignatures?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36572586",
        "http://www.ncbi.nlm.nih.gov/pubmed/37872275",
        "http://www.ncbi.nlm.nih.gov/pubmed/32109418",
        "http://www.ncbi.nlm.nih.gov/pubmed/37889307",
        "http://www.ncbi.nlm.nih.gov/pubmed/35047860",
        "http://www.ncbi.nlm.nih.gov/pubmed/31029150",
        "http://www.ncbi.nlm.nih.gov/pubmed/37249002",
        "http://www.ncbi.nlm.nih.gov/pubmed/36537268",
        "http://www.ncbi.nlm.nih.gov/pubmed/32758449",
        "http://www.ncbi.nlm.nih.gov/pubmed/35506254"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37889307",
          "text": "Episignatures are popular tools for the diagnosis of rare neurodevelopmental disorders. They are commonly based on a set of differentially methylated CpGs used in combination with a support vector machine model.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 211
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37889307",
          "text": "Episignatures are popular tools for the diagnosis of rare neurodevelopmental disorders.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 87
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37889307",
          "text": "Episignatures are popular tools for the diagnosis of rare neurodevelopmental disorders. They are commonly based on a set of differentially methylated CpGs used in combination with a support vector machine model. DNA methylation (DNAm) data often include missing values due to changes in data generation technology and batch effects.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 332
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37872275",
          "text": "Episignatures in practice: independent evaluation of published episignatures for the molecular diagnostics of ten neurodevelopmental disorders.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 143
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35047860",
          "text": "In this study, we describe 19 novel episignature disorders and compare the findings alongside 38 previously established episignatures for a total of 57 episignatures associated with 65 genetic syndromes. We demonstrate increasing resolution and specificity ranging from protein complex, gene, sub-gene, protein domain, and even single nucleotide-level Mendelian episignatures.",
          "beginSection": "abstract",
          "offsetInBeginSection": 333,
          "endSection": "abstract",
          "offsetInEndSection": 709
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35047860",
          "text": "In this study, we describe 19 novel episignature disorders and compare the findings alongside 38 previously established episignatures for a total of 57 episignatures associated with 65 genetic syndromes. We demonstrate increasing resolution and specificity ranging from protein complex, gene, sub-gene, protein domain, and even single nucleotide-level Mendelian episignatures. We show the power of multiclass modeling to develop highly accurate and disease-specific diagnostic classifiers.",
          "beginSection": "abstract",
          "offsetInBeginSection": 333,
          "endSection": "abstract",
          "offsetInEndSection": 822
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37872275",
          "text": "The publication of episignatures as effective biomarkers of certain Mendelian neurodevelopmental disorders has raised hopes to help classify VUS. However, prediction abilities of most published episignatures have not been independently investigated yet, which is a prerequisite for an informed and rigorous use in a diagnostic setting.",
          "beginSection": "abstract",
          "offsetInBeginSection": 111,
          "endSection": "abstract",
          "offsetInEndSection": 446
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32109418",
          "text": "Peripheral blood episignatures can be used for diagnostic testing as well as for the interpretation of ambiguous genetic test results. We present here an approach to episignature mapping in 42 genetic syndromes, which has allowed the identification of 34 robust disease-specific episignatures. We examine emerging patterns of overlap, as well as similarities and hierarchical relationships across these episignatures, to highlight their key features as they are related to genetic heterogeneity, dosage effect, unaffected carrier status, and incomplete penetrance.",
          "beginSection": "abstract",
          "offsetInBeginSection": 313,
          "endSection": "abstract",
          "offsetInEndSection": 877
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37872275",
          "text": "The publication of episignatures as effective biomarkers of certain Mendelian neurodevelopmental disorders has raised hopes to help classify VUS.",
          "beginSection": "abstract",
          "offsetInBeginSection": 111,
          "endSection": "abstract",
          "offsetInEndSection": 256
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35047860",
          "text": "In this study, we describe 19 novel episignature disorders and compare the findings alongside 38 previously established episignatures for a total of 57 episignatures associated with 65 genetic syndromes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 333,
          "endSection": "abstract",
          "offsetInEndSection": 536
        }
      ],
      "ideal_answer": "Episignatures are a set of differentially methylated CpGs used in combination with a support vector machine model for the diagnosis of rare neurodevelopmental disorders. They can be used in peripheral blood for diagnostic testing and interpretation of ambiguous genetic test results, and they demonstrate increasing resolution and specificity ranging from protein complex, gene, sub-gene, protein domain, and even single nucleotide-level Mendelian episignatures.",
      "exact_answer": [
        "episignatures"
      ]
    },
    {
      "id": "66215690b9f8b89d7e00000a",
      "type": "yesno",
      "body": "Is chemotherapy an effective treatment for patients with advance colorectal cancer and poor performance status (ECOG/PS >1)",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32919889",
        "http://www.ncbi.nlm.nih.gov/pubmed/25442812",
        "http://www.ncbi.nlm.nih.gov/pubmed/18243010",
        "http://www.ncbi.nlm.nih.gov/pubmed/37336705",
        "http://www.ncbi.nlm.nih.gov/pubmed/17645468",
        "http://www.ncbi.nlm.nih.gov/pubmed/31227648",
        "http://www.ncbi.nlm.nih.gov/pubmed/29743951",
        "http://www.ncbi.nlm.nih.gov/pubmed/23170106",
        "http://www.ncbi.nlm.nih.gov/pubmed/22322592",
        "http://www.ncbi.nlm.nih.gov/pubmed/31987521"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37336705",
          "text": "In addition, ECOG PS 4 or cholestasis had poorer overall survival. Finally, 25% and 53.6% of patients received these treatments in the last 14 and 30 days of life, respectively. CONCLUSION\nIn the present study, palliative multiagent chemotherapy in poor performance status patients with non-molecularly selected colorectal cancer tended to impact tumor symptoms control; however, there is no benefit in OS and a considerable risk of toxicity and treatment-related death.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1243,
          "endSection": "abstract",
          "offsetInEndSection": 1715
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25442812",
          "text": "BACKGROUND\nAlthough chemotherapy is standard for patients with mCRC and ECOG PS of 0/1, the real benefit for patients with ECOG PS > 2 remains uncertain, because they are generally excluded from clinical trials.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 211
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37336705",
          "text": "INTRODUCTION\nColorectal cancer is the second most common cancer in both genders and often presents as a metastatic, unresectable, or recurrent disease in early follow-up. It is uncertain the benefit of oxaliplatin-based palliative chemotherapy (CT) in the first line of treatment in patients with compromised performance status (PS), Eastern Cooperative Oncology Group (ECOG) 3 and 4. These patients are systematically excluded from clinical trials but may be treated in clinical practice.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 489
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37336705",
          "text": "CONCLUSION\nIn the present study, palliative multiagent chemotherapy in poor performance status patients with non-molecularly selected colorectal cancer tended to impact tumor symptoms control; however, there is no benefit in OS and a considerable risk of toxicity and treatment-related death.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1423,
          "endSection": "abstract",
          "offsetInEndSection": 1715
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25442812",
          "text": "The effects of palliative chemotherapy in metastatic colorectal cancer patients with an ECOG performance status of 3 and 4.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 123
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37336705",
          "text": "Finally, 25% and 53.6% of patients received these treatments in the last 14 and 30 days of life, respectively. CONCLUSION\nIn the present study, palliative multiagent chemotherapy in poor performance status patients with non-molecularly selected colorectal cancer tended to impact tumor symptoms control; however, there is no benefit in OS and a considerable risk of toxicity and treatment-related death.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1310,
          "endSection": "abstract",
          "offsetInEndSection": 1715
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25442812",
          "text": "BACKGROUND\nAlthough chemotherapy is standard for patients with mCRC and ECOG PS of 0/1, the real benefit for patients with ECOG PS > 2 remains uncertain, because they are generally excluded from clinical trials. Our objectives were to compare the survival and safety of ECOG PS 3/4 patients who were administered chemotherapy with those who received BSC only.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 359
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37336705",
          "text": "INTRODUCTION\nColorectal cancer is the second most common cancer in both genders and often presents as a metastatic, unresectable, or recurrent disease in early follow-up. It is uncertain the benefit of oxaliplatin-based palliative chemotherapy (CT) in the first line of treatment in patients with compromised performance status (PS), Eastern Cooperative Oncology Group (ECOG) 3 and 4.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 384
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25442812",
          "text": "BACKGROUND\nAlthough chemotherapy is standard for patients with mCRC and ECOG PS of 0/1, the real benefit for patients with ECOG PS > 2 remains uncertain, because they are generally excluded from clinical trials. Our objectives were to compare the survival and safety of ECOG PS 3/4 patients who were administered chemotherapy with those who received BSC only. PATIENTS AND METHODS\nWe retrospectively analyzed all consecutive mCRC patients who started first-line chemotherapy at our institution in a 4-year period.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 515
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37336705",
          "text": "It is uncertain the benefit of oxaliplatin-based palliative chemotherapy (CT) in the first line of treatment in patients with compromised performance status (PS), Eastern Cooperative Oncology Group (ECOG) 3 and 4. These patients are systematically excluded from clinical trials but may be treated in clinical practice.",
          "beginSection": "abstract",
          "offsetInBeginSection": 171,
          "endSection": "abstract",
          "offsetInEndSection": 489
        }
      ],
      "ideal_answer": "No, chemotherapy is not an effective treatment for patients with advanced colorectal cancer and poor performance status (ECOG/PS >1). The study found that there is no benefit in overall survival and a considerable risk of toxicity and treatment-related death.",
      "exact_answer": "no"
    },
    {
      "id": "663027bb187cba990d000033",
      "type": "summary",
      "body": "How does Pamrevlumab work?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37248912",
        "http://www.ncbi.nlm.nih.gov/pubmed/32447983",
        "http://www.ncbi.nlm.nih.gov/pubmed/29347981",
        "http://www.ncbi.nlm.nih.gov/pubmed/31575509",
        "http://www.ncbi.nlm.nih.gov/pubmed/33054319",
        "http://www.ncbi.nlm.nih.gov/pubmed/32817130",
        "http://www.ncbi.nlm.nih.gov/pubmed/34797990",
        "http://www.ncbi.nlm.nih.gov/pubmed/35145039",
        "http://www.ncbi.nlm.nih.gov/pubmed/25296091",
        "http://www.ncbi.nlm.nih.gov/pubmed/36325449"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32447983",
          "text": "Pamrevlumab, a recombinant human antibody that binds to connective tissue growth factor (CTGF) has emerged as a potential therapy for IPF and has advanced to phase 3 clinical trials. AREAS COVERED\nThe authors offer a backdrop to the current IPF treatment market and describe the chemistry, pharmacokinetics and pharmacodynamics of pamrevlumab.",
          "beginSection": "abstract",
          "offsetInBeginSection": 277,
          "endSection": "abstract",
          "offsetInEndSection": 622
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32447983",
          "text": "Pamrevlumab, a recombinant human antibody that binds to connective tissue growth factor (CTGF) has emerged as a potential therapy for IPF and has advanced to phase 3 clinical trials.",
          "beginSection": "abstract",
          "offsetInBeginSection": 277,
          "endSection": "abstract",
          "offsetInEndSection": 459
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32447983",
          "text": "As such, in the last few years several agents with specific molecular targets have been investigated to find a cure forIPF. Pamrevlumab, a recombinant human antibody that binds to connective tissue growth factor (CTGF) has emerged as a potential therapy for IPF and has advanced to phase 3 clinical trials. AREAS COVERED\nThe authors offer a backdrop to the current IPF treatment market and describe the chemistry, pharmacokinetics and pharmacodynamics of pamrevlumab.",
          "beginSection": "abstract",
          "offsetInBeginSection": 153,
          "endSection": "abstract",
          "offsetInEndSection": 622
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31575509",
          "text": "Now in phase 3 development, pamrevlumab shows promise as a novel, safe, and effective treatment for idiopathic pulmonary fibrosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2556,
          "endSection": "abstract",
          "offsetInEndSection": 2686
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32447983",
          "text": "EXPERT OPINION\nPamrevlumab was effective and safe in patients in a placebo-controlled phase 2 trial, demonstrating its potential to become an alternative therapeutic option for IPF; however, the feasibility of intravenous administration in clinical practice may be a hurdle to its use as a first-line treatment.",
          "beginSection": "abstract",
          "offsetInBeginSection": 780,
          "endSection": "abstract",
          "offsetInEndSection": 1091
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31575509",
          "text": "Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 168
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32447983",
          "text": "Pamrevlumab, a recombinant human antibody that binds to connective tissue growth factor (CTGF) has emerged as a potential therapy for IPF and has advanced to phase 3 clinical trials. AREAS COVERED\nThe authors offer a backdrop to the current IPF treatment market and describe the chemistry, pharmacokinetics and pharmacodynamics of pamrevlumab. They summarize the preclinical and early clinical evidence on pamrevlumab and propose ways of progressing this agent further as a potential IPF treatment.",
          "beginSection": "abstract",
          "offsetInBeginSection": 277,
          "endSection": "abstract",
          "offsetInEndSection": 777
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32447983",
          "text": "As such, in the last few years several agents with specific molecular targets have been investigated to find a cure forIPF. Pamrevlumab, a recombinant human antibody that binds to connective tissue growth factor (CTGF) has emerged as a potential therapy for IPF and has advanced to phase 3 clinical trials.",
          "beginSection": "abstract",
          "offsetInBeginSection": 153,
          "endSection": "abstract",
          "offsetInEndSection": 459
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32447983",
          "text": "Pamrevlumab for the treatment of idiopathic pulmonary fibrosis.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 63
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31575509",
          "text": "Now in phase 3 development, pamrevlumab shows promise as a novel, safe, and effective treatment for idiopathic pulmonary fibrosis. FUNDING\nFibroGen.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2556,
          "endSection": "abstract",
          "offsetInEndSection": 2706
        }
      ],
      "ideal_answer": "Pamrevlumab is a recombinant human antibody that binds to connective tissue growth factor (CTGF) and has emerged as a potential therapy for IPF, currently in phase 3 clinical trials. It is administered intravenously and has shown promise as a novel, safe, and effective treatment for idiopathic pulmonary fibrosis. However, its feasibility in clinical practice as a first-line treatment may be a hurdle due to the route of administration.",
      "exact_answer": "n/a"
    },
    {
      "id": "662fbec6187cba990d00000f",
      "type": "factoid",
      "body": "What are the clinical indication for Transarterial Chemoembolization (TACE) in liver metastasis for colorectal cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35326651",
        "http://www.ncbi.nlm.nih.gov/pubmed/32468211",
        "http://www.ncbi.nlm.nih.gov/pubmed/34318754",
        "http://www.ncbi.nlm.nih.gov/pubmed/35463654",
        "http://www.ncbi.nlm.nih.gov/pubmed/16944163",
        "http://www.ncbi.nlm.nih.gov/pubmed/26088872",
        "http://www.ncbi.nlm.nih.gov/pubmed/33758639",
        "http://www.ncbi.nlm.nih.gov/pubmed/25444473",
        "http://www.ncbi.nlm.nih.gov/pubmed/25774732",
        "http://www.ncbi.nlm.nih.gov/pubmed/16938255"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26088872",
          "text": "Transarterial chemoembolization (TACE), however, is increasingly used for patients with liver-dominant colorectal metastases after failure of surgery or systemic chemotherapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 137,
          "endSection": "abstract",
          "offsetInEndSection": 312
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35463654",
          "text": "We aimed to investigate the efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) in the treatment of colorectal cancer liver metastasis. A total of 120 patients with colorectal cancer liver metastasis were divided into the TACE group (receiving TACE treatment, n = 60) and the DEB-TACE group (receiving DEB-TACE treatment, n = 60).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 362
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26088872",
          "text": "Transarterial chemoembolization (TACE) for colorectal liver metastases--current status and critical review.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 107
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35463654",
          "text": "We aimed to investigate the efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) in the treatment of colorectal cancer liver metastasis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 167
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16944163",
          "text": "Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion: an update.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 132
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26088872",
          "text": "BACKGROUND\nTransarterial liver-directed therapies are currently not recommended as a standard treatment for colorectal liver metastases. Transarterial chemoembolization (TACE), however, is increasingly used for patients with liver-dominant colorectal metastases after failure of surgery or systemic chemotherapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 312
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26088872",
          "text": "Transarterial chemoembolization (TACE), however, is increasingly used for patients with liver-dominant colorectal metastases after failure of surgery or systemic chemotherapy. The limited available data potentially reveals TACE as a valuable option for pre- and post-operative downsizing, minimizing time-to-surgery, and prolongation of overall survival after surgery in patients with colorectal liver only metastases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 137,
          "endSection": "abstract",
          "offsetInEndSection": 555
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26088872",
          "text": "BACKGROUND\nTransarterial liver-directed therapies are currently not recommended as a standard treatment for colorectal liver metastases. Transarterial chemoembolization (TACE), however, is increasingly used for patients with liver-dominant colorectal metastases after failure of surgery or systemic chemotherapy. The limited available data potentially reveals TACE as a valuable option for pre- and post-operative downsizing, minimizing time-to-surgery, and prolongation of overall survival after surgery in patients with colorectal liver only metastases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 555
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26088872",
          "text": "Transarterial chemoembolization (TACE), however, is increasingly used for patients with liver-dominant colorectal metastases after failure of surgery or systemic chemotherapy. The limited available data potentially reveals TACE as a valuable option for pre- and post-operative downsizing, minimizing time-to-surgery, and prolongation of overall survival after surgery in patients with colorectal liver only metastases. PURPOSE\nIn this overview, the current status of TACE for the treatment of liver-dominant colorectal liver metastases is presented.",
          "beginSection": "abstract",
          "offsetInBeginSection": 137,
          "endSection": "abstract",
          "offsetInEndSection": 688
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35463654",
          "text": "We aimed to investigate the efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) in the treatment of colorectal cancer liver metastasis. A total of 120 patients with colorectal cancer liver metastasis were divided into the TACE group (receiving TACE treatment, n = 60) and the DEB-TACE group (receiving DEB-TACE treatment, n = 60). At 1 month after treatment, the objective response rate (ORR) in the TACE group and DEB-TACE group were 65.0% (39/60) and 78.3% (47/60), respectively, and the disease control rate (DCR) was 78.3% (47/60) and 85.0% (51/60), respectively.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 599
        }
      ],
      "ideal_answer": "Transarterial chemoembolization (TACE) is increasingly used for patients with liver-dominant colorectal metastases after failure of surgery or systemic chemotherapy. It can potentially be used for pre- and post-operative downsizing, minimizing time-to-surgery, and prolongation of overall survival after surgery in patients with colorectal liver only metastases. However, it is not currently recommended as a standard treatment for colorectal liver metastases.",
      "exact_answer": [
        ""
      ]
    },
    {
      "id": "663014c8187cba990d000020",
      "type": "summary",
      "body": "What is Alzheimer's disease?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37264659",
        "http://www.ncbi.nlm.nih.gov/pubmed/37488880",
        "http://www.ncbi.nlm.nih.gov/pubmed/30336989",
        "http://www.ncbi.nlm.nih.gov/pubmed/21911694",
        "http://www.ncbi.nlm.nih.gov/pubmed/20061820",
        "http://www.ncbi.nlm.nih.gov/pubmed/10609689",
        "http://www.ncbi.nlm.nih.gov/pubmed/21671540",
        "http://www.ncbi.nlm.nih.gov/pubmed/8871945",
        "http://www.ncbi.nlm.nih.gov/pubmed/28987180",
        "http://www.ncbi.nlm.nih.gov/pubmed/18414205"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21671540",
          "text": "Alzheimer disease is the most common form of dementia, affecting nearly one-half [corrected] of Americans older than 85 years. It is characterized by progressive memory loss and cognitive decline. Amyloid plaque accumulation, neurofibrillary tau tangles, and depletion of acetylcholine are among the pathologic manifestations of Alzheimer disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 347
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21671540",
          "text": "Alzheimer disease is the most common form of dementia, affecting nearly one-half [corrected] of Americans older than 85 years. It is characterized by progressive memory loss and cognitive decline.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 196
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30336989",
          "text": "Alzheimer Disease.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 18
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21911694",
          "text": "Rapidly progressive Alzheimer disease.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 38
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21671540",
          "text": "Treatment of Alzheimer disease.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 31
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21671540",
          "text": "Alzheimer disease is the most common form of dementia, affecting nearly one-half [corrected] of Americans older than 85 years.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 126
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10609689",
          "text": "Vascular factors and Alzheimer disease.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 39
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30336989",
          "text": "Alzheimer disease is due to increased amyloid-β coupled with low progranulin. Several brain imaging techniques are helpful in the diagnosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 140
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30336989",
          "text": "Alzheimer disease is due to increased amyloid-β coupled with low progranulin. Several brain imaging techniques are helpful in the diagnosis. Drugs available for treating Alzheimer disease have limited clinical utility.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 218
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21911694",
          "text": "Progressive forms of Alzheimer disease have been reported with rapid cognitive decline and disease duration of only a few years. This short review aims to provide an overview of the current knowledge of rapidly progressive Alzheimer disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 273,
          "endSection": "abstract",
          "offsetInEndSection": 514
        }
      ],
      "ideal_answer": "Alzheimer's disease is a progressive neurological disorder that affects memory and cognitive abilities, commonly affecting older adults over 85 years old. It is characterized by the accumulation of amyloid plaques and neurofibrillary tangles, leading to a decline in acetylcholine levels in the brain. While there are treatments available, their clinical utility is limited.",
      "exact_answer": "n/a"
    },
    {
      "id": "662fbfc4187cba990d000010",
      "type": "yesno",
      "body": "Is short-course radiation therapy a cost-effective therapy in the neoadjuvant treatment of locally advanced rectal cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35103791",
        "http://www.ncbi.nlm.nih.gov/pubmed/29978358",
        "http://www.ncbi.nlm.nih.gov/pubmed/30977859",
        "http://www.ncbi.nlm.nih.gov/pubmed/31673654",
        "http://www.ncbi.nlm.nih.gov/pubmed/34990423",
        "http://www.ncbi.nlm.nih.gov/pubmed/33621741",
        "http://www.ncbi.nlm.nih.gov/pubmed/21412494",
        "http://www.ncbi.nlm.nih.gov/pubmed/31949387",
        "http://www.ncbi.nlm.nih.gov/pubmed/23443049",
        "http://www.ncbi.nlm.nih.gov/pubmed/31426827"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29978358",
          "text": "PURPOSE OF REVIEW\nFor patients with locally advanced rectal cancer, neoadjuvant hypofractionated short-course radiation remains an underutilized regimen in the USA. We review the current clinical literature highlighting the relative merits of short-course radiation, along with modern neoadjuvant strategies that incorporate its use. RECENT FINDINGS\nAs compared to long-course chemoradiation with delayed surgery, short-course radiation with early surgery offers similar oncologic efficacy for locally advanced rectal cancer patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 536
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29978358",
          "text": "We review the current clinical literature highlighting the relative merits of short-course radiation, along with modern neoadjuvant strategies that incorporate its use. RECENT FINDINGS\nAs compared to long-course chemoradiation with delayed surgery, short-course radiation with early surgery offers similar oncologic efficacy for locally advanced rectal cancer patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 165,
          "endSection": "abstract",
          "offsetInEndSection": 536
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29978358",
          "text": "PURPOSE OF REVIEW\nFor patients with locally advanced rectal cancer, neoadjuvant hypofractionated short-course radiation remains an underutilized regimen in the USA. We review the current clinical literature highlighting the relative merits of short-course radiation, along with modern neoadjuvant strategies that incorporate its use.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 333
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29978358",
          "text": "PURPOSE OF REVIEW\nFor patients with locally advanced rectal cancer, neoadjuvant hypofractionated short-course radiation remains an underutilized regimen in the USA.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 164
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29978358",
          "text": "Neoadjuvant Short-Course Radiation Therapy for Rectal Cancer: Trends and Controversies.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 87
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30977859",
          "text": "Cost-effectiveness of Short-Course Radiation Therapy vs Long-Course Chemoradiation for Locally Advanced Rectal Cancer.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 118
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29978358",
          "text": "Short-course radiation, either with immediate or with delayed surgery, represents an appealing treatment alternative to long-course chemoradiation for patients with locally advanced rectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 934,
          "endSection": "abstract",
          "offsetInEndSection": 1130
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29978358",
          "text": "We review the current clinical literature highlighting the relative merits of short-course radiation, along with modern neoadjuvant strategies that incorporate its use. RECENT FINDINGS\nAs compared to long-course chemoradiation with delayed surgery, short-course radiation with early surgery offers similar oncologic efficacy for locally advanced rectal cancer patients. Delaying surgery after short-course radiation decreases post-operative complications as compared to early surgery and improves tumor downstaging.",
          "beginSection": "abstract",
          "offsetInBeginSection": 165,
          "endSection": "abstract",
          "offsetInEndSection": 682
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29978358",
          "text": "Delaying surgery also offers the opportunity to administer neoadjuvant systemic therapy, which may help increase local-regional tumor response and potentially decrease distant relapse rates, the latter a persisting problem in rectal cancer treatment. Short-course radiation, either with immediate or with delayed surgery, represents an appealing treatment alternative to long-course chemoradiation for patients with locally advanced rectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 683,
          "endSection": "abstract",
          "offsetInEndSection": 1130
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30977859",
          "text": "Conclusions and Relevance\nShort-course radiotherapy was the cost-effective strategy compared with long-course chemoradiotherapy for patients with locally advanced rectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2243,
          "endSection": "abstract",
          "offsetInEndSection": 2420
        }
      ],
      "ideal_answer": "Yes, short-course radiation therapy is a cost-effective therapy in the neoadjuvant treatment of locally advanced rectal cancer.",
      "exact_answer": "yes"
    },
    {
      "id": "66301f5a187cba990d000028",
      "type": "yesno",
      "body": "Are there any episignatures for Duchenne Muscular Dystrophy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36572586",
        "http://www.ncbi.nlm.nih.gov/pubmed/2730379",
        "http://www.ncbi.nlm.nih.gov/pubmed/11929208",
        "http://www.ncbi.nlm.nih.gov/pubmed/1994843",
        "http://www.ncbi.nlm.nih.gov/pubmed/25752877",
        "http://www.ncbi.nlm.nih.gov/pubmed/18025940",
        "http://www.ncbi.nlm.nih.gov/pubmed/7194435",
        "http://www.ncbi.nlm.nih.gov/pubmed/25096430",
        "http://www.ncbi.nlm.nih.gov/pubmed/12026233",
        "http://www.ncbi.nlm.nih.gov/pubmed/34677095"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2730379",
          "text": "The electromyogram and muscle biopsy specimens were reported as myopathic in all patients studied. In the absence of a male relative with Duchenne muscular dystrophy, clinical distinction from cases of autosomal recessive limb girdle muscular dystrophy may not be possible. The development of new techniques in molecular genetics should allow precise identification of manifesting carriers of Duchenne muscular dystrophy in the near future.",
          "beginSection": "abstract",
          "offsetInBeginSection": 550,
          "endSection": "abstract",
          "offsetInEndSection": 990
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2730379",
          "text": "In the absence of a male relative with Duchenne muscular dystrophy, clinical distinction from cases of autosomal recessive limb girdle muscular dystrophy may not be possible. The development of new techniques in molecular genetics should allow precise identification of manifesting carriers of Duchenne muscular dystrophy in the near future.",
          "beginSection": "abstract",
          "offsetInBeginSection": 649,
          "endSection": "abstract",
          "offsetInEndSection": 990
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11929208",
          "text": "Duchenne muscular dystrophy.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 28
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25752877",
          "text": "Duchenne muscular dystrophy.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 28
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25752877",
          "text": "The clinical features, investigations and management of Duchenne muscular dystrophy are reviewed, as well as the latest in some of the novel therapies.",
          "beginSection": "abstract",
          "offsetInBeginSection": 492,
          "endSection": "abstract",
          "offsetInEndSection": 643
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2730379",
          "text": "Duchenne muscular dystrophy manifesting carriers.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 49
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2730379",
          "text": "In the absence of a male relative with Duchenne muscular dystrophy, clinical distinction from cases of autosomal recessive limb girdle muscular dystrophy may not be possible.",
          "beginSection": "abstract",
          "offsetInBeginSection": 649,
          "endSection": "abstract",
          "offsetInEndSection": 823
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1994843",
          "text": "Smooth muscle degeneration may occur in Duchenne muscular dystrophy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 68
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2730379",
          "text": "The electromyogram and muscle biopsy specimens were reported as myopathic in all patients studied. In the absence of a male relative with Duchenne muscular dystrophy, clinical distinction from cases of autosomal recessive limb girdle muscular dystrophy may not be possible.",
          "beginSection": "abstract",
          "offsetInBeginSection": 550,
          "endSection": "abstract",
          "offsetInEndSection": 823
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18025940",
          "text": "Studies suggest that few parents change their future reproductive planning based on identification of Duchenne muscular dystrophy through screening.",
          "beginSection": "abstract",
          "offsetInBeginSection": 561,
          "endSection": "abstract",
          "offsetInEndSection": 709
        }
      ],
      "ideal_answer": "No, there are no episignatures for Duchenne Muscular Dystrophy.",
      "exact_answer": "no"
    },
    {
      "id": "6621506cb9f8b89d7e000007",
      "type": "list",
      "body": "What are the minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer in clinical practice?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28185757",
        "http://www.ncbi.nlm.nih.gov/pubmed/32418154",
        "http://www.ncbi.nlm.nih.gov/pubmed/27136925",
        "http://www.ncbi.nlm.nih.gov/pubmed/35780916",
        "http://www.ncbi.nlm.nih.gov/pubmed/35280747",
        "http://www.ncbi.nlm.nih.gov/pubmed/29577209",
        "http://www.ncbi.nlm.nih.gov/pubmed/20921207",
        "http://www.ncbi.nlm.nih.gov/pubmed/17981431",
        "http://www.ncbi.nlm.nih.gov/pubmed/24701697",
        "http://www.ncbi.nlm.nih.gov/pubmed/26499143"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27136925",
          "text": "UNLABELLED\nImaging techniques play a key role in the management of patients with colorectal cancer. The introduction of new advanced anatomical, functional, and molecular imaging techniques may improve the assessment of diagnosis, prognosis, planning therapy, and assessment of response to treatment of these patients. Functional and molecular imaging techniques in clinical practice may allow the assessment of tumour-specific characteristics and tumour heterogeneity.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 469
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27136925",
          "text": "The introduction of new advanced anatomical, functional, and molecular imaging techniques may improve the assessment of diagnosis, prognosis, planning therapy, and assessment of response to treatment of these patients. Functional and molecular imaging techniques in clinical practice may allow the assessment of tumour-specific characteristics and tumour heterogeneity. This paper will review recent developments in imaging technologies and the evolving roles for these techniques in colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 100,
          "endSection": "abstract",
          "offsetInEndSection": 602
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35780916",
          "text": "Prognostic and predictive molecular biomarkers in advanced colorectal cancer.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 77
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35280747",
          "text": "Colorectal cancer (CRC) is one of the leading causes of cancer related death in the western world. Its successful treatment requires early detection and removal of precursor lesions as well as individualized treatment of advanced disease. During recent years, molecular imaging techniques have shown promising results to improve current clinical practice.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 355
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27136925",
          "text": "UNLABELLED\nImaging techniques play a key role in the management of patients with colorectal cancer. The introduction of new advanced anatomical, functional, and molecular imaging techniques may improve the assessment of diagnosis, prognosis, planning therapy, and assessment of response to treatment of these patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 318
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27136925",
          "text": "Advanced imaging of colorectal cancer: From anatomy to molecular imaging.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 73
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35280747",
          "text": "Molecular Endoscopy for the Diagnosis and Therapeutic Monitoring of Colorectal Cancer.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 86
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27136925",
          "text": "Functional and molecular imaging techniques in clinical practice may allow the assessment of tumour-specific characteristics and tumour heterogeneity. This paper will review recent developments in imaging technologies and the evolving roles for these techniques in colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 319,
          "endSection": "abstract",
          "offsetInEndSection": 602
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27136925",
          "text": "Functional and molecular imaging techniques in clinical practice may allow the assessment of tumour-specific characteristics and tumour heterogeneity. This paper will review recent developments in imaging technologies and the evolving roles for these techniques in colorectal cancer. TEACHING POINTS\n• Imaging techniques play a key role in the management of patients with colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 319,
          "endSection": "abstract",
          "offsetInEndSection": 711
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27136925",
          "text": "TEACHING POINTS\n• Imaging techniques play a key role in the management of patients with colorectal cancer. • Advanced imaging techniques improve the evaluation of these patients. • Functional and molecular imaging allows assessment of tumour hallmarks and tumour heterogeneity.",
          "beginSection": "abstract",
          "offsetInBeginSection": 605,
          "endSection": "abstract",
          "offsetInEndSection": 882
        }
      ],
      "ideal_answer": "The minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer in clinical practice are not specified in the given context.",
      "exact_answer": [
        [
          "molecular biomarkers"
        ],
        [
          "molecular imaging"
        ]
      ]
    },
    {
      "id": "66301c47187cba990d000025",
      "type": "list",
      "body": "What are the most common issues that need to be addressed in adults with Duchenne Muscular Dystrophy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37724986",
        "http://www.ncbi.nlm.nih.gov/pubmed/18025940",
        "http://www.ncbi.nlm.nih.gov/pubmed/25096430",
        "http://www.ncbi.nlm.nih.gov/pubmed/21826385",
        "http://www.ncbi.nlm.nih.gov/pubmed/2730379",
        "http://www.ncbi.nlm.nih.gov/pubmed/12026233",
        "http://www.ncbi.nlm.nih.gov/pubmed/33602943",
        "http://www.ncbi.nlm.nih.gov/pubmed/26136844",
        "http://www.ncbi.nlm.nih.gov/pubmed/33072932",
        "http://www.ncbi.nlm.nih.gov/pubmed/10422002"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25096430",
          "text": "A not insignificant proportion of patients have cognitive and neuropsychiatric problems that must be addressed. Active intervention in response to signs of respiratory or cardiac failure is important. More causal treatment of Duchenne muscular dystrophy is under testing and offers cautious hope for future patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 819,
          "endSection": "abstract",
          "offsetInEndSection": 1135
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25096430",
          "text": "INTERPRETATION\nWith improved treatment and increased life expectancy come new challenges for patients with Duchenne muscular dystrophy and their families, as well as new demands on the support services. This patient group requires close and comprehensive follow-up, also in the transition from child to adult.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1138,
          "endSection": "abstract",
          "offsetInEndSection": 1447
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25096430",
          "text": "BACKGROUND\nDuchenne muscular dystrophy is one of the most severe muscle diseases to affect children. In the last twenty years, treatments have been established that have significantly improved patients' quality of life and life expectancy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 239
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25096430",
          "text": "BACKGROUND\nDuchenne muscular dystrophy is one of the most severe muscle diseases to affect children.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 100
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25096430",
          "text": "BACKGROUND\nDuchenne muscular dystrophy is one of the most severe muscle diseases to affect children. In the last twenty years, treatments have been established that have significantly improved patients' quality of life and life expectancy. The purpose of this article is to outline the main features of the disease and its treatment, and to examine possible future treatment options.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 383
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25096430",
          "text": "Duchenne muscular dystrophy.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 28
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25096430",
          "text": "More causal treatment of Duchenne muscular dystrophy is under testing and offers cautious hope for future patients. INTERPRETATION\nWith improved treatment and increased life expectancy come new challenges for patients with Duchenne muscular dystrophy and their families, as well as new demands on the support services. This patient group requires close and comprehensive follow-up, also in the transition from child to adult.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1020,
          "endSection": "abstract",
          "offsetInEndSection": 1447
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18025940",
          "text": "Duchenne muscular dystrophy: issues in expanding newborn screening.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 67
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21826385",
          "text": "SUBJECTS\nA sample of 70 men with Duchenne muscular dystrophy (age range 20-43 years). METHODS\nGeneral motor function and, in particular, upper limb distal motor function, were assessed with the Motor Function Measure.",
          "beginSection": "abstract",
          "offsetInBeginSection": 144,
          "endSection": "abstract",
          "offsetInEndSection": 363
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21826385",
          "text": "OBJECTIVE\nTo determine upper limb function and associated factors in adults with Duchenne muscular dystrophy. DESIGN\nCross-sectional study. SUBJECTS\nA sample of 70 men with Duchenne muscular dystrophy (age range 20-43 years).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 229
        }
      ],
      "ideal_answer": "The most common issues that need to be addressed in adults with Duchenne Muscular Dystrophy are cognitive and neuropsychiatric problems, respiratory or cardiac failure.",
      "exact_answer": [
        [
          "cognitive and neuropsychiatric problems"
        ],
        [
          "respiratory or cardiac failure"
        ]
      ]
    },
    {
      "id": "6621510eb9f8b89d7e000008",
      "type": "list",
      "body": "What histological features are described in colorectal tumors with BRAF mutation?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/16403224",
        "http://www.ncbi.nlm.nih.gov/pubmed/17143472",
        "http://www.ncbi.nlm.nih.gov/pubmed/22489692",
        "http://www.ncbi.nlm.nih.gov/pubmed/30592501",
        "http://www.ncbi.nlm.nih.gov/pubmed/27404270",
        "http://www.ncbi.nlm.nih.gov/pubmed/27984807",
        "http://www.ncbi.nlm.nih.gov/pubmed/23650027",
        "http://www.ncbi.nlm.nih.gov/pubmed/34139726",
        "http://www.ncbi.nlm.nih.gov/pubmed/32193591",
        "http://www.ncbi.nlm.nih.gov/pubmed/26681025"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16403224",
          "text": "The characteristic morphological features of tumors with BRAF mutation (infiltrating lymphocytes, poor grade, mucinous) remained after stratification according to microsatellite instability and methylator phenotypes. Mutations in BRAF were mutually exclusive with mutations in KRAS but showed no clear association with the presence of TP53 mutation. CONCLUSION\nBRAF mutation identifies a colorectal cancer subgroup with distinctive phenotypic properties independent of microsatellite instability status and thus could be a valuable marker for studies into the clinical properties of these tumors.",
          "beginSection": "abstract",
          "offsetInBeginSection": 877,
          "endSection": "abstract",
          "offsetInEndSection": 1475
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16403224",
          "text": "The characteristic morphological features of tumors with BRAF mutation (infiltrating lymphocytes, poor grade, mucinous) remained after stratification according to microsatellite instability and methylator phenotypes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 876,
          "endSection": "abstract",
          "offsetInEndSection": 1092
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16403224",
          "text": "The characteristic morphological features of tumors with BRAF mutation (infiltrating lymphocytes, poor grade, mucinous) remained after stratification according to microsatellite instability and methylator phenotypes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 877,
          "endSection": "abstract",
          "offsetInEndSection": 1093
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16403224",
          "text": "The aim of the present study was to evaluate the clinical, pathological and molecular phenotype of colorectal tumors with BRAF mutations. RESULTS\nMutations in BRAF were identified in 8% (23/275) of colorectal cancers. They were 5-10-fold more frequent in tumors with infiltrating lymphocytes, location in the proximal colon, poor histological grade and mucinous appearance (P < 0.002 for each).",
          "beginSection": "abstract",
          "offsetInBeginSection": 305,
          "endSection": "abstract",
          "offsetInEndSection": 701
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17143472",
          "text": "Mutational analysis of the BRAF gene in colorectal mucinous carcinoma in association with histological configuration.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 117
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16403224",
          "text": "BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 165
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17143472",
          "text": "We also examined the association between these molecular alterations and clinicopathological features including histological configuration. BRAF mutation was detected in 4 (9.3%) tumors and was located at codon 599 of exon 15 in all cases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 670,
          "endSection": "abstract",
          "offsetInEndSection": 909
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16403224",
          "text": "RESULTS\nMutations in BRAF were identified in 8% (23/275) of colorectal cancers. They were 5-10-fold more frequent in tumors with infiltrating lymphocytes, location in the proximal colon, poor histological grade and mucinous appearance (P < 0.002 for each). Tumors with BRAF mutation were also 10-fold more likely to show microsatellite instability and frequent DNA methylation (P < 0.0001) compared to tumors without this mutation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 445,
          "endSection": "abstract",
          "offsetInEndSection": 876
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16403224",
          "text": "RESULTS\nMutations in BRAF were identified in 8% (23/275) of colorectal cancers. They were 5-10-fold more frequent in tumors with infiltrating lymphocytes, location in the proximal colon, poor histological grade and mucinous appearance (P < 0.002 for each).",
          "beginSection": "abstract",
          "offsetInBeginSection": 445,
          "endSection": "abstract",
          "offsetInEndSection": 701
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17143472",
          "text": "We also examined the association between these molecular alterations and clinicopathological features including histological configuration. BRAF mutation was detected in 4 (9.3%) tumors and was located at codon 599 of exon 15 in all cases. K-ras mutation was detected in 13 tumors (30.2%).",
          "beginSection": "abstract",
          "offsetInBeginSection": 670,
          "endSection": "abstract",
          "offsetInEndSection": 959
        }
      ],
      "ideal_answer": "Colorectal tumors with BRAF mutation are characterized by infiltrating lymphocytes, poor grade, and mucinous histological features.",
      "exact_answer": [
        [
          "infiltrating lymphocytes"
        ],
        [
          "poor grade"
        ],
        [
          "mucinous"
        ]
      ]
    },
    {
      "id": "662e44e9187cba990d00000b",
      "type": "yesno",
      "body": "Is vaccination against all arboviruses indicated for pregnant women?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37517630",
        "http://www.ncbi.nlm.nih.gov/pubmed/30685232",
        "http://www.ncbi.nlm.nih.gov/pubmed/29748029",
        "http://www.ncbi.nlm.nih.gov/pubmed/30777706",
        "http://www.ncbi.nlm.nih.gov/pubmed/34462162",
        "http://www.ncbi.nlm.nih.gov/pubmed/34227102",
        "http://www.ncbi.nlm.nih.gov/pubmed/25381784",
        "http://www.ncbi.nlm.nih.gov/pubmed/22521842",
        "http://www.ncbi.nlm.nih.gov/pubmed/25796339",
        "http://www.ncbi.nlm.nih.gov/pubmed/27592517"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30685232",
          "text": "Diagnosis of arboviruses was performed by real-time PCR (RT-qPCR) and laboratorial screening for syphilis, toxoplasmosis, rubella, cytomegalovirus and HIV was assessed. Demographic data was used for georeferencing analysis. FINDINGS\nWe included 121 pregnant women, of whom Zika virus was detected in 45 cases (37.2%), chikungunya in 33 (27.3%) and dengue in one (0.8%).",
          "beginSection": "abstract",
          "offsetInBeginSection": 742,
          "endSection": "abstract",
          "offsetInEndSection": 1113
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30685232",
          "text": "Considering pregnant women infected with arboviruses and other infections, 41% resided in urban slums, mostly in Niterói. MAIN CONCLUSIONS\nSimultaneous circulation of arboviruses and other agents responsible for congenital infections were observed; however, we did not identify co-infections between arboviruses. In this scenario, we emphasize the importance of adequate prenatal care to provide an accurate diagnosis of maternal rash.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1466,
          "endSection": "abstract",
          "offsetInEndSection": 1903
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30685232",
          "text": "Considering pregnant women infected with arboviruses and other infections, 41% resided in urban slums, mostly in Niterói. MAIN CONCLUSIONS\nSimultaneous circulation of arboviruses and other agents responsible for congenital infections were observed; however, we did not identify co-infections between arboviruses.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1466,
          "endSection": "abstract",
          "offsetInEndSection": 1780
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29748029",
          "text": "In 2014, the recommendation of influenza vaccination expanded to include all pregnant women.",
          "beginSection": "abstract",
          "offsetInBeginSection": 130,
          "endSection": "abstract",
          "offsetInEndSection": 222
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29748029",
          "text": "Pregnant women who were vaccinated were more likely to be aware of the recommendation for vaccination and the risks of influenza illness during pregnancy and to perceive the vaccine as safe and effective, compared to unvaccinated pregnant women (p-values < 0.001).",
          "beginSection": "abstract",
          "offsetInBeginSection": 1139,
          "endSection": "abstract",
          "offsetInEndSection": 1403
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30685232",
          "text": "BACKGROUND\nArboviruses (Zika, dengue and chikungunya) represent a major risk for pregnant women, especially because their vertical transmission can lead to neurological damage in newborns.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 188
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30777706",
          "text": "Vaccinating pregnant women is the primary strategy to protect them and their infants from influenza. This study aims to assess influenza vaccination coverage during three influenza seasons (2012-2015) from a national probability-based sampling survey and evaluate potential factors that influence vaccination uptake among pregnant women.",
          "beginSection": "abstract",
          "offsetInBeginSection": 121,
          "endSection": "abstract",
          "offsetInEndSection": 458
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30777706",
          "text": "Vaccinating pregnant women is the primary strategy to protect them and their infants from influenza.",
          "beginSection": "abstract",
          "offsetInBeginSection": 121,
          "endSection": "abstract",
          "offsetInEndSection": 221
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30685232",
          "text": "BACKGROUND\nArboviruses (Zika, dengue and chikungunya) represent a major risk for pregnant women, especially because their vertical transmission can lead to neurological damage in newborns. Early diagnosis can be difficult due to similar clinical presentation with other congenital infections that are associated with congenital abnormalities.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 342
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30685232",
          "text": "Considering pregnant women infected with arboviruses and other infections, 41% resided in urban slums, mostly in Niterói.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1466,
          "endSection": "abstract",
          "offsetInEndSection": 1587
        }
      ],
      "ideal_answer": "No, vaccination against all arboviruses is not indicated for pregnant women. The context states that Zika virus, chikungunya, and dengue are arboviruses that can cause neurological damage in newborns if transmitted vertically. However, it does not mention any vaccines for these arboviruses. Instead, it emphasizes the importance of accurate prenatal care for diagnosis. Additionally, the context states that influenza vaccination is recommended for all pregnant women, but this is a different virus than the arboviruses mentioned.",
      "exact_answer": "no"
    },
    {
      "id": "662fc4b1187cba990d000016",
      "type": "list",
      "body": "What are the mechanisms of action of regorafenib on tumor cells?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31715423",
        "http://www.ncbi.nlm.nih.gov/pubmed/26419617",
        "http://www.ncbi.nlm.nih.gov/pubmed/36551679",
        "http://www.ncbi.nlm.nih.gov/pubmed/28489887",
        "http://www.ncbi.nlm.nih.gov/pubmed/24763611",
        "http://www.ncbi.nlm.nih.gov/pubmed/37620408",
        "http://www.ncbi.nlm.nih.gov/pubmed/24911215",
        "http://www.ncbi.nlm.nih.gov/pubmed/32720931",
        "http://www.ncbi.nlm.nih.gov/pubmed/29944884",
        "http://www.ncbi.nlm.nih.gov/pubmed/24347491"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24763611",
          "text": "However, the mechanisms of action of regorafenib in colorectal cancer cells have been unclear. We investigated how regorafenib suppresses colorectal cancer cell growth and potentiates effects of other chemotherapeutic drugs. EXPERIMENTAL DESIGN\nWe determined whether and how regorafenib induces the expression of PUMA, a p53 target and a critical mediator of apoptosis in colorectal cancer cells.",
          "beginSection": "abstract",
          "offsetInBeginSection": 162,
          "endSection": "abstract",
          "offsetInEndSection": 560
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24763611",
          "text": "However, the mechanisms of action of regorafenib in colorectal cancer cells have been unclear. We investigated how regorafenib suppresses colorectal cancer cell growth and potentiates effects of other chemotherapeutic drugs.",
          "beginSection": "abstract",
          "offsetInBeginSection": 162,
          "endSection": "abstract",
          "offsetInEndSection": 386
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24763611",
          "text": "However, the mechanisms of action of regorafenib in colorectal cancer cells have been unclear.",
          "beginSection": "abstract",
          "offsetInBeginSection": 162,
          "endSection": "abstract",
          "offsetInEndSection": 256
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28489887",
          "text": "The underlying mechanisms were demonstrated using molecular biology techniques. RESULTS\nWe found that regorafenib inhibited cell proliferation and invasion at the concentration of 20μmol/L and in a dose dependent manner. The anti-tumor effects of regorafenib related to the decreased expression of CXCR4, and elevated expression and activation of CXCR4 could reverse the inhibition effect of regorafenib on gastric cancer cells.",
          "beginSection": "abstract",
          "offsetInBeginSection": 641,
          "endSection": "abstract",
          "offsetInEndSection": 1071
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36551679",
          "text": "Strikingly, this effect was accompanied by transcriptional regulation of epithelial to mesenchymal transition (EMT) genes and by an increased ability of surviving tumor cells to invade the surrounding matrix. Taken together, our data suggest that regorafenib limits cell growth, however, it might induce an invasive phenotype.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1083,
          "endSection": "abstract",
          "offsetInEndSection": 1409
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28489887",
          "text": "In this study, we would assess the potential anti-tumor effects and the underlying mechanisms of regorafenib in gastric cancer cells, and explore novel biomarkers for patients selecting of regorafenib. METHODS\nThe anti-tumor effects of regorafenib on gastric cancer cells were analyzed via cell proliferation and invasion. The underlying mechanisms were demonstrated using molecular biology techniques.",
          "beginSection": "abstract",
          "offsetInBeginSection": 316,
          "endSection": "abstract",
          "offsetInEndSection": 720
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36551679",
          "text": "Here we report an in vitro characterization of GBM tumor cells' response to regorafenib, performed both on cell lines and on patient-derived glioma stem cells (GSCs). Overall, regorafenib significantly reduced cell growth of 2D tumor cell cultures and of 3D tumor spheroids. Strikingly, this effect was accompanied by transcriptional regulation of epithelial to mesenchymal transition (EMT) genes and by an increased ability of surviving tumor cells to invade the surrounding matrix.",
          "beginSection": "abstract",
          "offsetInBeginSection": 808,
          "endSection": "abstract",
          "offsetInEndSection": 1291
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28489887",
          "text": "METHODS\nThe anti-tumor effects of regorafenib on gastric cancer cells were analyzed via cell proliferation and invasion. The underlying mechanisms were demonstrated using molecular biology techniques. RESULTS\nWe found that regorafenib inhibited cell proliferation and invasion at the concentration of 20μmol/L and in a dose dependent manner.",
          "beginSection": "abstract",
          "offsetInBeginSection": 520,
          "endSection": "abstract",
          "offsetInEndSection": 863
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28489887",
          "text": "METHODS\nThe anti-tumor effects of regorafenib on gastric cancer cells were analyzed via cell proliferation and invasion. The underlying mechanisms were demonstrated using molecular biology techniques.",
          "beginSection": "abstract",
          "offsetInBeginSection": 520,
          "endSection": "abstract",
          "offsetInEndSection": 720
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24763611",
          "text": "We investigated how regorafenib suppresses colorectal cancer cell growth and potentiates effects of other chemotherapeutic drugs. EXPERIMENTAL DESIGN\nWe determined whether and how regorafenib induces the expression of PUMA, a p53 target and a critical mediator of apoptosis in colorectal cancer cells.",
          "beginSection": "abstract",
          "offsetInBeginSection": 257,
          "endSection": "abstract",
          "offsetInEndSection": 560
        }
      ],
      "ideal_answer": "Regorafenib suppresses colorectal cancer cell growth by inhibiting cell proliferation and inducing EMT genes, specifically by decreasing CXCR4 expression. This effect is dose-dependent and may also induce an invasive phenotype in surviving tumor cells.",
      "exact_answer": [
        [
          "inhibits cell proliferation"
        ],
        [
          "induces EMT genes"
        ],
        [
          "elevates CXCR4 expression"
        ]
      ]
    },
    {
      "id": "661d5fe1eac11fad33000024",
      "type": "list",
      "body": "What are the types of Polycystic Kidney Disease?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24584572",
        "http://www.ncbi.nlm.nih.gov/pubmed/10063927",
        "http://www.ncbi.nlm.nih.gov/pubmed/27938556",
        "http://www.ncbi.nlm.nih.gov/pubmed/25753522",
        "http://www.ncbi.nlm.nih.gov/pubmed/14658173",
        "http://www.ncbi.nlm.nih.gov/pubmed/1450634",
        "http://www.ncbi.nlm.nih.gov/pubmed/16227765",
        "http://www.ncbi.nlm.nih.gov/pubmed/30869429",
        "http://www.ncbi.nlm.nih.gov/pubmed/33319200",
        "http://www.ncbi.nlm.nih.gov/pubmed/35487607"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27938556",
          "text": "There are two common types of hereditary polycystic kidney diseases, autosomal dominant polycystic kidney disease and autosomal recessive polycystic kidney disease. Congenital hepatic fibrosis is an autosomal recessive disorder and can occur in hereditary polycystic kidney disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 282
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27938556",
          "text": "There are two common types of hereditary polycystic kidney diseases, autosomal dominant polycystic kidney disease and autosomal recessive polycystic kidney disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 164
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27938556",
          "text": "There are two common types of hereditary polycystic kidney diseases, autosomal dominant polycystic kidney disease and autosomal recessive polycystic kidney disease. Congenital hepatic fibrosis is an autosomal recessive disorder and can occur in hereditary polycystic kidney disease. Therefore, hereditary polycystic kidney disease is one of the causes of unexplained liver fibrosis and liver cirrhosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 402
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16227765",
          "text": "Polycystic kidney disease.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 26
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30869429",
          "text": "[Polycystic kidney disease].",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 28
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25753522",
          "text": "Polycystic kidney disease (PKD) is a cystic genetic disorder of the kidneys which is typically associated with cystic bile duct dilatation in the liver in humans, and domestic and laboratory animals. In humans, there are two types of PKD, autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 350
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25753522",
          "text": "Polycystic kidney disease (PKD) is a cystic genetic disorder of the kidneys which is typically associated with cystic bile duct dilatation in the liver in humans, and domestic and laboratory animals. In humans, there are two types of PKD, autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD). ADPKD is caused by mutations in PKD1 or PKD2 gene while ARPKD is caused by mutation or loss of the PKHD1 (polycystic kidney and hepatic disease 1) gene.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 503
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25753522",
          "text": "In humans, there are two types of PKD, autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD).",
          "beginSection": "abstract",
          "offsetInBeginSection": 200,
          "endSection": "abstract",
          "offsetInEndSection": 350
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10063927",
          "text": "Autosomal dominant polycystic liver disease occurs commonly in association with autosomal dominant polycystic kidney disease, types 1 and 2. It may also exist as a separate entity, genetically distinct from autosomal dominant polycystic kidney disease types 1 and 2, as has been recently established to exist in a Belgian family.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 329
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16227765",
          "text": "Polycystic kidney disease, an inherited systemic disorder, is characterized by the development of multiple cysts in the kidneys and other organs.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 145
        }
      ],
      "ideal_answer": "There are two types of Polycystic Kidney Disease: autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD).",
      "exact_answer": [
        [
          "autosomal dominant polycystic kidney disease"
        ],
        [
          "autosomal recessive polycystic kidney disease"
        ]
      ]
    },
    {
      "id": "66214f52b9f8b89d7e000005",
      "type": "yesno",
      "body": "Is tumor expression of Topoisomerase I a biomarker of response to irinotecan in colorectal cancer patients therapy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19775480",
        "http://www.ncbi.nlm.nih.gov/pubmed/22108516",
        "http://www.ncbi.nlm.nih.gov/pubmed/20371676",
        "http://www.ncbi.nlm.nih.gov/pubmed/30881507",
        "http://www.ncbi.nlm.nih.gov/pubmed/24256029",
        "http://www.ncbi.nlm.nih.gov/pubmed/29261002",
        "http://www.ncbi.nlm.nih.gov/pubmed/28077117",
        "http://www.ncbi.nlm.nih.gov/pubmed/25515240",
        "http://www.ncbi.nlm.nih.gov/pubmed/16943524",
        "http://www.ncbi.nlm.nih.gov/pubmed/33235468"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24256029",
          "text": "OBJECTIVE\nDNA topoisomerase I is a putative biomarker of irinotecan efficacy with clinical associations previously demonstrated at the protein level. The purpose of the present study was to perform the first clinical investigation of the association between the DNA topoisomerase I gene (TOP1) copy number and objective response following irinotecan treatment in patients with metastatic colorectal cancer. MATERIALS AND METHODS\nFormalin-fixed, paraffin-embedded tumor samples from 78 patients, who received irinotecan monotherapy in second line, were included.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 563
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24256029",
          "text": "OBJECTIVE\nDNA topoisomerase I is a putative biomarker of irinotecan efficacy with clinical associations previously demonstrated at the protein level. The purpose of the present study was to perform the first clinical investigation of the association between the DNA topoisomerase I gene (TOP1) copy number and objective response following irinotecan treatment in patients with metastatic colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 406
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24256029",
          "text": "Assessment of the topoisomerase I gene copy number as a predictive biomarker of objective response to irinotecan in metastatic colorectal cancer.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 145
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24256029",
          "text": "The purpose of the present study was to perform the first clinical investigation of the association between the DNA topoisomerase I gene (TOP1) copy number and objective response following irinotecan treatment in patients with metastatic colorectal cancer. MATERIALS AND METHODS\nFormalin-fixed, paraffin-embedded tumor samples from 78 patients, who received irinotecan monotherapy in second line, were included.",
          "beginSection": "abstract",
          "offsetInBeginSection": 150,
          "endSection": "abstract",
          "offsetInEndSection": 563
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24256029",
          "text": "The purpose of the present study was to perform the first clinical investigation of the association between the DNA topoisomerase I gene (TOP1) copy number and objective response following irinotecan treatment in patients with metastatic colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 150,
          "endSection": "abstract",
          "offsetInEndSection": 406
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24256029",
          "text": "The purpose of the present study was to perform the first clinical investigation of the association between the DNA topoisomerase I gene (TOP1) copy number and objective response following irinotecan treatment in patients with metastatic colorectal cancer. MATERIALS AND METHODS\nFormalin-fixed, paraffin-embedded tumor samples from 78 patients, who received irinotecan monotherapy in second line, were included. TOP1 was assessed by fluorescence in situ hybridization using a technically validated dual-probe combination that hybridizes to TOP1, located at 20q12-q13.1, and to the centromere region of chromosome 20 (CEN-20).",
          "beginSection": "abstract",
          "offsetInBeginSection": 150,
          "endSection": "abstract",
          "offsetInEndSection": 777
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29261002",
          "text": "Topoisomerase 1 (TOPO-1) and carboxylesterase 2 (CES-2) are found to play crucial roles in the pathogenesis of various cancers. The prognostic role of TOPO-1 and CES-2 in patients with metastatic colorectal cancer (mCRC) who underwent irinotecan chemotherapy was largely unknown. In the current study, we assessed the expression of TOPO-1 and CES-2 in mCRC and analyzed its potential relevance to irinotecan based therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 422
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30881507",
          "text": "Tumor response to irinotecan is associated with CYP3A5 expression in colorectal cancer.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 87
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29261002",
          "text": "Topoisomerase 1 (TOPO-1) and carboxylesterase 2 (CES-2) are found to play crucial roles in the pathogenesis of various cancers. The prognostic role of TOPO-1 and CES-2 in patients with metastatic colorectal cancer (mCRC) who underwent irinotecan chemotherapy was largely unknown.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 279
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29261002",
          "text": "The prognostic role of TOPO-1 and CES-2 in patients with metastatic colorectal cancer (mCRC) who underwent irinotecan chemotherapy was largely unknown. In the current study, we assessed the expression of TOPO-1 and CES-2 in mCRC and analyzed its potential relevance to irinotecan based therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 128,
          "endSection": "abstract",
          "offsetInEndSection": 422
        }
      ],
      "ideal_answer": "No, tumor expression of Topoisomerase I is not a biomarker of response to irinotecan in colorectal cancer patients therapy.",
      "exact_answer": "no"
    },
    {
      "id": "662f401b187cba990d00000e",
      "type": "yesno",
      "body": "Is Vitamin D deficiency associated with sepsis mortality?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36265656",
        "http://www.ncbi.nlm.nih.gov/pubmed/36769240",
        "http://www.ncbi.nlm.nih.gov/pubmed/37892385",
        "http://www.ncbi.nlm.nih.gov/pubmed/35715206",
        "http://www.ncbi.nlm.nih.gov/pubmed/27632669",
        "http://www.ncbi.nlm.nih.gov/pubmed/26800186",
        "http://www.ncbi.nlm.nih.gov/pubmed/29184435",
        "http://www.ncbi.nlm.nih.gov/pubmed/32198863",
        "http://www.ncbi.nlm.nih.gov/pubmed/32597305",
        "http://www.ncbi.nlm.nih.gov/pubmed/25475621"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36769240",
          "text": "It has been suggested that vitamin D deficiency plays a role in sepsis and septic shock because vitamin-D-related pathways are associated with various immunological, endocrine, and endothelial functions. Previous research has yielded inconclusive results regarding the link between mortality and vitamin D deficiency in sepsis patients. In patients with sepsis and severe vitamin D deficiency, an adequate vitamin D concentration may reduce mortality.",
          "beginSection": "abstract",
          "offsetInBeginSection": 87,
          "endSection": "abstract",
          "offsetInEndSection": 538
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36769240",
          "text": "Previous research has yielded inconclusive results regarding the link between mortality and vitamin D deficiency in sepsis patients. In patients with sepsis and severe vitamin D deficiency, an adequate vitamin D concentration may reduce mortality. Randomized controlled trials to assess the influence of vitamin D supplementation on clinical outcomes in sepsis patients with vitamin D deficiency are uncommon.",
          "beginSection": "abstract",
          "offsetInBeginSection": 291,
          "endSection": "abstract",
          "offsetInEndSection": 700
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35715206",
          "text": "Severe vitamin D deficiency in patients admitted to the emergency department with severe sepsis is associated with an increased 90-day mortality.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 145
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36769240",
          "text": "Previous research has yielded inconclusive results regarding the link between mortality and vitamin D deficiency in sepsis patients. In patients with sepsis and severe vitamin D deficiency, an adequate vitamin D concentration may reduce mortality.",
          "beginSection": "abstract",
          "offsetInBeginSection": 291,
          "endSection": "abstract",
          "offsetInEndSection": 538
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37892385",
          "text": "Effects of Vitamin D Deficiency on Sepsis.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 42
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27632669",
          "text": "OBJECTIVES\nVitamin D deficiency has been implicated as a pathogenic factor in sepsis and ICU mortality but causality of these associations has not been demonstrated.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 165
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36769240",
          "text": "It has been suggested that vitamin D deficiency plays a role in sepsis and septic shock because vitamin-D-related pathways are associated with various immunological, endocrine, and endothelial functions. Previous research has yielded inconclusive results regarding the link between mortality and vitamin D deficiency in sepsis patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 87,
          "endSection": "abstract",
          "offsetInEndSection": 423
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36769240",
          "text": "Previous research has yielded inconclusive results regarding the link between mortality and vitamin D deficiency in sepsis patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 291,
          "endSection": "abstract",
          "offsetInEndSection": 423
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36769240",
          "text": "In patients with sepsis and severe vitamin D deficiency, an adequate vitamin D concentration may reduce mortality.",
          "beginSection": "abstract",
          "offsetInBeginSection": 424,
          "endSection": "abstract",
          "offsetInEndSection": 538
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27632669",
          "text": "OBJECTIVES\nVitamin D deficiency has been implicated as a pathogenic factor in sepsis and ICU mortality but causality of these associations has not been demonstrated. To determine whether sepsis and severe sepsis are associated with vitamin D deficiency and to determine whether vitamin D deficiency influences the severity of sepsis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 333
        }
      ],
      "ideal_answer": "Yes, vitamin D deficiency is associated with sepsis mortality in patients with severe vitamin D deficiency.",
      "exact_answer": "yes"
    },
    {
      "id": "66214b9cb9f8b89d7e000001",
      "type": "list",
      "body": "Which countries have a higher incidence of colorectal cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35397795",
        "http://www.ncbi.nlm.nih.gov/pubmed/33618551",
        "http://www.ncbi.nlm.nih.gov/pubmed/34048685",
        "http://www.ncbi.nlm.nih.gov/pubmed/28281292",
        "http://www.ncbi.nlm.nih.gov/pubmed/27716537",
        "http://www.ncbi.nlm.nih.gov/pubmed/19505900",
        "http://www.ncbi.nlm.nih.gov/pubmed/37323313",
        "http://www.ncbi.nlm.nih.gov/pubmed/31105047",
        "http://www.ncbi.nlm.nih.gov/pubmed/2278112",
        "http://www.ncbi.nlm.nih.gov/pubmed/22047622"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34048685",
          "text": "Conversely, colorectal cancer incidence increased in most countries where no large-scale screening programmes were available (eg, Bulgaria, Estonia, Norway, and Ukraine), with AAPCs ranging from 0·3% (95% CI 0·1 to 0·5) to 1·9% (1·2 to 2·6) in men and from 0·6% (0·4 to 0·8) to 1·1% (0·8 to 1·4) in women. The largest decreases in colorectal cancer mortality were seen in countries with long-standing screening programmes. INTERPRETATION\nWe observed divergent trends in colorectal cancer incidence, mortality, and stage distribution across European countries, which appear to be largely explained by different levels of colorectal cancer screening implementation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1933,
          "endSection": "abstract",
          "offsetInEndSection": 2598
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34048685",
          "text": "Conversely, colorectal cancer incidence increased in most countries where no large-scale screening programmes were available (eg, Bulgaria, Estonia, Norway, and Ukraine), with AAPCs ranging from 0·3% (95% CI 0·1 to 0·5) to 1·9% (1·2 to 2·6) in men and from 0·6% (0·4 to 0·8) to 1·1% (0·8 to 1·4) in women. The largest decreases in colorectal cancer mortality were seen in countries with long-standing screening programmes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1933,
          "endSection": "abstract",
          "offsetInEndSection": 2355
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34048685",
          "text": "Conversely, colorectal cancer incidence increased in most countries where no large-scale screening programmes were available (eg, Bulgaria, Estonia, Norway, and Ukraine), with AAPCs ranging from 0·3% (95% CI 0·1 to 0·5) to 1·9% (1·2 to 2·6) in men and from 0·6% (0·4 to 0·8) to 1·1% (0·8 to 1·4) in women.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1933,
          "endSection": "abstract",
          "offsetInEndSection": 2238
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28281292",
          "text": "Among the 29 countries investigated, colorectal cancer incidence was observed to decrease after reaching the very high human development threshold for 12 countries; decreases were also observed in a further five countries, but the age-standardized incidence rates remained higher than that observed at the threshold.",
          "beginSection": "abstract",
          "offsetInBeginSection": 811,
          "endSection": "abstract",
          "offsetInEndSection": 1127
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28281292",
          "text": "Among the 29 countries investigated, colorectal cancer incidence was observed to decrease after reaching the very high human development threshold for 12 countries; decreases were also observed in a further five countries, but the age-standardized incidence rates remained higher than that observed at the threshold. Such declines or stabilizations are likely due to colorectal cancer screening in some populations, as well as varying levels of exposure to protective factors.",
          "beginSection": "abstract",
          "offsetInBeginSection": 811,
          "endSection": "abstract",
          "offsetInEndSection": 1287
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34048685",
          "text": "Where high screening coverage and uptake were rapidly achieved (ie, Denmark, the Netherlands, and Slovenia), age-standardised incidence rates initially increased but then subsequently decreased. Conversely, colorectal cancer incidence increased in most countries where no large-scale screening programmes were available (eg, Bulgaria, Estonia, Norway, and Ukraine), with AAPCs ranging from 0·3% (95% CI 0·1 to 0·5) to 1·9% (1·2 to 2·6) in men and from 0·6% (0·4 to 0·8) to 1·1% (0·8 to 1·4) in women. The largest decreases in colorectal cancer mortality were seen in countries with long-standing screening programmes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1738,
          "endSection": "abstract",
          "offsetInEndSection": 2355
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34048685",
          "text": "Where high screening coverage and uptake were rapidly achieved (ie, Denmark, the Netherlands, and Slovenia), age-standardised incidence rates initially increased but then subsequently decreased. Conversely, colorectal cancer incidence increased in most countries where no large-scale screening programmes were available (eg, Bulgaria, Estonia, Norway, and Ukraine), with AAPCs ranging from 0·3% (95% CI 0·1 to 0·5) to 1·9% (1·2 to 2·6) in men and from 0·6% (0·4 to 0·8) to 1·1% (0·8 to 1·4) in women.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1738,
          "endSection": "abstract",
          "offsetInEndSection": 2238
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33618551",
          "text": "Global trends in the incidence and mortality rates of colorectal cancer show a steady increase with significant predilection to western developed countries, possibly linking it to westernized lifestyles among other risk factors. This study aims to investigate the incidence and trends of colorectal cancer in Lebanon, a country in the Middle East and North Africa region, and to compare these rates to those in regional and western countries.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 442
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28281292",
          "text": "Colorectal cancer incidence has paralleled increases in human development across most countries. Yet, marked decreases in incidence are now observed in countries that have attained very high human development.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 209
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34048685",
          "text": "FINDINGS\nIn countries with long-standing programmes of screening colonoscopy and faecal tests (ie, Austria, the Czech Republic, and Germany), colorectal cancer incidence decreased substantially over time, with AAPCs ranging from -2·5% (95% CI -2·8 to -2·2) to -1·6% (-2·0 to -1·2) in men and from -2·4% (-2·7 to -2·1) to -1·3% (-1·7 to -0·9) in women.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1028,
          "endSection": "abstract",
          "offsetInEndSection": 1379
        }
      ],
      "ideal_answer": "Bulgaria, Estonia, Norway, and Ukraine have a higher incidence of colorectal cancer.",
      "exact_answer": [
        [
          "Bulgaria"
        ],
        [
          "Estonia"
        ],
        [
          "Norway"
        ],
        [
          "Ukraine"
        ]
      ]
    },
    {
      "id": "66302978187cba990d000034",
      "type": "list",
      "body": "What are the primary and secondary endpoints of Pamrevlumab?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37248912",
        "http://www.ncbi.nlm.nih.gov/pubmed/31575509",
        "http://www.ncbi.nlm.nih.gov/pubmed/32447983",
        "http://www.ncbi.nlm.nih.gov/pubmed/29347981",
        "http://www.ncbi.nlm.nih.gov/pubmed/33054319",
        "http://www.ncbi.nlm.nih.gov/pubmed/9408717",
        "http://www.ncbi.nlm.nih.gov/pubmed/22729929",
        "http://www.ncbi.nlm.nih.gov/pubmed/9408718",
        "http://www.ncbi.nlm.nih.gov/pubmed/27080628",
        "http://www.ncbi.nlm.nih.gov/pubmed/22733687"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37248912",
          "text": "METHODS\nMISSION (Study 079; NCT02606136) was an open-label, Phase II, single-arm trial of pamrevlumab in 21 non-ambulatory patients with DMD (aged≥12 years, receiving corticosteroids) who received 35-mg/kg intravenous infusions every 2 weeks for 2 years. The primary endpoint was change from baseline in percent predicted forced vital capacity (ppFVC). Secondary endpoints included other pulmonary function tests, upper limb function and strength assessments, and changes in upper arm fat and fibrosis scores on magnetic resonance imaging.",
          "beginSection": "abstract",
          "offsetInBeginSection": 409,
          "endSection": "abstract",
          "offsetInEndSection": 948
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31575509",
          "text": "The primary efficacy outcome was change from baseline in percentage of predicted FVC at week 48. Disease progression (defined as a decline from baseline in percentage of predicted FVC of ≥10%, or death) at week 48 was a key secondary efficacy outcome. All patients in the pamrevlumab group received at least one dose of the study drug and were analysed for safety.",
          "beginSection": "abstract",
          "offsetInBeginSection": 958,
          "endSection": "abstract",
          "offsetInEndSection": 1322
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31575509",
          "text": "Disease progression (defined as a decline from baseline in percentage of predicted FVC of ≥10%, or death) at week 48 was a key secondary efficacy outcome. All patients in the pamrevlumab group received at least one dose of the study drug and were analysed for safety.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1055,
          "endSection": "abstract",
          "offsetInEndSection": 1322
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31575509",
          "text": "Disease progression (defined as a decline from baseline in percentage of predicted FVC of ≥10%, or death) at week 48 was a key secondary efficacy outcome. All patients in the pamrevlumab group received at least one dose of the study drug and were analysed for safety. Two patients in the placebo group were excluded from the intention-to-treat population for the efficacy analyses because of enrolment error.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1055,
          "endSection": "abstract",
          "offsetInEndSection": 1463
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31575509",
          "text": "Of the three (6%) deaths in the pamrevlumab group and six (11%) in the placebo group, none was considered treatment related.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2322,
          "endSection": "abstract",
          "offsetInEndSection": 2446
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31575509",
          "text": "Now in phase 3 development, pamrevlumab shows promise as a novel, safe, and effective treatment for idiopathic pulmonary fibrosis. FUNDING\nFibroGen.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2556,
          "endSection": "abstract",
          "offsetInEndSection": 2706
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31575509",
          "text": "Of the three (6%) deaths in the pamrevlumab group and six (11%) in the placebo group, none was considered treatment related. INTERPRETATION\nPamrevlumab attenuated progression of idiopathic pulmonary fibrosis and was well tolerated. Now in phase 3 development, pamrevlumab shows promise as a novel, safe, and effective treatment for idiopathic pulmonary fibrosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2322,
          "endSection": "abstract",
          "offsetInEndSection": 2686
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31575509",
          "text": "Now in phase 3 development, pamrevlumab shows promise as a novel, safe, and effective treatment for idiopathic pulmonary fibrosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2556,
          "endSection": "abstract",
          "offsetInEndSection": 2686
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31575509",
          "text": "Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 168
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37248912",
          "text": "METHODS\nMISSION (Study 079; NCT02606136) was an open-label, Phase II, single-arm trial of pamrevlumab in 21 non-ambulatory patients with DMD (aged≥12 years, receiving corticosteroids) who received 35-mg/kg intravenous infusions every 2 weeks for 2 years. The primary endpoint was change from baseline in percent predicted forced vital capacity (ppFVC).",
          "beginSection": "abstract",
          "offsetInBeginSection": 409,
          "endSection": "abstract",
          "offsetInEndSection": 761
        }
      ],
      "ideal_answer": "The primary endpoint of Pamrevlumab is change from baseline in percent predicted forced vital capacity (ppFVC). Secondary endpoints include other pulmonary function tests, upper limb function and strength assessments, and changes in upper arm fat and fibrosis scores on magnetic resonance imaging.",
      "exact_answer": []
    },
    {
      "id": "66099ac8fdcbea915f00001f",
      "type": "list",
      "body": "What are the mechanisms of secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24913799",
        "http://www.ncbi.nlm.nih.gov/pubmed/22722830",
        "http://www.ncbi.nlm.nih.gov/pubmed/32718285",
        "http://www.ncbi.nlm.nih.gov/pubmed/23281932",
        "http://www.ncbi.nlm.nih.gov/pubmed/34663410",
        "http://www.ncbi.nlm.nih.gov/pubmed/17438669",
        "http://www.ncbi.nlm.nih.gov/pubmed/17049015",
        "http://www.ncbi.nlm.nih.gov/pubmed/25293556",
        "http://www.ncbi.nlm.nih.gov/pubmed/20222160",
        "http://www.ncbi.nlm.nih.gov/pubmed/29045518"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23281932",
          "text": "Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 141
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23281932",
          "text": "INTRODUCTION\nA number of anti-EGFR monoclonal antibodies (mAbs) have been recently developed for the treatment of refractory metastatic colorectal cancer (mCRC). These mAbs, blocking ligand/receptor interactions, exert their biological activity via multiple mechanisms, including inhibition of cell cycle progression, potentiation of cell apoptosis, inhibition of angiogenesis, tumor cell invasion and metastasis and, potentially, induction of immunological effector mechanisms.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 478
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32718285",
          "text": "BACKGROUND\nAnti-EGFR monoclonal antibodies (mAbs) have become a relevant solution for the treatment of patients with metastatic colorectal cancer. Current anti-EGFR monoclonal antibodies face a series of problems, including resistance and non-durable response, and RAS and BRAF mutations serve as exclusion criteria for treatment with anti-EGFR mAbs. Advances in molecular tumor profiling and information on subsequent pathways responsible for disease progression and drug resistance helped develop a new generation of anti-EGFR mAbs.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 534
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32718285",
          "text": "OBJECTIVE\nIn this review, we summarize and evaluate current data regarding ongoing research and completed clinical trials for different second-generation anti-EGFR monoclonal antibodies. CONCLUSION\nAnti-EGFR mAbs exhibit efficacy in advanced colorectal cancer, but second-generation mAbs failed to prove their benefit in the treatment of metastatic colorectal cancer. Understanding the biological basis of primary and acquired drug resistance could allow scientists to design better clinical trials and develop improved second-generation mAbs.",
          "beginSection": "abstract",
          "offsetInBeginSection": 798,
          "endSection": "abstract",
          "offsetInEndSection": 1343
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32718285",
          "text": "BACKGROUND\nAnti-EGFR monoclonal antibodies (mAbs) have become a relevant solution for the treatment of patients with metastatic colorectal cancer. Current anti-EGFR monoclonal antibodies face a series of problems, including resistance and non-durable response, and RAS and BRAF mutations serve as exclusion criteria for treatment with anti-EGFR mAbs.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 350
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34663410",
          "text": "Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 113
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32718285",
          "text": "A Critical Review of Second-Generation Anti-EGFR Monoclonal Antibodies in Metastatic Colorectal Cancer.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 103
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23281932",
          "text": "INTRODUCTION\nA number of anti-EGFR monoclonal antibodies (mAbs) have been recently developed for the treatment of refractory metastatic colorectal cancer (mCRC). These mAbs, blocking ligand/receptor interactions, exert their biological activity via multiple mechanisms, including inhibition of cell cycle progression, potentiation of cell apoptosis, inhibition of angiogenesis, tumor cell invasion and metastasis and, potentially, induction of immunological effector mechanisms. AREAS COVERED\nCetuximab is an anti-EGFR mAb currently used in mCRC treatment.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 558
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32718285",
          "text": "BACKGROUND\nAnti-EGFR monoclonal antibodies (mAbs) have become a relevant solution for the treatment of patients with metastatic colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 146
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17438669",
          "text": "Epidermal growth factor receptor (EGFR) is overexpressed in 70%-80% of colorectal cancers (CRC). EGFR overexpression is known to be involved in carcinogenic processes, such as cell proliferation, apoptosis, angiogenesis and metastasis. Monoclonal antibodies targeting EGFR have shown antitumor activity and improved the efficacy of chemotherapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 160,
          "endSection": "abstract",
          "offsetInEndSection": 505
        }
      ],
      "ideal_answer": "Secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment can occur through several mechanisms, including RAS mutations, BRAF mutations, cell cycle progression, cell apoptosis, angiogenesis, tumor cell invasion and metastasis, and immunological effector mechanisms. These mechanisms can lead to a non-durable response and exclusion from treatment with anti-EGFR mAbs.",
      "exact_answer": [
        [
          "RAS mutations"
        ],
        [
          "BRAF mutations"
        ],
        [
          "Cell cycle progression"
        ],
        [
          "Cell apoptosis"
        ],
        [
          "Angiogenesis"
        ],
        [
          "Tumor cell invasion and metastasis"
        ],
        [
          "Immunological effector mechanisms"
        ]
      ]
    },
    {
      "id": "661d19d5eac11fad33000007",
      "type": "yesno",
      "body": "Can the neonatal Pediatric Sepsis Biomarker Risk Model (nPERSEVERE) accurately predict mortality in neonatal sepsis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36513805",
        "http://www.ncbi.nlm.nih.gov/pubmed/27997530",
        "http://www.ncbi.nlm.nih.gov/pubmed/28991832",
        "http://www.ncbi.nlm.nih.gov/pubmed/34560770",
        "http://www.ncbi.nlm.nih.gov/pubmed/32617051",
        "http://www.ncbi.nlm.nih.gov/pubmed/23025259",
        "http://www.ncbi.nlm.nih.gov/pubmed/37656048",
        "http://www.ncbi.nlm.nih.gov/pubmed/11765663",
        "http://www.ncbi.nlm.nih.gov/pubmed/24754535",
        "http://www.ncbi.nlm.nih.gov/pubmed/18603896"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36513805",
          "text": "Biomarkers estimating baseline mortality risk for neonatal sepsis: nPERSEVERE: neonate-specific sepsis biomarker risk model.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 124
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36513805",
          "text": "BACKGROUND\nPrognostic biomarker research neonatal sepsis is lacking. We assessed the utility of a validated pediatric prognostic tool called PERSEVERE II that uses decision tree methodology to predict mortality at discharge in neonates who experienced sepsis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 259
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28991832",
          "text": "OBJECTIVES\nThe original Pediatric Sepsis Biomarker Risk Model and revised (Pediatric Sepsis Biomarker Risk Model-II) biomarker-based risk prediction models have demonstrated utility for estimating baseline 28-day mortality risk in pediatric sepsis. Given the paucity of prediction tools in pediatric acute respiratory distress syndrome, and given the overlapping pathophysiology between sepsis and acute respiratory distress syndrome, we tested the utility of Pediatric Sepsis Biomarker Risk Model and Pediatric Sepsis Biomarker Risk Model-II for mortality prediction in a cohort of pediatric acute respiratory distress syndrome, with an a priori plan to revise the model if these existing models performed poorly. DESIGN\nProspective observational cohort study.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 763
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28991832",
          "text": "OBJECTIVES\nThe original Pediatric Sepsis Biomarker Risk Model and revised (Pediatric Sepsis Biomarker Risk Model-II) biomarker-based risk prediction models have demonstrated utility for estimating baseline 28-day mortality risk in pediatric sepsis. Given the paucity of prediction tools in pediatric acute respiratory distress syndrome, and given the overlapping pathophysiology between sepsis and acute respiratory distress syndrome, we tested the utility of Pediatric Sepsis Biomarker Risk Model and Pediatric Sepsis Biomarker Risk Model-II for mortality prediction in a cohort of pediatric acute respiratory distress syndrome, with an a priori plan to revise the model if these existing models performed poorly.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 714
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28991832",
          "text": "OBJECTIVES\nThe original Pediatric Sepsis Biomarker Risk Model and revised (Pediatric Sepsis Biomarker Risk Model-II) biomarker-based risk prediction models have demonstrated utility for estimating baseline 28-day mortality risk in pediatric sepsis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 248
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36513805",
          "text": "BACKGROUND\nPrognostic biomarker research neonatal sepsis is lacking. We assessed the utility of a validated pediatric prognostic tool called PERSEVERE II that uses decision tree methodology to predict mortality at discharge in neonates who experienced sepsis. METHODS\nProspective study in a dual-center cohort of neonates with sepsis admitted between June 2020 and December 2021.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 381
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36513805",
          "text": "IMPACT\nPrognostic and predictive biomarker research is lacking in the newborn intensive care unit. Biomarkers can be used at the time of evaluation for neonatal sepsis (blood culture acquisition) to identify neonates with high baseline mortality risk.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1322,
          "endSection": "abstract",
          "offsetInEndSection": 1573
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36513805",
          "text": "Biomarkers can be used at the time of evaluation for neonatal sepsis (blood culture acquisition) to identify neonates with high baseline mortality risk.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1421,
          "endSection": "abstract",
          "offsetInEndSection": 1573
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36513805",
          "text": "IMPACT\nPrognostic and predictive biomarker research is lacking in the newborn intensive care unit. Biomarkers can be used at the time of evaluation for neonatal sepsis (blood culture acquisition) to identify neonates with high baseline mortality risk. Stratification is an important step toward precision medicine in neonatal sepsis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1322,
          "endSection": "abstract",
          "offsetInEndSection": 1655
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36513805",
          "text": "We assessed the utility of a validated pediatric prognostic tool called PERSEVERE II that uses decision tree methodology to predict mortality at discharge in neonates who experienced sepsis. METHODS\nProspective study in a dual-center cohort of neonates with sepsis admitted between June 2020 and December 2021. Biomarker analysis was done on serum samples obtained at the time of evaluation for the event.",
          "beginSection": "abstract",
          "offsetInBeginSection": 69,
          "endSection": "abstract",
          "offsetInEndSection": 476
        }
      ],
      "ideal_answer": "No, the neonatal Pediatric Sepsis Biomarker Risk Model (nPERSEVERE) cannot accurately predict mortality in neonatal sepsis.",
      "exact_answer": "no"
    },
    {
      "id": "662fc0bc187cba990d000011",
      "type": "yesno",
      "body": "Can calcium dietary supplementation reduce the risk of colorectal cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26675033",
        "http://www.ncbi.nlm.nih.gov/pubmed/16481636",
        "http://www.ncbi.nlm.nih.gov/pubmed/19116875",
        "http://www.ncbi.nlm.nih.gov/pubmed/14974021",
        "http://www.ncbi.nlm.nih.gov/pubmed/16034903",
        "http://www.ncbi.nlm.nih.gov/pubmed/18254022",
        "http://www.ncbi.nlm.nih.gov/pubmed/12467133",
        "http://www.ncbi.nlm.nih.gov/pubmed/19064518",
        "http://www.ncbi.nlm.nih.gov/pubmed/8515888",
        "http://www.ncbi.nlm.nih.gov/pubmed/8922297"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14974021",
          "text": "REVIEWER'S CONCLUSIONS\nAlthough the evidence from two RCTs suggests that calcium supplementation might contribute to a moderate degree to the prevention of colorectal adenomatous polyps, this does not constitute sufficient evidence to recommend the general use of calcium supplements to prevent colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2550,
          "endSection": "abstract",
          "offsetInEndSection": 2863
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16034903",
          "text": "AUTHORS' CONCLUSIONS\nAlthough the evidence from two RCTs suggests that calcium supplementation might contribute to a moderate degree to the prevention of colorectal adenomatous polyps, this does not constitute sufficient evidence to recommend the general use of calcium supplements to prevent colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2550,
          "endSection": "abstract",
          "offsetInEndSection": 2861
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14974021",
          "text": "Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 88
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16034903",
          "text": "For the development of recurrent colorectal adenoma, a reduction was found (OR 0.74, CI 0.58,0.95) when the results from both trials were combined. AUTHORS' CONCLUSIONS\nAlthough the evidence from two RCTs suggests that calcium supplementation might contribute to a moderate degree to the prevention of colorectal adenomatous polyps, this does not constitute sufficient evidence to recommend the general use of calcium supplements to prevent colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2400,
          "endSection": "abstract",
          "offsetInEndSection": 2861
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14974021",
          "text": "For the development of recurrent colorectal adenoma, a reduction was found (OR 0.74, CI 0.58,0.95) when the results from both trials were combined. REVIEWER'S CONCLUSIONS\nAlthough the evidence from two RCTs suggests that calcium supplementation might contribute to a moderate degree to the prevention of colorectal adenomatous polyps, this does not constitute sufficient evidence to recommend the general use of calcium supplements to prevent colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2400,
          "endSection": "abstract",
          "offsetInEndSection": 2863
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14974021",
          "text": "BACKGROUND\nSeveral dietary factors have been considered to be involved in the increasing incidence of colorectal cancer in industrialised countries. Experimental and epidemiological evidence has been suggestive but not conclusive for a protective role for high dietary calcium intake.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 284
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16034903",
          "text": "BACKGROUND\nSeveral dietary factors have been considered to be involved in the increasing incidence of colorectal cancer in industrialised countries. Experimental and epidemiological evidence has been suggestive but not conclusive for a protective role for high dietary calcium intake.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 284
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16034903",
          "text": "The rates of loss to follow -up were 14 % and 11%. For the development of recurrent colorectal adenoma, a reduction was found (OR 0.74, CI 0.58,0.95) when the results from both trials were combined. AUTHORS' CONCLUSIONS\nAlthough the evidence from two RCTs suggests that calcium supplementation might contribute to a moderate degree to the prevention of colorectal adenomatous polyps, this does not constitute sufficient evidence to recommend the general use of calcium supplements to prevent colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2349,
          "endSection": "abstract",
          "offsetInEndSection": 2861
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14974021",
          "text": "The rates of loss to follow -up were 14 % and 11%. For the development of recurrent colorectal adenoma, a reduction was found (OR 0.74, CI 0.58,0.95) when the results from both trials were combined. REVIEWER'S CONCLUSIONS\nAlthough the evidence from two RCTs suggests that calcium supplementation might contribute to a moderate degree to the prevention of colorectal adenomatous polyps, this does not constitute sufficient evidence to recommend the general use of calcium supplements to prevent colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2349,
          "endSection": "abstract",
          "offsetInEndSection": 2863
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14974021",
          "text": "OBJECTIVES\nThis systematic review aims to assess the effect of supplementary dietary calcium on the incidence of colorectal cancer and the incidence or recurrence of adenomatous polyps. SEARCH STRATEGY\nWe searched the Cochrane Controlled Trials Register, the Cochrane Colorectal Cancer Group specialised register, MEDLINE, Cancerlit, and Embase, to April 2002.",
          "beginSection": "abstract",
          "offsetInBeginSection": 589,
          "endSection": "abstract",
          "offsetInEndSection": 951
        }
      ],
      "ideal_answer": "No, calcium dietary supplementation does not reduce the risk of colorectal cancer. While there is some evidence that calcium supplementation might contribute to a moderate degree to the prevention of colorectal adenomatous polyps, this does not constitute sufficient evidence to recommend the general use of calcium supplements to prevent colorectal cancer.",
      "exact_answer": "no"
    },
    {
      "id": "66300ee7187cba990d00001c",
      "type": "factoid",
      "body": "What is the prevalence of intellectual developmental disorders in Duchenne Muscular Dystrophy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36440509",
        "http://www.ncbi.nlm.nih.gov/pubmed/7194435",
        "http://www.ncbi.nlm.nih.gov/pubmed/29795071",
        "http://www.ncbi.nlm.nih.gov/pubmed/7032457",
        "http://www.ncbi.nlm.nih.gov/pubmed/1743411",
        "http://www.ncbi.nlm.nih.gov/pubmed/21527393",
        "http://www.ncbi.nlm.nih.gov/pubmed/16417872",
        "http://www.ncbi.nlm.nih.gov/pubmed/25660133",
        "http://www.ncbi.nlm.nih.gov/pubmed/19385447",
        "http://www.ncbi.nlm.nih.gov/pubmed/29305139"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29795071",
          "text": "The literature shows that about 30-40% of DMD subjects have intellectual disability. In males with Duchenne muscular dystrophy, neuropsychiatric disorders have also been observed: attention deficit disorder and hyperactivity, autism spectrum disorders, and obsessive-compulsive disorder.",
          "beginSection": "abstract",
          "offsetInBeginSection": 109,
          "endSection": "abstract",
          "offsetInEndSection": 396
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29795071",
          "text": "The literature shows that about 30-40% of DMD subjects have intellectual disability. In males with Duchenne muscular dystrophy, neuropsychiatric disorders have also been observed: attention deficit disorder and hyperactivity, autism spectrum disorders, and obsessive-compulsive disorder. Duchenne muscular dystrophy is not just a muscle disorder, but also a disease that affects the brain.",
          "beginSection": "abstract",
          "offsetInBeginSection": 109,
          "endSection": "abstract",
          "offsetInEndSection": 498
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29795071",
          "text": "BACKGROUND\nDuchenne muscular dystrophy (DMD) is the most frequent and severe form of the dystrophinopathies. The literature shows that about 30-40% of DMD subjects have intellectual disability. In males with Duchenne muscular dystrophy, neuropsychiatric disorders have also been observed: attention deficit disorder and hyperactivity, autism spectrum disorders, and obsessive-compulsive disorder.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 396
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29795071",
          "text": "BACKGROUND\nDuchenne muscular dystrophy (DMD) is the most frequent and severe form of the dystrophinopathies. The literature shows that about 30-40% of DMD subjects have intellectual disability.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 193
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21527393",
          "text": "The school-age group showed no significant differences in general intellectual abilities. However, our data identified that boys with Duchenne muscular dystrophy experience mild cognitive dysfunction across multiple domains, including visual memory, and verbal and nonverbal executive functioning. Parental reports of 11 boys with the disorder revealed high rates of general behavioral problems (54.5%).",
          "beginSection": "abstract",
          "offsetInBeginSection": 291,
          "endSection": "abstract",
          "offsetInEndSection": 694
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16417872",
          "text": "In this study, we set out to reject the hypothesis that Duchenne muscular dystrophy and autism spectrum disorder/pervasive developmental disorder co-occur no more often than expected by chance. Two index cases and six additional boys with concomitant Duchenne muscular dystrophy and autism spectrum disorder were identified in a muscular dystrophy clinic that approximates the total number of Duchenne muscular dystrophy boys (158) in the state of Massachusetts. The rate of prevalence (6 of 158) was compared with the prevalence rate of autism spectrum disorder in boys in the general population (1.6 in 1,000).",
          "beginSection": "abstract",
          "offsetInBeginSection": 157,
          "endSection": "abstract",
          "offsetInEndSection": 769
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21527393",
          "text": "However, our data identified that boys with Duchenne muscular dystrophy experience mild cognitive dysfunction across multiple domains, including visual memory, and verbal and nonverbal executive functioning. Parental reports of 11 boys with the disorder revealed high rates of general behavioral problems (54.5%).",
          "beginSection": "abstract",
          "offsetInBeginSection": 381,
          "endSection": "abstract",
          "offsetInEndSection": 694
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21527393",
          "text": "Parental reports of 11 boys with the disorder revealed high rates of general behavioral problems (54.5%). The cognitive profile of boys with Duchenne muscular dystrophy in South Africa is similar to that described elsewhere in the world.",
          "beginSection": "abstract",
          "offsetInBeginSection": 589,
          "endSection": "abstract",
          "offsetInEndSection": 826
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16417872",
          "text": "Two index cases and six additional boys with concomitant Duchenne muscular dystrophy and autism spectrum disorder were identified in a muscular dystrophy clinic that approximates the total number of Duchenne muscular dystrophy boys (158) in the state of Massachusetts. The rate of prevalence (6 of 158) was compared with the prevalence rate of autism spectrum disorder in boys in the general population (1.6 in 1,000).",
          "beginSection": "abstract",
          "offsetInBeginSection": 351,
          "endSection": "abstract",
          "offsetInEndSection": 769
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21527393",
          "text": "The preschool group performed significantly worse than the controls in measures of general developmental performance. The school-age group showed no significant differences in general intellectual abilities. However, our data identified that boys with Duchenne muscular dystrophy experience mild cognitive dysfunction across multiple domains, including visual memory, and verbal and nonverbal executive functioning.",
          "beginSection": "abstract",
          "offsetInBeginSection": 173,
          "endSection": "abstract",
          "offsetInEndSection": 588
        }
      ],
      "ideal_answer": "The prevalence of intellectual developmental disorders in Duchenne Muscular Dystrophy is 30-40%.",
      "exact_answer": [
        "30-40%"
      ]
    },
    {
      "id": "660999bffdcbea915f00001b",
      "type": "yesno",
      "body": "Is treatment with acetyl salicylic acid indicated to prevent colorectal adenomas?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/12621132",
        "http://www.ncbi.nlm.nih.gov/pubmed/930630",
        "http://www.ncbi.nlm.nih.gov/pubmed/3229444",
        "http://www.ncbi.nlm.nih.gov/pubmed/17274829",
        "http://www.ncbi.nlm.nih.gov/pubmed/4024050",
        "http://www.ncbi.nlm.nih.gov/pubmed/19640262",
        "http://www.ncbi.nlm.nih.gov/pubmed/22716465",
        "http://www.ncbi.nlm.nih.gov/pubmed/22691184",
        "http://www.ncbi.nlm.nih.gov/pubmed/8670201",
        "http://www.ncbi.nlm.nih.gov/pubmed/22610182"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19640262",
          "text": "It was concluded that acetyl salicylic acid caffeine complex can be used safely for rectal administration.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1106,
          "endSection": "abstract",
          "offsetInEndSection": 1212
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22716465",
          "text": "It was concluded that acetyl salicylic acid caffeine complex can be used safely for rectal administration.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1106,
          "endSection": "abstract",
          "offsetInEndSection": 1212
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/930630",
          "text": "The effect of acetyl-salicylic acid to prevent thromboembolic complications in coronary angiography is reported.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 112
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17274829",
          "text": "Anti-inflammatory drug acetyl salicylic acid appears to be a promising agent for treating peripheral nerve injuries and hence elucidation of its neuroprotective pathways is necessary.",
          "beginSection": "abstract",
          "offsetInBeginSection": 921,
          "endSection": "abstract",
          "offsetInEndSection": 1104
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17274829",
          "text": "In comparison with normal saline treatment, acetyl salicylic acid (100 mg/kg/day) significantly improved functional recovery following sciatic nerve crush. Anti-inflammatory drug acetyl salicylic acid appears to be a promising agent for treating peripheral nerve injuries and hence elucidation of its neuroprotective pathways is necessary.",
          "beginSection": "abstract",
          "offsetInBeginSection": 765,
          "endSection": "abstract",
          "offsetInEndSection": 1104
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19640262",
          "text": "The effects of acetyl salicylic acid and complex on the rectal tissues showed destruction in the mucosal epithelium in case of acetyl salicylic acid; however, no change in the rectal tissues was noticed upon the administration of the complex.",
          "beginSection": "abstract",
          "offsetInBeginSection": 261,
          "endSection": "abstract",
          "offsetInEndSection": 503
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22716465",
          "text": "The effects of acetyl salicylic acid and complex on the rectal tissues showed destruction in the mucosal epithelium in case of acetyl salicylic acid; however, no change in the rectal tissues was noticed upon the administration of the complex.",
          "beginSection": "abstract",
          "offsetInBeginSection": 261,
          "endSection": "abstract",
          "offsetInEndSection": 503
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17274829",
          "text": "In comparison with normal saline treatment, acetyl salicylic acid (100 mg/kg/day) significantly improved functional recovery following sciatic nerve crush.",
          "beginSection": "abstract",
          "offsetInBeginSection": 765,
          "endSection": "abstract",
          "offsetInEndSection": 920
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17274829",
          "text": "In this study we have evaluated the effect of acetyl salicylic acid on functional recovery following sciatic nerve crush in mice.",
          "beginSection": "abstract",
          "offsetInBeginSection": 295,
          "endSection": "abstract",
          "offsetInEndSection": 424
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17274829",
          "text": "Acetyl salicylic acid augments functional recovery following sciatic nerve crush in mice.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 89
        }
      ],
      "ideal_answer": "No, treatment with acetyl salicylic acid is not indicated to prevent colorectal adenomas.",
      "exact_answer": "no"
    }
  ]
}